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Abstract 
Research has demonstrated that the timing, type, duration and intensity of exercise can all 
impact blood glucose levels differently in patients with type 1 diabetes. Continuous steady state 
moderate intensity ‘aerobic’ exercise tends to drop blood glucose levels, while vigorous-to-
maximal intensity exercise tends to cause blood glucose levels to rise. The purpose of this 
dissertation was to test different basal insulin strategies to improve glycemia during various 
forms of exercise and in recovery in patients with type 1 diabetes on continuous subcutaneous 
insulin infusion (CSII) therapy. A secondary purpose was to examine the effectiveness of 
continuous glucose monitor (CGM) technology to track interstitial glucose levels during exercise 
and in recovery.  
Initially, we examined the effects of insulin pump suspension on glycemia during aerobic 
and circuit-based exercise. We found that pump suspension at exercise onset caused a greater 
drop in glycemia during aerobic vs. circuit-based exercise. Aerobic exercise also modestly 
increased the time spent in hypoglycemia 12 hours post-exercise. We then investigated the 
effects of a reduced insulin infusion rate (‘pump on’) vs. pump suspension (‘pump off’) during 
intermittent high intensity exercise and found neither an advantage nor disadvantage on blood 
glucose level with pump removal for exercise. Interestingly, ‘pump on’ resulted in slightly 
higher time spent in hypoglycemia in the 12-hour period post-exercise vs. ‘pump off’.  
In a third study, we tested the strategy of lowering basal insulin delivery by 50% or 80% 
well in advance of exercise vs. pump suspension at exercise onset in an attempt to reduce 
hypoglycemia risk. Overall, we found that a 50-80% basal rate reduction set 90 mins pre-
exercise attenuated the drop in blood glucose level better than pump suspension at exercise start. 
Finally, we assessed CGM accuracy during exercise and in the meal post-exercise and found that 
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CGM underestimated the drop in glycemia during exercise and appeared to lag behind self-
monitoring blood glucose values when glycemia was changing rapidly.  
This thesis dissertation highlights a number of novel strategies, including basal insulin 
rate reductions and altering the type of exercise for improved exercise management in people 
living with type 1 diabetes on CSII.  
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1.0 Introduction & Background 
Type 1 diabetes is an autoimmune disease characterized by the absolute destruction of 
insulin producing beta (β) cells (1). Without β-cells to produce endogenous insulin, the body 
experiences excursions in glycemia that are outside of the physiological range. Therefore, for the 
management of type 1 diabetes, patients require exogenous insulin administration via multiple 
daily injections or insulin pump therapy and frequent self-monitoring of blood glucose (SMBG) 
using traditional fingerstick capillary sampling and a handheld glucose meter (2).  
Regular physical activity has been shown to have many health benefits for individuals 
with type 1 diabetes including reduced cardiovascular disease risk factors (3), improvements in 
insulin sensitivity (4), and overall wellbeing (5). However, exercise and physical activity can 
also cause dramatic, and sometimes dangerous, excursions in blood glucose concentration, 
thereby increasing the complexity and challenges involved with overall glycemic control. 
Despite the recommendations for individuals with type 1 diabetes to engage in regular physical 
activity, the exact type of training and insulin adjustments required to maintain blood glucose 
levels in a target range is up for debate. For patients with type 1 diabetes, many factors need to 
be taken into consideration prior to engaging in physical activity and exercise such as the timing, 
duration, and intensity of exercise, possible adjustments in basal insulin rates, nutrition, and the 
amount of active or ‘on-board’ insulin present at the onset of exercise. If these factors are 
ignored and not managed accordingly, there is an increased risk of developing hypoglycemia or 
hyperglycemia during activity. Maintaining a blood glucose concentration between 6.0-8.0 
mmol/L (108-144 mg/dL) during activity is believed by some to be the ‘optimal blood glucose 
range’ for exercise performance in adolescents with type 1 diabetes (6); however, whether this 
range applies to all patients and for all settings of physical activity and exercise is currently 
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unknown. Nonetheless, this is something that most patients with type 1 diabetes strive for during 
physical activity and exercise, but often with very limited success.  
With advancements in technology such as continuous glucose monitor (CGM) devices, 
patients can wear a glucose sensor subcutaneously that is connected to a transmitter and monitors 
interstitial glucose level over 24 hours. CGM devices also provide information on the directional 
rate of change in interstitial glucose and can be extremely beneficial before, during, and after an 
exercise session. Real-time CGM (rtCGM) devices are also extremely valuable because they can 
be used to alert patients of an impending hypo- or hyperglycemic event (7), for example during 
aerobic exercise that is often associated with declines in glycemia and subsequently can lead to 
hypoglycemia (8). Using rtCGM, studies are now better able to monitor glucose variability, 
fluctuations, and recurring trends in glycemia.  
4 
1.1 Physiology of physical activity and exercise 
1.1.1 Exercise modalities 
Although the terms ‘physical activity’ and ‘exercise’ have many similarities and are often 
used interchangeably, there are slight differences worth distinguishing. Physical activity is 
described as any movement carried out by the skeletal muscles that results in an increase in 
energy expenditure relative to the resting state (i.e. sitting or lying down) (9). Physical activity is 
often expressed in kilocalories (kcals). Energy expenditure is often estimated by the volume of 
activity (i.e. light, moderate, vigorous, and vigorous-to-maximum) per minute, relative to body 
mass (10) and is expressed in kilojoules or kilocalories. Exercise, however, is a planned, 
repetitive, and structured movement that aims to improve physical fitness (11). 
The human body uses three main energy sources to maintain homeostasis and these 
include immediate, oxidative, and non-oxidative energy sources (12). Activities are often 
simplistically classified as being either ‘aerobic’ (oxidative) or ‘anaerobic’ (non-oxidative) in 
nature; however, most activities rely on the interplay between both oxidative and non-oxidative 
energy sources (13). Aerobic exercises are generally continuous steady state light-moderate-
vigorous intensity, rhythmic movements using large muscle groups such as brisk walking, light 
jogging, cycling, and recreational swimming (14). Light-to-moderate intensity physical activity 
is generally associated with an intensity between 3–6 metabolic equivalents (METs), or ~50–
75% of an individual’s age-predicted maximum heart rate (10). Mixed or circuit-based activities 
are still aerobic in nature and sometimes referred to as high intensity interval or intermittent 
activities. More specifically, these are light-to-moderate intensity activities interspersed with 
intermittent, moderate-to-vigorous and vigorous-to-maximal intensity bouts. Individual and team 
sports (e.g. baseball, basketball, tennis, soccer, etc.) or interval training are some examples of 
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mixed activities. During mixed activities, these high intensity workloads can reach 6-10 METs or 
approximately 75–100% of an individual’s maximum heart rate (15). Resistance exercises are 
often more brief, repetitive movements that incorporate weights, weight machines, resistance 
bands, or simply one’s own body weight (14). During intense muscle contractions, there is a 
greater reliance on muscle phosphagens [adenosine triphosphate (ATP) and phosphocreatine 
(PCr)] and anaerobic glycolysis and these types of activities tend to cause a more dramatic rise in 
glucose counterregulatory hormones (catecholamines, glucagon, cortisol, and growth hormone) 
(16).  
1.1.2 Common terminology misclassifications 
 Traditionally, activities that last a few seconds up to one minute are often described as 
‘anaerobic’ and activities that are two minutes or longer are predominantly ‘aerobic’ (12). 
However, in this section, these words will be explained in further detail and we will highlight 
how this terminology is often misrepresented in sports medicine and academia.  
Specifically, at lower intensities and continuous steady state activity, aerobic metabolism 
is the dominant system. The key source of energy provision during continuous steady state 
exercise is plasma free fatty acids (15). Conversely, it has been argued that ‘oxidative 
phosphorylation’ more accurately describes activities that are ‘aerobic’ in nature as most 
activities are not purely dependent on one single energy system. As the intensity of exercise 
increases and energy demands rise, there is a greater interplay of ATP-PCr and glycolysis energy 
systems. At very intense contraction rates, plasma glucose uptake and utilization is minimal and 
the primary fuel is muscle phosphocreatine and muscle glycogen (15). Another important 
distinction is that ‘anaerobic’ metabolism is a pathway that functions ‘independent of oxygen’ 
rather than being referred to it as working ‘in the absence of oxygen’ (17). More importantly and 
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often overlooked, is that maximal sprints or exercises lasting less than 30 seconds still have a 
small aerobic component during the activity and oxygen consumption can be increased for four 
or more hours in recovery (18, 19). In the present day, it is accepted that energy provision is a 
permutation of all three pathways working together, often with one of those systems functioning 
above the others (20). For the purposes of this thesis dissertation, the term ‘aerobic’ refers to 
continuous steady state light-to-moderate intensity exercise and the term ‘circuit or intermittent 
high intensity’ exercise refers to light-to-moderate intensity activity interspersed with variable 
bursts of moderate-vigorous-maximal intensity activity. In addition, activities lasting < 40 
minutes will be referred to as ‘short’ duration exercise, whereas activities that are > 40 minutes 
will be referred to as ‘prolonged’ exercise.  
1.2 Metabolic responses to structured exercise in non-T1D 
1.2.1 Glucose homeostasis during exercise  
For individuals without type 1 diabetes, the body is able to maintain blood glucose 
concentration in a tight range (between 4.0-6.0 mmol/L or 72-108 mg/dL) during exercise 
through a number of different mechanisms (16). Insulin and glucagon are two of the major 
hormones responsible for the body’s ability to maintain glucose homeostasis at rest and during 
aerobic exercise. During aerobic exercise, the body begins to break down liver and muscle 
glycogen stores in order to preserve blood glucose in large part because of the rise in the 
glucagon-to-insulin ratio (21). Contraction-mediated glucose uptake and use by the skeletal 
muscles can cause glucose oxidation to increase as much as 10-fold, and circulating blood 
glucose levels will drop markedly without adjustments to this hormone ratio (21). Specifically, 
with prolonged, moderate intensity aerobic exercise, these carbohydrate stores are limited and 
blood glucose concentration may begin to drop even in patients without diabetes if no oral 
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carbohydrate is ingested (22). To combat this drop in glycemia as muscle glucose uptake is 
markedly increased, the body responds with a decrease in insulin secretion, a rise in glucagon 
secretion among other counterregulatory hormones, and an increase in hepatic glucose 
production to prevent hypoglycemia (23). Following exercise, insulin sensitivity has been shown 
to persist for up to 48 hours in recovery (24).  
During vigorous-to-maximal exercise (> 80% maximum oxygen uptake), the body 
secretes a number of different counterregulatory hormones such as cortisol, growth hormone, and 
catecholamines (e.g. epinephrine and norepinephrine) that tend to increase blood glucose 
concentration above normal levels (25). This type of exercise cannot be maintained for a 
sustained duration, therefore when catecholamines (specifically epinephrine and norepinephrine) 
are secreted, this stimulates the liver to release glucose into the circulation beyond what can be 
utilized by skeletal muscle (21). Vigorous-to-maximal intensity exercise is also associated with 
drastic elevations in lactate levels, particularly when the rate of lactate production far exceeds 
lactate oxidation or clearance (26). An increase in counterregulatory hormones and acid-base 
disturbance is associated with reduced lactate oxidation. This can lead to temporary elevations in 
blood glucose concentration even in individuals without diabetes, but this phenomenon is further 
exaggerated in type 1 diabetes (25). Similarly, research suggests that vigorous-to-maximal 
intensity resistance exercise elicits similar metabolic and hormonal responses (27).  
1.3 Type 1 diabetes 
Type 1 diabetes is an autoimmune disease caused by the body’s destruction of insulin 
producing beta (β) cells of the pancreas (2). Type 1 diabetes results in complete insulin 
deficiency and accounts for approximately 5-10% of all diabetes cases (2). Based on the 
Diabetes Canada 2018 Guidelines, type 1 diabetes is often diagnosed with a fasting plasma 
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glucose concentration of ≥ 7.0 mmol/L or two hour plasma glucose level ≥ 11.1 mmol/L 
following a 75 gram oral glucose load (2). Although there is no immediate cure for type 1 
diabetes to date, treatment options include the administration of exogenous insulin via multiple 
daily injections (MDI) or continuous subcutaneous insulin infusion (CSII) using insulin pump 
therapy. These treatment strategies are used in combination with SMBG using a glucose meter, 
which is a small, compact device and a glucose test strip that requires a small amount (~ 2-10 μL) of 
capillary blood usually from the fingertip.   
Some common symptoms associated with type 1 diabetes include hypo- and 
hyperglycemia. Hypoglycemia is used to describe blood glucose concentration ≤ 3.9 mmol/L and 
can range from feelings of shakiness, irritability, hunger, increased sweating, weakness, and 
numbness or tingling in the tongue or lips. Hypoglycemia often results from a combination of 
factors including too little food, too much exercise, and/or too much insulin (2). Hyperglycemia 
is used to describe a fasting blood glucose concentration > 7.0 mmol/L or ≥ 10.0 mmol/L two-
hours postprandial. Symptoms of hyperglycemia may include thirst, frequent urination, and/or 
fatigue and is commonly a result of too much food, too little insulin, too little exercise, or a 
combination of these factors (2). In patients with poorly controlled diabetes, chronic 
hyperglycemia has also been linked to long-term damage of various organs including the 
kidneys, eyes, blood vessels, and the heart (28).  
1.3.1 Glycated Hemoglobin (HbA1c) 
Glycated hemoglobin, better known as HbA1c or sometimes A1c in the United States of 
America, is a standard measure of diabetes (glycemic) control over the previous 8-12 weeks (2, 
29). The Diabetes Control and Complications Trial (DCCT) was the first large randomized study 
to correlate higher HbA1c (> 7.0%) values to an increased risk of microvascular and 
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cardiovascular complications (30). Therefore, the general recommendation for individuals with 
type 1 diabetes is a target HbA1c level of ≤ 7.0% to reduce the likelihood of complications (30).  
The T1D Exchange Clinical Network gathered HbA1c values from over 16,000 patients 
living with type 1 diabetes and assessed mean HbA1c by year of age (31). This invaluable data 
showed that the majority of individuals with type 1 diabetes were not maintaining optimal 
glycemic control and in fact, most 13-17 year olds were well above the recommended guidelines 
with a mean HbA1c of ~ 9.0% (31). According to this dataset, glycemic control appears to 
improve and plateau with a mean HbA1c between 7.5-7.8% after the age of 30 (31). It is of 
concern that even with all of the new technological advancements in diabetes management, very 
modest improvements in overall diabetes management have occurred over the past 20 years (31).  
An ongoing topic of debate is whether exercise training improves HbA1c in type 1 
diabetes. Some studies have found that regular structured exercise participation does not 
markedly improve HbA1c levels in individuals with type 1 diabetes (32-35) and may even be 
associated with a slight elevation in HbA1c if the activities are frequent and intense (36). Other 
studies have demonstrated slight improvements in HbA1c with exercise training in both well-
controlled (37) and poorly controlled (38, 39) patients with type 1 diabetes, typically by ~0.3-
0.5% according to recent meta-analyses with considerable inconsistency among the limited 
number of studies published to date (40). However, due to considerable differences in 
measurement devices used, the duration, intensity, type of exercise, and baseline HbA1c levels, 
this may account for the outcome variation among these exercise-training interventions (40).  
One of the limitations of HbA1c is that it fails to capture the variability of glucose, 
specifically the intra- and inter-day excursions that may lead to extreme hypo- and 
hyperglycemic events (41, 42). Therefore, more recent studies have focused on incorporating 
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measures such as glucose variability (GV) and Glucose Management Indicators (GMI) as 
additional diabetes management tools (42, 43). Both GV and GMI metrics can be calculated 
from continuous glucose monitoring (CGM) systems that will be discussed in a later chapter.  
1.3.2 Exogenous insulin therapy 
Individuals with type 1 diabetes are unable to produce endogenous insulin once the β-
cells have been destroyed and therefore insulin administration must occur exogenously. Whether 
individuals with type 1 diabetes are using MDI (insulin pen or syringe) or CSII (insulin pump) 
therapy, insulin administration varies. Since the discovery of insulin in 1921, insulin 
formulations have continued to improve (44). Insulin action is often differentiated based on 
pharmacokinetic and pharmacodynamic properties. Insulin is given in the form of a ‘bolus’ of 
rapid-acting insulin analog or short-acting insulin or a ‘basal’ dose of intermediate-acting or 
long-acting insulin. Patients that use MDI therapy usually administer both short-acting and long-
acting insulin analogues via injections whereas CSII therapy uses an insulin pump device with 
only short-acting insulin for both continuous basal insulin infusion and bolus insulin infusion. A 
bolus of insulin is often taken before a meal or to correct hyperglycemia (1). Bolus insulins 
include insulin aspart (NovoRapid®), glulisine (Apidra®), lispro (Humalog®), faster-acting aspart 
(Fiasp®), and regular (Humulin®-R). Basal insulins include insulin neutral protamine Hagedorn 
(Humulin®-N, and Novolin ge®), detemir (Levemir®), glargine (Lantus®, Basaglar®, and 
Toujeo®), and degludec (Tresiba®), all of which have different pharmacokinetics to cover insulin 
needs in-between meals and overnight (2). Together, this ‘basal-bolus insulin regimen’ is trying 
to mimic the natural physiological response of insulin in individuals without type 1 diabetes 
(Figure 1.1). 
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Figure 1.1: ‘Basal-bolus insulin regimen’ and interstitial glucose. 
Standard ‘basal-bolus insulin regimen’ overlaid with interstitial glucose over 24 hours. Black 
represents the interstitial glucose data captured using a real-time continuous glucose monitor. 
Green represents the bolus insulin. Blue represents the basal insulin. Modified from Subramanian 
et al. (45).  
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Studies suggest that CSII versus MDI therapy is typically more effective for improving 
glucose variability and perhaps also HbA1c levels (46-48). In some cases, CSII therapy has been 
more advantageous for patients with initial poor glycemic control (49, 50), while other studies 
found significant improvements with the transition from MDI to CSII therapy in well-controlled 
patients with type 1 diabetes (47, 51). In general, CSII treatment provides an efficient and more 
flexible means of delivering insulin and allows for more immediate basal insulin rate 
adjustments relative to MDI (52). Since a growing percentage of the type 1 diabetes population 
are transitioning to insulin pump therapy (53, 54), CSII will likely be the primary management 
strategy in the future for patients living with type 1 diabetes. As such, this thesis is limited to 
exercise studies on patients with type 1 diabetes that are using CSII therapy.  
1.4 Physical activity and exercise 
1.4.1 General exercise training adaptations 
Habitual moderate-to-vigorous intensity aerobic training generally causes increases in 
overall heart mass and volume (26). More specifically, aerobic training leads to central and 
peripheral cardiovascular adaptations in a dose-dependent manner. Some of these central 
adaptations include improvements in stroke volume, cardiac output, blood volume, increases in 
end-diastolic volume, and greater oxygen extraction (55). Peripheral adaptations can include 
enhanced muscle blood flow and vasculature, and improved mitochondrial function and 
enzymatic activity. During exercise, blood flow is increased in the cardiovascular system to 
increase the delivery of oxygen and nutrients to meet the demands of the working muscles, and 
to remove carbon dioxide. Aerobic training also increases glucose transporter 4 (GLUT-4) 
content and improves glucose uptake into the skeletal muscles (56, 57).   
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Maximal intensity activities, commonly referred to as ‘anaerobic’, more fully engage all 
of the motor units especially the fast-twitch oxidative and glycolytic muscle fibres for very short 
bursts (10 seconds or less) and therefore, almost exclusively rely on energy from ATP and PCr in 
the muscles (26). Anaerobic training is very demanding on the human body and requires 
maximal or near-maximal effort which is not tolerated well by non-athletic individuals and 
therefore is less frequently undertaken when compared to aerobic training (12). With intermittent 
high intensity training, however, the bursts can vary from 10 seconds to three minutes and are 
interspersed with lower-intensity or rest periods in between. The difference with intermittent 
high intensity training is that in addition to the aerobic training benefits, there is added stress to 
the glycolytic system in the muscle and an improvement in the removal of lactate accumulation 
in skeletal muscles (12).  
Resistance training includes activities that are progressive manipulations of volume, 
intensity, and frequency against a resistive force (e.g. free weights, weight machines, 
bodyweight, or resistance bands) (13). Moderate-to-vigorous intensity resistance training has 
been shown to cause muscle hypertrophy, increased muscle power, endurance, balance, agility 
and coordination (58). Based on the American College of Sports Medicine (ACSM) position 
statement, resistance training improves muscular strength on average from 15% in trained 
individuals to an average of 40% in untrained individuals (59). Progressive resistance training 
increases fast-twitch muscle fibres, mitochondrial density, and cross-sectional area, but appears 
to cause little-to-no change in glycolytic enzyme activity (12). Overall, safely executed 
resistance training has been shown to also increase muscular strength (60) and improve glucose 
tolerance and insulin sensitivity (61).  
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1.4.2 Physical activity and exercise benefits in T1D 
Regular physical activity not only improves a number of health outcomes in individuals 
living with type 1 diabetes, but it can also improve the overall wellbeing (62), quality of life (5), 
and life expectancy (63) in this patient population. Some of these established health benefits 
include an increased aerobic fitness (64), increased insulin sensitivity (4, 65), improved lipid 
profiles (66, 67), improved endothelial function (68, 69), and reductions in cardiovascular 
disease (70) and mortality (63). In addition, increased levels of physical activity have also been 
associated with reductions in diabetes complications such as neuropathy, nephropathy, and 
retinopathy (71). Physical activity can be performed safely and yield these described benefits for 
individuals living with type 1 diabetes, but often requires significant pre-planning and 
knowledge of the upcoming activity in order to minimize hypoglycemia risk (72). These 
improvements in health outcomes need to be recognized as important tools and motivational 
strategies for patients with type 1 diabetes to be regularly active.  
1.4.3 Exercise guidelines in T1D 
Current guidelines and position statements recommend that adults with type 1 diabetes 
accumulate 150 minutes of physical activity per week with no more than two days of rest in 
between and additionally incorporating resistance training 2-3 times per week (2, 13, 14). 
Performing vigorous-intensity exercises at least 75 minutes weekly, although shorter in duration, 
can still elicit similar improvements in cardiovascular and overall fitness (73, 74). Based on the 
International Society for Pediatric Diabetes (ISPAD) clinical guidelines, toddlers are 
recommended to accumulate 60-90 minutes of physical activity daily (75). For preschoolers the 
recommendations are 90-120 minutes of physical activity daily, and for children and adolescents, 
the guidelines suggest at least 60 minutes of daily physical activity (75). Exercise guidelines and 
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position statements are intended to promote physical activity, but may still need to be customized 
to patients’ individual needs. Interestingly, research has found that many children with type 1 
diabetes are not adhering to clinical guidelines and in fact are participating in less than the 
recommended daily physical activity (76) and adults were also found to engage in fewer minutes 
of moderate-to-vigorous physical activity compared to individuals without type 1 diabetes (77).  
Although exercise guidelines and position statements for individuals with type 1 diabetes 
exist (2, 13, 14, 78), a greater focus needs to be placed on determining what specific factors are 
contributing to this lack of activity. Brazeau et al. (77) suggest that the highest ranked barriers to 
physical activity in individuals with type 1 diabetes are a fear of severe hypoglycemia, loss of 
diabetes control, work schedule and low fitness levels. The use of CGM technology may help 
decrease the fear associated with hypoglycemia for individuals with type 1 diabetes as patients 
will be able to respond to glucose fluctuations sooner, before hypoglycemia ensues (79). In order 
to further reduce the burden or eliminate some of these barriers, more effective strategies around 
glycemic management during and post-exercise are required.  
1.5 Metabolic responses to exercise in T1D 
1.5.1 Glucose homeostasis during exercise in T1D 
Dysglycemia associated with physical activity and exercise is caused by a number of 
factors including the timing, type, duration, and intensity of exercise. Blood glucose responses to 
physical activity and exercise are also impacted by prior hypoglycemia (80), starting glucose 
levels (81), and circulating insulin levels (82).  
Aerobic activities tend to cause blood glucose levels to drop, primarily due to the body’s 
inability to lower circulating insulin concentrations at exercise onset (82). In fact, a few studies 
have even shown insulin concentrations rise at the beginning of exercise and this is possibly 
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attributed to an increase in blood flow and subcutaneous insulin absorption (83, 84). Without 
additional carbohydrate supplementation before, during, or after exercise, hypoglycemia is a 
common occurrence with aerobic exercise. In type 1 diabetes, research suggests that impaired 
glucose counterregulation may be influencing the body’s ability to attenuate the drop in glycemia 
during aerobic exercise (85). However, vigorous-to-maximal intensity activities generally shift 
fuel utilization from fat to carbohydrates (86). These higher-intensity activities also have an 
opposite effect on glycemia compared to aerobic activities and attenuate the drop in blood 
glucose level or cause blood glucose level to rise (87). This increase in blood glucose level 
during vigorous-to-maximal intensity bursts may be associated with a rise in counterregulatory 
and metabolic hormones (i.e. catecholamines, cortisol, growth hormone, etc.) restricting glucose 
disposal (88). 
1.6 Hypoglycemia in T1D 
 For years, the primary research focus for patients living with type 1 diabetes has been on 
reducing the burden and incidence of hypoglycemia, a term often described as the limiting factor 
in glycemic control in patients using CSII therapy (89). In the past, the exact glycemic threshold 
for hypoglycemia occurrence has been argued, but the American Diabetes Association (ADA) 
workgroup determined that SMBG level of ≤ 3.9 mmol/L (≤ 70 mg/dL) is when individuals with 
type 1 diabetes often experience impaired cognition with hypoglycemia and this is the threshold 
for activating glucose counterregulation in patients without type 1 diabetes (90). 
1.6.1 Glucose counterregulation in T1D 
For individuals living with type 1 diabetes, the maintenance of euglycemia is often 
compromised with recurrent and sometimes frequent episodes of hypoglycemia. Exercise itself is 
a major contributor to hypoglycemia and it can also be a trigger for recurrent hypoglycemia over 
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the next 24 hours (16). Hypoglycemia symptoms are commonly divided into two categories: 1) 
neuroglycopenic and 2) neurogenic. Neuroglycopenic symptoms refer to impairments in 
cognition and behaviour and neurogenic symptoms refer to sweating, hunger, tremors and 
anxiety. In addition, patients with type 1 diabetes that experience repeated episodes of 
hypoglycemia can also become less symptomatic and develop decreased awareness of low blood 
glucose levels, termed hypoglycemia unawareness (91). 
Hypoglycemia may be better described as iatrogenic hypoglycemia because it often 
occurs as a result of an accidental (i.e. unintentional) interplay between excess insulin and 
compromised physiological and behavioural defenses against decreasing glycemia (91). Episodes 
of symptomatic hypoglycemia for this population occur on average two times per week (92) and 
one in six experience at least one severe hypoglycemia episode per year (93). Three common 
defects contribute to the increased frequency of hypoglycemia in type 1 diabetes. These include: 
1) the loss of β-cell function leading to the reliance of exogenous insulin therapy; 2) impaired 
counterregulation particularly with an abnormal glucagon response; and 3) reduced autonomic 
nervous system responses that often occur by 10 years of disease duration (94, 95). More 
specifically, research has established that in patients living with type 1 diabetes, the 
physiological defences against hypoglycemia including decreases in insulin and increases in 
glucagon are lost and increases in epinephrine are often attenuated (96-98) (Table 1.1). Without 
proper defence mechanisms against hypoglycemia, patients with type 1 diabetes are at a greater 
risk for developing severe hypoglycemia that can lead to a coma or ultimately death, if left 
untreated (99).  
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 Individuals without type 1 diabetes Individuals with Type 1 diabetes 
Pancreas ↓ insulin Lost in T1D 
Liver ↑ glucagon Attenuated/lost in T1D 
Kidneys ↑ epinephrine Attenuated in T1D 
Brain ↑ neurogenic symptoms Attenuated in T1D  
Table 1.1: Defences against hypoglycemia. 
Physiological and behaviour defences against hypoglycemia in patients without and with type 1 
diabetes. Modified from Cryer PE. The Barrier of Hypoglycemia in Diabetes. Diabetes, 2008, 
57:12 (92). 
 
1.6.2 Hypoglycemia unawareness in T1D 
 Geddes et al. (100) found that hypoglycemia unawareness leads to a six-fold increase in 
the likelihood of developing iatrogenic hypoglycemia. This increase in hypoglycemia 
unawareness is associated with the attenuation in epinephrine secretion that causes defective 
glucose counterregulation in patients with type 1 diabetes (92). The attenuation of epinephrine 
has been linked to a concept known as ‘hypoglycemia-associated autonomic failure’ (HAAF) 
that is associated with the following three factors: 1) recent (antecedent) hypoglycemia (98, 101); 
2) prior exercise (102); or 3) sleep (103). Hypoglycaemia, exercise and sleep have all been 
shown to blunt the counterregulatory hormone response to subsequent hypoglycaemia. More 
specifically during sleep, Banaerer et al. (103) demonstrated that patients with type 1 diabetes 
were substantially less likely to be awakened by hypoglycemia due to reduced sympathoadrenal 
responses to hypoglycemia.  
Interestingly, studies have reported that in most patients with type 1 diabetes, 
hypoglycemia unawareness is reversible with as little as a 2-3 week intervention of strict diabetes 
monitoring and avoidance of hypoglycemia (104, 105). Even in adults with long-standing type 1 
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diabetes (mean duration ~35 years), the HypoCOMPaSS trial showed recovery of hypoglycemia 
awareness with a 24-week intervention using an educational tool aimed at avoidance of 
hypoglycemia without worsening of overall glycemic control (106). Given the high incidence of 
hypoglycemia in type 1 diabetes, the use of rtCGM technology is on the rise since these systems 
can alert the patients that glucose levels are in, or are approaching, the hypoglycemic range (see 
below). 
1.6.3 Exercise-related hypoglycemia in T1D 
 Regular physical activity and exercise increase the risk of severe hypoglycemia (107) and 
contribute to greater hypoglycemia risk following activity, for upwards of 24 hours in recovery 
(16, 108). A number of studies have found that 45 minutes of continuous steady state moderate 
intensity aerobic exercise in the late afternoon increases the risk of overnight (nocturnal) 
hypoglycemia for youth living with type 1 diabetes (81, 109, 110). Yardley et al. (111) were the 
first to suggest that performing resistance exercise before aerobic exercise in trained adults living 
with type 1 diabetes could lead to a smaller decrease in glycemia during exercise, but more 
importantly, may decrease the severity of potential nocturnal hypoglycemia. Since many 
individuals living with type 1 diabetes avoid physical activity due to a fear of hypoglycemia 
(112, 113), a number of novel strategies to promote exercise and help to reduce the fear of 
hypoglycemia will be discussed throughout this dissertation.  
1.7 Glycemic management strategies during exercise in T1D 
As previously discussed, regular physical activity and exercise can improve a number of 
health outcomes in a dose-dependent manner for individuals living with type 1 diabetes. 
However, physical activity and exercise can also lead to large fluctuations in glycemia during 
activity. Therefore, one of the biggest challenges is managing optimal glycemic control, 
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specifically around exercise. There are a number of strategies that can help reduce these 
glycemic disturbances associated with exercise; however, no one strategy has proven to be 
entirely effective. Some of the most common strategies discussed in the literature include 1) 
basal insulin adjustments, 2) bolus insulin adjustments, 3) carbohydrate feeding, and 4) a 
combination of these strategies. These strategies are discussed in detail below. In this section, 
short duration generally refers to exercise < 40 minutes in length whereas more prolonged refers 
to activity that is > 40 minutes in duration.   
1.7.1 Basal insulin strategies 
Basal insulin adjustments vary slightly for individuals using MDI versus CSII treatment. 
For individuals using MDI, basal insulin adjustments can only be made when long-acting insulin 
is administered, often in the early morning or before bedtime. For individuals using CSII 
therapy; however, there is greater flexibility around the timing of basal insulin adjustments. 
Since basal insulin is infused in a small dose over 24 hours, the adjustments can be made any 
time of the day.  
Specifically in response to exercise, basal insulin adjustments can be made at the start of 
exercise, or several hours in advance of the activity. For patients using CSII, a basal-bolus 
reduction combination can be implemented in advance of exercise. Depending on the timing of 
exercise relative to meal ingestion, individuals can decide whether it is appropriate to adjust 
basal insulin, bolus insulin, or both. If individuals are exercising shortly after meal consumption 
(in the postprandial state), adjustments to bolus insulin can be made. Patients exercising in the 
post-absorptive state (often > three hours post-meal) often benefit from basal insulin adjustments 
because there is sufficient time to reduce circulating insulin levels (Figure 1.2). 
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Figure 1.2: Basal rate reduction (BRR) strategies during and post-exercise. 
Basal rate reductions (BRR) should made ~90 minutes before exercise and last until the end of 
exercise. Post-exercise, ~20% BRR are recommended at bedtime for six hours overnight to help 
combat nocturnal hypoglycemia. Published by Zaharieva & Riddell, Can J Diabetes 2017 (114). 
Reproduced with permission from the publisher. 
 
When physical activity and exercise is spontaneous or unplanned, basal rate reductions 
(BRR) can only be made at the start of activity and/or in recovery. For shorter duration (< 40 
minutes) aerobic exercise, studies have shown that BRR at exercise onset may decrease the 
likelihood of hypoglycemia during exercise (83, 115), but is still associated with a large drop in 
glycemia (116). In a more recent study, even with an 80% BRR set 40 minutes pre-exercise, 
hypoglycemia could not be reduced (117). Ideally, BRR should be set at least 60-90 minutes 
before the onset of exercise, in order for insulin concentrations to have time to drop in the 
circulation (13, 117). However, this type of BRR requires significant pre-planning and may not 
be feasible for many children or adolescents that more commonly engage in unplanned activity. 
Further research is required to understand whether this recommendation applies to all patients 
living with type 1 diabetes and whether this strategy is still effective with more prolonged 
aerobic activity. One of the concerns about reducing basal insulin well in advance of the exercise 
22 
is that blood glucose level may begin to rise before the exercise onset (118). Also, reducing basal 
insulin too far in advance of exercise may ultimately contribute to post-exercise rebound 
hyperglycemia.  
For resistance and circuit-based exercise, blood glucose concentrations tend to remain 
more stable than during aerobic exercise. Therefore, BRR for this type of exercise may not need 
to be as aggressive as those recommended for aerobic exercise. At rest, the time that it takes for 
insulin levels to drop in the circulation remains the same (119), therefore, reducing basal insulin 
would still be recommended 60-90 minutes before resistance and circuit-based exercise. In a 
study by Yardley et al. (120), patients using MDI therapy reduced basal insulin by 10% on 
exercise days and patients using CSII performed a 50% BRR 1 hour before exercise until the end 
of exercise and both groups found that blood glucose levels dropped more rapidly with aerobic 
compared to resistance exercise. However, these BRR strategies with resistance exercise may not 
be enough to protect from late-onset nocturnal hypoglycemia (120). Therefore, in addition to 
reducing basal insulin, mealtime bolus insulin reductions may also be required to better protect 
against hypoglycemia in recovery (see section 1.7.2 bolus insulin strategies). 
It is also important to consider BRR strategies that can protect against exercise-associated 
hypoglycemia in recovery and overnight. For example, since exercise increases insulin 
sensitivity (4) and studies have shown that this increase can last for up to 24 hours post-exercise 
(108), reducing basal insulin by 20% for 6 hours overnight can help protect against post-exercise 
nocturnal hypoglycemia (13). Table 1.2 represents various BRR strategies that individuals using 
CSII therapy may want to consider for both short duration and more prolonged activities, as well 
as post-exercise. 
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Table 1.2: Basal insulin adjustment strategies for CSII 
 Exercise 
(< 40 Minutes) 
Exercise 
(> 40 Minutes) After Exercise 
AEROBIC 
Light-to-moderate 
intensity continuous 
exercise 
50% BRR, set 60-90 
min pre-exercise) 
 
or 
 
Pump suspension at 
exercise onset* 
50-80% BRR set 60-
90 min pre-exercise) 
 
or 
 
Pump suspension at 
exercise onset* 
20% BRR overnight 
from bedtime lasting 6 
h 
RESISTANCE 
Moderate-to-
vigorous intensity 
No reduction typically 
performed 
50% BRR, set 60-90 
min pre-exercise) 
20% BRR overnight 
from bedtime for 6 h 
BRIEF INTENSE 
ANAEROBIC 
Maximal intensity 
Not applicable: Exercise typically lasts seconds 
to minutes 
No reduction typically 
performed † 
MIXED 
Low-to-moderate 
with intermittent 
moderate-to-
vigorous intensity 
bursts 
Pump suspension at 
exercise onset* 
50% BRR, set 60-90 
min pre-exercise)  
 
or 
 
Pump suspension at 
exercise onset* 
20% BRR overnight 
from bedtime for 6 h 
Notes: Suggested starting points for basal rate reductions (BRR) for various types and durations 
of exercise (not all recommendations have been formally tested). BRR are typically made when 
the exercise is in the fasted state or several (three or more hours) after a meal. For activities that 
occur soon after meals (within three hours), bolus insulin should be adjusted (see table 1.2 
above). Knowing the type of activity that is being performed will guide the basal rate 
adjustments, as described above. This summary table is based on studies conducted in type 1 
diabetes (83, 116, 117, 120-122). * = Carbohydrate may be required since insulin levels may not 
drop fast enough during the activity. † = Post-exercise hyperglycemia should be treated with a 
bolus insulin correction rather than a basal rate change. Adapted from Zaharieva & Riddell, Can 
J Diabetes 2017 (114). 
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1.7.2 Bolus insulin strategies 
 
Another strategy to reduce the likelihood of hypoglycemia during exercise is to reduce 
bolus insulin, often relative to mealtime. Generally, the best time to perform bolus adjustments 
would be when aerobic exercise is performed within 1-3 hours of a meal (114, 123). In order to 
effectively execute this strategy, knowledge about the timing, duration, and intensity of the 
activity and also some advanced planning are required. Moreover, in situations where physical 
activity is going to be performed more than three hours following a mealtime bolus, then bolus 
reductions are often unnecessary (Figure 1.3). 
 
 
Figure 1.3: Bolus insulin adjustment strategies for exercise. 
Strategies of bolus adjustments for exercise relative to meal ingestion. A, exercise occurring 
three or more hours post-meal, generally does not require a bolus adjustment. B, for exercise 
taking place 1-3 hours post-meal, generally, a 50% reduction in bolus insulin is required with the 
meal before exercise. These recommendations are applicable for aerobic exercise lasting > 40 
minutes. Published by Zaharieva & Riddell, Can J Diabetes 2017 (114), reproduced with 
permission from the publisher. 
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  When deciding on the appropriate bolus insulin adjustment necessary to maintain blood 
glucose concentration, the type, duration, and intensity of exercise being performed will impact 
the amplitude of change. For example, a larger mealtime bolus reduction is required with 
prolonged light-to-moderate intensity aerobic activities compared to intermittent high intensity 
exercise (13). This occurs because muscle glucose uptake exceeds glucose production by the 
liver and insulin levels do not drop during aerobic exercise (16). Intermittent high intensity 
exercise increases counterregulatory hormones (124, 125) and lactate concentration that 
stimulates gluconeogenesis and often cause increases in glucose concentration during and post-
exercise (125). Therefore, intermittent high intensity exercise is generally associated with lower 
hypoglycemia risk during and within two hours post-exercise, and typically requires a smaller 
bolus insulin reduction.  
In general, short duration aerobic exercises (< 40 minutes) require a 25-50% meal bolus 
reduction, whereas more prolonged aerobic activities (> 40 minutes) require a 50-75% bolus 
reduction at mealtime (123, 126, 127). Ultimately, a more aggressive reduction in bolus insulin 
and a delay in exercise start time can increase the risk of elevated blood glucose levels before 
exercise onset, but as long as some insulin is administered, ketone production does not appear to 
be significantly impacted (126, 128). Table 1.3 represents various bolus adjustment strategies 
relative to the intensity and duration of exercise and are based on previously published studies.  
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Table 1.3: Bolus insulin adjustments for post-prandial exercise 
 Meal Before Exercise Meal After 
Exercise Exercise 
(< 40 Minutes) 
Exercise 
(> 40 Minutes) 
AEROBIC 
Continuous steady 
state light-to-moderate 
intensity exercise 
25-50% bolus 
reduction 
50-75% bolus 
reduction 
25-50% bolus 
reduction 
RESISTANCE 
Moderate-to-vigorous 
intensity 
No reduction 
typically performed 
25-50% bolus 
reduction No change in bolus 
BRIEF INTENSE 
ANAEROBIC 
Maximal intensity 
Not applicable: Exercise typically lasts only a 
few minutes 
Small (~50%) bolus 
correction if 
hyperglycemic* 
MIXED 
Low-to-moderate with 
intermittent moderate-
to-vigorous intensity 
bursts 
~ 25% bolus 
reduction ~ 50% bolus reduction 
25-50% bolus 
reduction 
Notes: Suggested starting points for bolus insulin reductions for various types and durations of 
exercise (not all recommendations have been formally tested). These suggestions are for rapid-
acting insulin only. Bolus insulin adjustments are typically made when the exercise is performed 
within 1-3 hours following a meal. Knowing the type of activity that is being performed will 
guide the bolus insulin adjustments, as described above. This summary table is based on studies 
conducted on patients with type 1 diabetes using bolus adjustments (122, 123, 126, 129-132). * = 
Requires continued monitoring to help protect against post-exercise hypoglycemia, particularly 
overnight. Adapted from Zaharieva & Riddell, Can J Diabetes 2017 (114).  
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Research studies often focus on bolus insulin adjustment strategies for aerobic exercise 
since this particular type of activity increases the risk of hypoglycemia. Activities that are mixed 
in nature, which includes light-to-moderate intensity activities that are interspersed with 
intermittent, moderate-to-vigorous and vigorous-to-maximal intensity bursts, have a lower risk of 
hypoglycemia and therefore, may require a less aggressive insulin dose reduction with the meal 
preceding exercise (88). For moderate-intensity resistance exercise performed under fasting 
conditions in the morning, Turner et al. (132) found that the delivery of an individualized dose of 
rapid-acting insulin, based on the patient’s own insulin sensitivity index (i.e. a 50% correction 
factor), could reduce the likelihood of post-exercise hyperglycemia. This study is a good starting 
point to help reduce hyperglycemia following morning exercise, but further investigations are 
required for the delivery of rapid-acting insulin following resistance exercise. 
1.7.3 Carbohydrate feeding strategies  
 
Carbohydrate ingestion is often used as a treatment for hypoglycemia, but for the 
prevention of hypoglycemia during exercise, the exact timing and amount of carbohydrates 
remains unclear. In terms of prevention strategies for exercise-associated hypoglycemia, 
carbohydrate feeding often requires less pre-planning compared to basal and bolus adjustments 
and therefore may be more common than the two previously discussed strategies. 
Carbohydrate feeding to prevent hypoglycemia does not only depend on the intensity and 
duration of exercise (13, 133), but can also change depending on circulating insulin 
concentration. Specifically, in underinsulinized or low insulin conditions, fewer grams of 
carbohydrates are needed to prevent hypoglycemia compared to overinsulinized or high insulin 
conditions (13). In many cases, it is more beneficial for individuals with type 1 diabetes to begin 
exercising with lower circulating insulin concentrations and therefore, reduce the amount of 
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carbohydrate supplementation needed pre-exercise. Although this strategy may not always be 
feasible or preferred, it is important to attempt exercising with lower insulin in the circulation or 
‘on-board’, where applicable. Starting blood glucose levels pre-exercise are also a strong 
predictor for the amount of carbohydrate ingestion required to prevent hypoglycemia during 
exercise (81).   
1.7.4 Carbohydrate and insulin strategies combined 
 
Grimm et al. (134) showed that proper supplementation of carbohydrates or carbohydrate 
feeding and insulin adjustments for exercise are more effective at reducing hypoglycemia 
compared to insulin reduction strategies alone or no changes to insulin at all. This is likely 
because carbohydrate supplementation is easier to apply and requires less pre-planning compared 
to reducing basal insulin levels well before the start of exercise. When combining carbohydrate 
feeding and insulin adjustments, the recommendations also can change depending on the 
duration and type of exercise being performed.  
Taking into consideration starting blood glucose concentration at exercise onset and the 
approximate amount of circulating insulin, we created a schematic called the “Zone-Based 
Approach for Exercise” (Figure 1.4). This schematic shows that higher levels of insulin in the 
circulation at exercise start will require greater carbohydrate supplementation compared to low 
circulating insulin during exercise in order to prevent hypoglycemia (134).  
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Figure 1.4: ‘The Zone-Based Approach for Exercise’. 
Carbohydrate and insulin strategies for aerobic exercise based on starting blood glucose and 
relative circulating insulin levels. Zone 1 is suitable for prolonged aerobic exercise and for 
anaerobic and mixed exercise. Zone 2 is suitable for prolonged aerobic exercise but typically 
requires some carbohydrate feeding and/or basal insulin reductions if possible (patients using 
CSII only). Anaerobic and mixed exercise can be initiated. Zone 3 requires ketone monitoring 
before exercise and insulin administration if ketones are elevated above trace level. Exercise 
should be avoided until control is re-established. Zone 4 also requires ketone monitoring to 
confirm that ketones are low before start of moderate-intensity aerobic exercise. Zone 5 requires 
carbohydrate feeding before the start of exercise (~15–30 g, depending on the amount of insulin 
in the circulation). In all of these zones, close glucose monitoring is advised. CHO, carbohydrate. 
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Published by Zaharieva & Riddell, Can J Diabetes 2017 (114). Reproduced with permission 
from the publisher. 
Referring to Figure 1.4, Zone 1 occurs when the blood glucose level is in target range 
with low circulating insulin levels. This zone does not require significant carbohydrate feeding 
(< 0.5 grams per kilogram per hour of exercise) during aerobic exercise to maintain glycemia in 
target range. Zone 1 usually requires the reduction of basal insulin before exercise and limited 
carbohydrate consumption pre-exercise. Adolfsson et al. (135) suggests for prolonged aerobic 
exercise, higher carbohydrate intake may be preferred for performance reasons (up to 75 grams 
per hour) and in this case, insulin is typically required. If insulin is administered with high 
carbohydrate feeding, individuals will now be in Zone 2.  
Zone 2 is when blood glucose level is in target range with relatively high insulin levels in 
circulation. At the start of aerobic exercise, this is a common situation for patients who have not 
pre-planned by lowering basal insulin in advance of the activity. Because of the relatively high 
circulating insulin levels, blood glucose concentrations can be expected to drop shortly after 
exercise is initiated, and hypoglycemia risk will be high unless carbohydrates are consumed. By 
increasing carbohydrate intake [up to ~ 60 grams/hour (136)] to offset the increase in insulin 
sensitivity while also lowering basal insulin levels, blood glucose levels can still be maintained 
in a reasonable range during exercise.  
Zone 3 is when pre-exercise blood glucose level is elevated but patients have relatively 
low circulating insulin levels. In this situation, a small bolus insulin correction (i.e. 30%–50% of 
correction dose) may be required to treat hyperglycemia and limit ketone production before 
exercise.  
Zone 4 is when blood glucose level is elevated and patients have high circulating insulin. 
This situation may be caused by high carbohydrate intake pre-exercise relative to the insulin 
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dosage or from competition stress. In this setting, patients can begin mild to moderate aerobic 
exercise (~40%–60% maximal aerobic capacity), since blood glucose will likely drop during 
exercise. Patients receiving a CSII therapy have an advantage over those receiving MDI therapy 
with this zone-based approach, since the former group can observe the level of ‘on-board’ or 
‘active’ bolus insulin on the insulin pump device before starting exercise and can lower or 
suspend insulin delivery if blood glucose levels trend toward hypoglycemia during the activity.  
Zone 5 is when patients are already experiencing hypoglycemia ([blood glucose] < 3.9 
mmol/L) and often occurs if the insulin dose was miscalculated and exceeded the necessary 
amount for the carbohydrates consumed at the meal or snack before exercise. In this situation, 
exercise should be delayed until carbohydrate ingestion occurs (~20–30 grams) and/or basal 
insulin level is reduced (this applied to patients receiving CSII therapy only) in order to increase 
blood glucose level.  
1.7.5 Blood glucose estimations 
As we know, the type, intensity and duration of exercise can impact blood glucose 
concentration differently (13). Therefore, it is essential for patients with type 1 diabetes to know 
their blood glucose level, particularly before engaging in physical activity or exercise. Cox et al. 
(137) were the first to describe that estimating blood glucose fluctuations is not a fixed 
phenomenon, but varies across individuals. As such, throughout this thesis dissertation, we 
compared estimated versus measured blood glucose level, particularly during exercise. We 
blinded our participants to their measured blood glucose values and they were directed to 
estimate their glucose level at each SMBG measurement during exercise. If hypoglycemia 
occurred during exercise, the measured blood glucose value was immediately revealed to the 
participant and the exercise was suspended.  
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1.8 Technological advancements in T1D 
1.8.1 Continuous and Flash Glucose Monitoring 
Continuous glucose monitoring (CGM) devices often consist of a glucose sensor that is 
placed subcutaneous and is connected to a transmitter that can measure interstitial glucose levels 
every few minutes for approximately 7-10 days (41). These devices can report glucose values 
either in ‘real-time’ or they are ‘blinded’ and report data retrospectively. These ‘blinded’ devices 
are often called professional glucose-monitoring devices. Similar to the CGM, a flash glucose-
monitoring (FGM) device requires a remote ‘reader’ to be scanned over the monitor in order to 
report a glucose reading. Eversense® recently launched the first ever patented polymer 
technology glucose sensor that is implanted by a trained professional (138). This device uses an 
external transmitter that sits on top of the skin and continually measures interstitial glucose levels 
for up to 90 days. Table 1.4 outlines all of the current personal and professional glucose 
monitoring devices on the market to date.  
Pickup et al. (139) showed that in individuals with type 1 diabetes, CGM devices 
improve overall glycemic control compared to SMBG. Although frequent SMBG is an important 
tool for diabetes management and has been shown to lower HbA1c levels (140, 141), it cannot 
predict the impending rise and fall in glycemia or provide alerts which CGM devices are capable 
of doing (142). More importantly, with the use of CGM, studies have shown that following 
afternoon exercise, there is an increased risk of nocturnal hypoglycemia (116, 143) and this can 
last up to 24 hours post-exercise (144). As previously discussed, a number of studies have 
contributed to the recent recommendations of reducing basal insulin overnight to better protect 
against post-exercise nocturnal hypoglycemia (121, 122, 145).  
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Glucose-monitoring devices are robust research tools and are evolving into the standard 
of care for type 1 diabetes management (146). These devices should be used alongside HbA1c 
measures to improve glycemic control (41). As previously mentioned, GV and GMI are two 
measures that provide a more personalized profile of diabetes management using CGM. A 
mathematical calculation that measures the amplitude and timing of glucose excursions using 
CGM data is referred to as GV (42). In order to optimize glucose concentrations, there must be a 
reduction in GV and in turn, fewer episodes of hypoglycemia. As an additional measure of 
diabetes control, GMI can be calculated using CGM values from as little as 10-14 days to 
determine mean glucose and estimate HbA1c levels (43, 147).  
However, a primary concern regarding CGM and/or FGM use for patients with diabetes 
is that insurance companies and governments in most countries around the world do not offer 
cost reimbursement for these devices (148). Now that this technology is emerging as the standard 
of care for diabetes management (146), cost reduction and/or increased coverage nationwide is 
necessary.
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 PERSONAL 
INTERSTITIAL GLUCOSE-MONITORING DEVICES 
PROFESSIONAL  
INTERSTITIAL GLUCOSE-
MONITORING DEVICES 
Model 
Dexcom 
G4® or 
G5® 
Dexcom 
G6® 
Medtronic 
Guardian™ 
Link 
Medtronic 
Guardian™ 
Link 3 
Medtronic 
Guardian 
Connect 
Abbott 
FreeStyle 
Libre 
Eversense® 
Senseonics™ 
Dexcom 
G4® 
Platinum 
Medtronic 
iPro™ 2 
Freestyle 
Libre Pro 
Receiver 
Stand-
alone 
receiver or 
smart 
phone 
Stand-
alone 
receiver or 
smart 
phone 
Enlite 
sensor 
 
630G 
insulin 
pump 
Guardian 
sensor 3 
 
670G 
insulin 
pump 
Compatible 
smart 
phone 
Stand-alone 
“reader” Smart phone 
Stand-
alone 
receiver 
Enlite 
sensor 
Stand-
alone 
“reader” 
Sensor Life 7 days 10 days 7 days 7 days 7 days 14 days 90 days 7 days 7 days 14 days 
Warm-up 
Period 2 hours 2 hours 2 hours 2 hours 2 hours 1 hour 24 hours 2 hours 2 hours 1 hour 
Calibration 
At least 
every 12 
hours 
Factory 
calibrated 
At least 
every 12 
hours 
At least 
every 12 
hours 
At least 
every 12 
hours 
Factory 
calibrated 2x daily 
At least 
every 12 
hours 
At least 
every 12 
hours 
Factory 
calibrated 
Receiver 
Range 7m 7m 1.8m 1.8m 7m 
Scan reader 
(1.5” from 
sensor) 
7.6m 7m N/A 
Scan reader 
(1.5” from 
sensor) 
 
Table 1.4: Personal and professional glucose-monitoring devices. 
A comparison and description of different personal and professional (blinded) interstitial glucose-monitoring devices. Information 
includes the model, type of receiver, sensor life, warm-up period, calibration, and receiver range. Data retrieved from the following 
sources: (7, 149).   
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1.8.2 Closed-loop systems 
Closed-loop insulin delivery systems, sometimes referred to as artificial pancreas 
systems, combine insulin pump therapy and rtCGM with a control algorithm that automates 
insulin delivery depending on changes in sensor glucose levels (150). The rtCGM and control 
algorithm communicate with one another in order to compute the appropriate amount of insulin 
and/or glucagon that needs to be delivered every few minutes to the patient in order to maintain 
near-physiological glucose ranges (151). Closed-loop systems can refer to single-hormone 
(insulin only) or dual-hormone (insulin and glucagon) systems that automate the delivery of one, 
or both hormones in a glucose-responsive fashion. This advanced technology communicates 
directly to an insulin pump or to a separate smartphone device. A number of earlier randomized 
control trials showed that closed-loop systems significantly increased the percent time in target 
glucose range and also reduced the time spent in hypoglycaemia (152-154). Recently, closed-
loop studies have also showed improvements in overall glycemic control and decreases in HbA1c 
with safe, in-home studies lasting upwards of 3-6 months (155, 156). These studies were the 
foundation around the clinical importance of closed-loop systems in type 1 diabetes 
management. 
Because hypoglycemia is a prominent concern in patients living with type 1 diabetes, 
closed-loop studies focus on increasing time in range particularly overnight since during this 
time period, fewer variables (i.e. food, stress, exercise) impact glycemia. A number of studies 
showed improvements in glycemic management and reductions in nocturnal hypoglycemia with 
closed-loop systems, even with physical activity and exercise (157-160). Jacobs et al. (161) 
showed that with a dual-hormone closed-loop system that adjusted insulin and glucagon at 
exercise onset, hypoglycemia was significantly reduced compared to no adjustments.  
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In addition to fewer hypoglycemia events and overall improvements in HbA1c, the goal of 
closed-loop systems is to remove some of the patient load and pre-planning often associated with 
diabetes management. Recently, Adams et al. (162) investigated the impact of a closed-loop trial 
on psychosocial and human factors and found that participants’ management distress decreased, 
thereby showing that closed-loop systems provide promise for reducing the burden associated 
with diabetes control.  
1.9 Challenges with technology 
1.9.1 Challenges with CGM technology 
 Limitations in CGM technology are often related to a physiologic lag between sensor 
glucose and blood glucose concentration, estimated to range from a 7-8 minute delay in patients 
with type 1 diabetes in the fasting state (163). Physiologic delays in CGM can increase 
significantly with rapid changes in glycemia (7), such as during aerobic exercise and can differ 
depending on the CGM devices being used (164). The lag in sensor and blood glucose is often 
described in parts including (1) physiologic lag; (2) sensor reaction time; and (3) sensor signal 
processing time (7). Physiologic lag, sometimes referred to as equilibration time, is related to a 
time lag associated with the movement of glucose from the vascular to the interstitial fluid space 
in the subcutaneous adipose tissue (165). It takes time for the diffusion of glucose across 
capillary vessels and into the interstitial space (166). The sensor reaction time is the time it takes 
for glucose to diffuse into the sensor, which requires the collection and storage of data (167). 
This may also be related to delays in converting the voltage signal from the sensor to an estimate 
of blood glucose. And finally, sensor-processing time may lag because it incorporates a moving 
average filter to the data in order to smooth sensor glucose values (167). 
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With the use of technology, there is also a chance of user and/or measurement error in the 
devices themselves. The differences in CGM and blood glucose values may also be impacted by 
errors in the timing of CGM calibration or errors in the reference blood glucose measurement 
(167).  
1.9.2 Challenges with closed-loop technology 
Most of the challenges around closed-loop technology often occur in the daytime hours 
where factors such as the timing and type of food ingestion and/or exercise vary and can 
significantly impact glycemic control. Particularly challenging with meal ingestion and 
following insulin infusion is the delayed postprandial glucose response. To overcome these 
challenges, closed-loop systems in the present day are often referred to as ‘hybrid closed-loop’ 
systems because they are not all fully automated and some still require user input. For example, 
meal and/or exercise announcements are manually entered into the insulin pump (160). This user 
input allows the control algorithm to respond and make appropriate adjustments to insulin and/or 
glucagon before glycemic excursions occur. As previously discussed, depending on the intensity, 
type, and duration of exercise being performed, the energy utilization, glycemic responses, and 
ultimately insulin needs can vary as well. Therefore, closed-loop systems need to be able to 
assess the type of activity being performed in real-time (15) and the incorporation of wearable 
activity monitors has made this easier (168). Interestingly, Turksoy et al. (151) recently reported 
fewer hypoglycemia events during exercise with their control algorithm that requires no exercise 
announcements. However, in this study, glucose concentration still declined consistently during 
exercise and in recovery periods.   
There is still some debate whether single or dual hormone closed-loop systems are more 
safe and effective for preventing hypoglycemia, improving time in range, and reducing glucose 
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variability in patients living with type 1 diabetes. Some additional challenges with the dual-
hormone closed-loop system is the stability of glucagon once it has been reconstituted (150) and 
the potential side effects of chronic glucagon delivery that have yet to be assessed (169). More 
specifically, when glucagon is reconstituted in an aqueous solution, it is unstable and undergoes 
aggregation and rapid breakdown (170). Although glucagon is the primary treatment for 
emergency hypoglycemia because it works fast and effectively, following the reconstitution of 
the lyophilized powder, if kept in an aqueous solution over time, it begins to form firm gels that 
eventually can lead to a blockage in insulin pump infusion sites (171). As such, glucagon use in 
closed-loop systems remains a challenge and is currently limited to research studies with 
frequent replacements to prevent a blockage.  
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2.0 SUMMARY OF INTENT 
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2.1 Overall Research Objectives 
The studies presented in this thesis examined the impact of different insulin strategies on 
blood glucose during and after exercise in individuals living with type 1 diabetes. These research 
projects also investigated the accuracy and impact of glucose monitoring devices during exercise 
as well as the impact of exercise on interstitial glucose concentration overnight. The overall 
purpose of this thesis dissertation was to elucidate optimal strategies to reduce the likelihood of 
hypoglycemia during exercise and in recovery. 
2.2 Research Purpose 
1) To examine the effect of suspending basal insulin at the onset of continuous steady state 
moderate intensity aerobic exercise versus circuit-based exercise. In addition, to 
investigate whether participants would be able to accurately estimate their blood glucose 
level during both types of exercise (academic paper #1). 
2) To determine the impact of suspending basal insulin (i.e. ‘pump off’) at exercise onset 
versus administering a 50% basal insulin reduction (i.e. ‘pump on’) during intermittent 
high intensity exercise. Also, to examine whether participants would be able to accurately 
estimate their blood glucose level during both conditions (academic paper #2). 
3) To investigate whether 80% or 50% basal insulin reduction set 90 minutes pre-exercise 
would attenuate the drop in blood glucose concentration compared to basal insulin 
suspension at the onset of continuous steady state moderate intensity aerobic exercise. 
Also, to investigate how reducing basal insulin 90 minutes pre-exercise would impact 
glycemic control following the meal post-exercise (academic paper #3). 
4) To assess the accuracy of newer rtCGM technology versus SMBG levels during and after 
continuous steady state moderate intensity aerobic exercise (academic paper #4).  
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2.3 Research Hypotheses 
1) Suspending basal insulin at the onset of aerobic exercise would lead to a greater drop in 
glycemia compared to circuit exercise. Participants would be able to accurately estimate 
their blood glucose level during both types of exercise. 
2) Insulin ‘pump off’ at the onset of intermittent high intensity exercise would lead to a 
smaller drop in glycemia versus ‘pump on’ (at 50% of usual basal rate) during 
intermittent high intensity exercise and participants would be able to accurately estimate 
their blood glucose level during both conditions. 
3) Reducing basal insulin 90 minutes before aerobic exercise would attenuate the drop in 
glycemia versus suspension of basal insulin at the onset of exercise in type 1 diabetes. 
Reducing basal insulin 90 minutes pre-exercise would also lead to greater blood glucose 
excursions during the meal post-exercise. 
4) Real-time continuous glucose monitoring would underestimate the true drop in glycemia 
associated with aerobic exercise due to a time delay between blood and interstitial 
glucose level.  
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Abstract 
Aim: To examine whether suspending basal insulin at the onset of exercise can reduce 
the likelihood of hypoglycemia during 40 minutes of continuous (CON) steady state moderate 
intensity exercise versus circuit-based (CIRC) exercise. Also, to examine whether blood glucose 
(BG) estimations are accurate during CON vs. CIRC exercise. 
Methods: Twelve individuals (6 males, 6 females) with type 1 diabetes on insulin pump 
therapy were recruited for the study. All participants completed a maximal oxygen consumption 
(VO2max) test and two 40-minute sessions (consisting of either a continuous treadmill 
walking/light jogging or circuit workout). Basal insulin was stopped at the onset of both exercise 
modalities and resumed to the regular rate immediately post-exercise.  
Results: Relative VO2 (47.5 ± 7.5 vs. 54.5 ± 13.5 mL·kg·min-1, P = 0.03) and heart rate 
(122 ± 20 vs. 144 ± 20 beats per minute, P = 0.003) were lower with CON vs. CIRC exercise. A 
trial by time interaction (P = 0.001) shows significantly lower BG concentrations with CON 
compared to CIRC exercise. The overall drop in BG was greater in CON vs. CIRC exercise 
(delta -3.7 ± 1.5 vs. -1.3 ± 2.6 mmol·L-1). A group analysis indicated that participants frequently 
estimated their BG levels within 20% of the measured reference value with reasonable accuracy 
during both forms of exercise (71% vs. 63% with a mean bias of -0.1 ± 2.6 mmol/L [± 2 SD] vs. 
-0.1 ± 4.4 mmol/L for the CON versus CIRC conditions, respectively). Participants were able to 
estimate their BG levels more accurately during CON (r = 0.83) vs. CIRC exercise (r = 0.33) 
based on a regression analysis.  
Conclusion: Therefore, even with basal insulin suspension and lower exercise intensity, 
CON results in a larger drop in BG level compared with CIRC exercise. These findings may 
have implications for single hormone-based artificial pancreas development for exercise. 
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Suspension of insulin infusion at the onset of CON exercise may not be sufficient to prevent 
hypoglycemia. While this study does not negate the importance of frequent capillary BG 
monitoring during exercise, it does suggest that if persons are knowledgeable about their pre-
exercise BG level, they can exercise safely without the need for stopping to monitor over at least 
a 40-minute period of CON physical activity.  
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Introduction 
Regular physical activity (PA) is recommended for improving insulin sensitivity, blood 
lipid profiles and for reducing the risk of cardiovascular disease for individuals with type 1 
diabetes (T1D) (13). Aerobic exercise can increase the likelihood of hypoglycemia and may also 
lead to challenges in maintaining blood glucose (BG) control overall (172). Without insulin dose 
adjustments or carbohydrate intake, continuous steady state moderate intensity aerobic exercise 
(CON) typically leads to large reductions in BG level (81), whereas sprint-based exercise and 
intermittent high intensity circuit-based (CIRC) exercise either attenuates the decrease, or may 
even cause a small rise in BG level (124, 173, 174). While both CON and CIRC can lead to 
specific training adaptations, individuals with T1D would likely choose CIRC exercise for a 
variety of reasons, including enhanced fitness (175) without promoting nocturnal hypoglycemia 
(174). 
Tsalikian and colleagues (176) demonstrated that the risk of developing exercise-
associated hypoglycemia could be effectively reduced with the suspension of insulin infusion 
(i.e. pump suspend) in children on continuous subcutaneous insulin infusion (CSII) therapy. In 
contrast, Admon et al. (115) found that pump suspension did not attenuate the drop in glycemia 
compared to leaving the pump on with a reduced basal rate (i.e. 50%). In a more recent study, 
McAuley et al. (84) reported that a basal rate reduction of 50% performed 60 minutes prior to the 
start of exercise failed to cause a significant reduction in circulating insulin levels during 
exercise compared to baseline. In all of these studies, only one type of exercise was performed 
(i.e. CON). Therefore, further research is required on the impact of different types and intensities 
of exercise on BG levels.  
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Since exercise can increase the likelihood of glycemic disturbances in patients with T1D, 
it is important for frequent BG monitoring before, during, and after activity. A few studies have 
assessed the accuracy of estimating BG level versus measured BG level in individuals with T1D 
(137, 177); however, to our knowledge, no studies have assessed the accuracy of BG estimations 
specifically during exercise. In certain situations, capillary BG monitoring may be difficult 
during sport. As such, we need to better understand how exercise may impact the ability for 
patients to estimate their BG level. 
The primary purpose of this study was to examine the effects of basal insulin suspension 
at the onset of two different forms of exercise (i.e. CON versus CIRC). The secondary purpose 
was to assess the accuracy of BG estimation when participants were provided with their 
measured BG value 10 minutes prior to the onset of exercise. Our hypothesis was that 
suspending basal insulin at the onset of CON would lead to a greater drop in glycemia compared 
to CIRC because of the higher reliance on anaerobic metabolism in the later activity. We also 
hypothesized that participants could accurately estimate their BG concentration during both 
forms of exercise. 
Methods  
Study Participants 
The experimental protocol conformed to the standards set by the Declaration of Helsinki 
and is approved by the Research Ethics Board at York University. The study was registered at 
clinicaltrials.gov in 2017 (identifier: NCT03034798). Twelve participants with T1D were 
recruited for the study. All of the participants engaged in regular PA, including structured 
exercise and reported monitoring BG level regularly with capillary testing and a handheld 
glucose meter (four or more times per day). The inclusion criteria included the following: T1D 
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for > 1 year; on CSII for at least three months; at least in fair glycemic control (last HbA1c ≤ 
9.0% or 75 mmol·mol-1). Exclusion criteria included the following: frequent and unpredictable 
hypoglycemia; unable to exercise on a regular basis due to an injury; or having conditions that 
may make exercise unsafe (i.e. high blood pressure, late pregnancy, etc.). 
Experimental Design 
Participants completed a total of three exercise visits at the Human Performance 
Laboratory at York University. The first visit was for the determination of maximal oxygen 
consumption (VO2max) followed by two visits consisting of either CON or CIRC exercise, 
performed in random order. Participants were asked to avoid alcohol and caffeine consumption 
and refrain from all forms of vigorous exercise (i.e. activities > six metabolic equivalents) for 24 
hours prior to each visit. To accommodate participant scheduling, the experimental visits (CON 
and CIRC exercise) were conducted either in the late morning (~1100h, n = 6) or in the late 
afternoon (~1600h, n = 6). For each participant, the timing of both CON and CIRC visits were 
standardized to try and control for as many variables as possible (pre-exercise meal, time of day, 
and circulating insulin levels). Participants were asked to consume the same meal of their choice, 
at least four hours before coming to the laboratory, and take their regular insulin bolus for the 
meal before the exercise start time. Participants were asked to refrain from food or drink 
following their last meal before the exercise session, unless hypoglycemia developed (BG level < 
3.9 mmol·L-1). There were no reported incidents of hypoglycemia pre-exercise for CON and 
CIRC conditions and it was confirmed by examining the participants’ pump history that no 
additional insulin bolus was given after the last meal. This protocol ensured that participants 
arrived at the laboratory with little or no ‘on-board’ or active bolus insulin based on the 
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pharmacokinetics of their rapid acting insulin analog (119). Basal insulin rates were kept to the 
usual rate (100%) until the exercise start time.  
Fitness Assessment (Visit 1)     
During the initial visit, anthropometric measurements (height, body mass, and body fat 
percentage) were completed. Participants were screened for any cardiovascular complications 
using the Physical Activity Readiness Questionnaire for Everyone (PAR-Q+) (178). VO2max 
and peak heart rate (HR) were measured using an incremental-to-maximum effort treadmill 
protocol. Participants also completed a supramaximal workload with increasing incline to 
confirm the attainment of VO2max following a two-minute break (179). After the exercise, an 
enhanced EnliteTM sensor with iPro2 continuous glucose monitor (CGM) (retrospective, non 
real-time analysis) was placed on the abdomen using an EnliteTM Serter according to the 
manufacturer’s instructions (Medtronic MiniMed®, Northridge, CA). Participants wore the CGM 
for one week and were instructed to use the glucose meter provided (Contour® Next Link, 
Ascensia Diabetes Care) for self-monitoring of blood glucose (SMBG) throughout the study. 
Following an initial calibration one hour after sensor insertion, participants were advised to 
calibrate four times daily with no more than 12 hours in between each calibration. The timing of 
the CGM placement was at least 24 hours before exercise visits 2 and 3. If visit 3 was scheduled 
more than one week after the VO2max test, a new CGM was inserted at least 24 hours prior to 
the exercise visit. 
Exercise Sessions (Visits 2 and 3) 
Participants completed either 40 minutes of CON or CIRC in a randomized and 
counterbalanced design, with each visit separated by at least two days. Figure 3.1 represents a 
timeline and study design for both CON and CIRC visits. The CON visit consisted of treadmill 
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walking/light jogging at 40-50% of the participant’s pre-determined VO2max, while the CIRC 
visit included treadmill walking (four min); marching on the spot with dumbbells (45 sec); squats 
with front sweep (60 sec); four jumping jacks; quadruped (30 sec); two jumping jacks; four 
push-ups; prone forearm planks (20 sec); marching on the spot with dumbbells (30 sec); 
weighted ball lifts (60 sec); four push-ups; prone forearm plank (20 sec), cycling at a moderate 
workload (four min). This CIRC was performed three times (~13 min each time), lasting a total 
of 40 minutes (any time lost or gained by the participant doing the CIRC was made up for by 
varying the duration of cycling at the end of each CIRC.  
Participants were fitted with a disposable armband (MetriaTM IH1; Vancive, USA) that 
reports physical activity and energy expenditure throughout the study duration. For both CON 
and CIRC, basal insulin delivery was stopped at the onset of both exercise modalities (using the 
‘suspend insulin’ feature) and resumed to the usual rate immediately post-exercise, as is the 
customary approach by many patients who exercise regularly. Capillary BG level and lactate 
measurements were determined approximately every 10 minutes throughout exercise using a 
handheld glucose meter (Contour® Next Link, Ascensia, ON, Canada) and lactate analyzer 
(Scout+, EKF Diagnostics, Cardiff, UK), respectively. During CON and CIRC exercise visits, 
participants were told their measured BG value 10 minutes prior to the onset of exercise in both 
CON and CIRC visits and then they were blinded to their measured glucose meter values until 20 
minutes into recovery. Participants were asked to estimate their BG concentration at each 
measured glucose time point (i.e. every 10 minutes). The discrepancy between estimated and 
measured BG concentrations was assessed according to Clarke Error Grid analyses (180) (using 
measured and perceived BG level) and a modified Bland Altman plot (181) [(measured BG level 
– (estimated BG level)) / measured BG level]. If a participant developed hypoglycemia (whole 
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BG level of < 3.9 mmol·L-1), they were instructed to stop exercising (if it was during exercise) 
and 16 grams of oral dextrose (Dex4®, AMG, QC, Canada) was provided. 
Statistics  
 The BG measurements between CON and CIRC, as measured by the handheld glucose 
meter, were compared using two-way (time by trial) repeated measures ANOVA. Bonferroni 
post-hoc tests were used if significant interactions were found and statistical significance was set 
at P < 0.05, unless otherwise indicated. Participant anthropometric and descriptive characteristics 
were reported using mean and standard deviation. Paired t-tests were used to compare energy 
expenditure (in kilocalories or kcal) and percent of VO2max during CON and CIRC. A linear 
regression was used to compare the measured BG concentrations with perceived BG 
concentrations during CON and CIRC. The percent of time spent in different BG ranges (i.e. 
hypoglycemia, euglycemia, and hyperglycemia) 12 hours after CON and CIRC, as measured by 
CGM, were compared using the Mann–Whitney test for non-parametric statistics. For this 
analysis, euglycemia was defined by the iPro2 CGM as a BG concentration of 3.9–10.0 mmol·L-
1, hypoglycemia as < 3.9 mmol·L-1, and hyperglycemia as > 10.0 mmol·L-1. All statistical 
analyses were conducted using STATISTICA 7.0 (StatSoft, USA) and GraphPad Prism software 
(Version 7.0). Fingerstick capillary BG level was measured with the glucose meter and used as a 
reference to evaluate the accuracy of the EnliteTM/iPro2 CGM. The mean absolute relative 
difference (MARD) was calculated as the absolute relative difference between the glucose meter 
value and sensor value over the glucose meter value multiplied by 100. Paired t-tests were used 
to compare the absolute relative difference between CON and CIRC conditions pre-, during, and 
post-exercise. 
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Results 
Anthropometric measurements of all participants (6 males, 6 females) are shown in Table 
3.1. Most participants were young adults (mean age 32 ± 11 years [mean ± SD]), lean (body fat 
21.8 ± 9.4 %,) and in good glycemic control (HbA1c 7.0 ± 0.9 %). Disease duration ranged from 
2-43 years and total daily insulin dose averaged 39 ± 14 U in the group. Participants were using 
Medtronic® (n = 6), Animas® (n = 4), or OmniPod® (n = 2) insulin pumps. 
Both BG level (7.5 ± 2.6 to 9.9 ± 4.4 mmol·L-1) and lactate level (1.0 ± 0.3 to 13.2 ± 4.2 
mmol·L-1) increased from pre to post VO2max (P < 0.05 for both). Figure 3.2 shows the change 
in BG level from pre-exercise (-10 minutes) to recovery (+30 minutes) during both CON and 
CIRC visits. During the CIRC visit, pre-exercise BG level was 8.2 ± 0.4 mmol·L-1 (mean ± SD), 
dropping to 6.8 ± 0.6 mmol·L-1 by the end of the activity. During CON, the pre-exercise BG 
level was 9.5 ± 0.7 mmol·L-1, dropping to 5.7 ± 0.4 mmol·L-1 by the end of exercise. The drop 
during CON was greater than the drop during CIRC in 10 of the 12 participants (83%) and for 
the group as a whole (P < 0.05). Figure 3.3 represents the mean energy expenditure (in kcal) 
during CON and CIRC visits (panel a) and the percent of VO2max during CON and CIRC (panel 
b). On average, participants worked at a higher percent of their VO2max during CIRC compared 
to CON (P = 0.03) and tended to expend greater energy during CIRC than in CON (P = 0.07). 
Figure 3.4 shows the lactate concentrations before, during and immediately after exercise in both 
visits. Lactate concentrations were significantly higher during CIRC compared to CON (P = 
0.001 at t = 20 and t = 40, respectively). 
Figure 3.5 demonstrates the accuracy of perceived to measured BG concentration via 
Clarke Error Grids (a) and Bland-Altman plots (b) for the two exercise sessions. Table 3.2 
represents BG level estimations separated by zones A-
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and CIRC. These zones depict the likelihood of inappropriate treatment based on the perceived 
versus measured BG values.13 Based on regression analyses and our assessment using Clarke 
Error Grid analyses, participants were able to more accurately estimate their BG level throughout 
CON (r = 0.83) compared to CIRC (r = 0.33), although both conditions showed reasonably ‘safe’ 
BG level estimations overall, with 97% of the values within zones A and B of the Clarke Error 
Grid (Figure 3.5). Figure 3.6 (panel a) represents the 12 hour recovery CGM data following the 
CON and CIRC sessions (n = 8 only because of technical limitations in data capture from CGM) 
and (panel b) the percentage of time spent in each of the following zones: euglycemia (3.9-10.0 
mmol·L-1); hypoglycemia (< 3.9 mmol·L-1); and hyperglycemia (> 10.0 mmol·L-1). Compared to 
CIRC, CON elicited greater glucose variability and led to a higher percentage of time spent in 
hypoglycemia post-exercise (3% vs. 10% of the time in hypoglycemia, respectively), although 
not significantly different (P = 0.3). 
Table 3.3 shows the CGM sensor performance data during the CON and CIRC trials. 
Sensor performance was good overall, with MARD values all below 15% pre- during and post- 
exercise in both trials. However, during the exercise period itself, the MARD was significantly 
lower during CIRC versus CON (P = 0.03).  
Discussion 
It is recommended that basal insulin reductions be performed 60-90 minutes before 
exercise to allow for circulating insulin levels to drop by the onset of exercise (13, 14, 75). 
However, in reality, many individuals with T1D suspend basal insulin at the start of exercise 
with varying degrees of success for hypoglycemia prevention (182). This study demonstrates that 
with basal insulin suspension at the onset of exercise, the mean drop in BG level is greater during 
CON versus CIRC (P = 0.001), as seen in Figure 3.2. Similarly, Moser et al. (131) found that the 
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drop in BG level with intermittent high intensity exercise (IHE) was less than with CON exercise 
in MDI patients. Interestingly in our study, the energy expenditure (measured in kcal by the 
Metria IH1 armband) during exercise was similar between conditions (P = 0.07); however, the 
intensity of exercise, as measured by the percent of VO2max was slightly, but significantly 
greater in CIRC versus CON (P = 0.03, Figure 3.3). These findings suggest that basal insulin 
suspension at the onset of exercise is more protective against the drop in glycemia for mixed 
activities when compared to activities that are primarily aerobic in nature. These findings also 
reveal that CON is likely a more challenging form of exercise for the development of automated 
insulin delivery systems that rely on single hormone therapy and technologies that trigger 
changes in an algorithm at the time of exercise start (like HR or accelerometry) (183).  
We first performed a pilot study, in a subset of participants (n = 3), to determine if CON 
could be performed safely without any changes to the usual basal rate. All participants developed 
moderate hypoglycemia within 30 minutes of starting CON. Thus, for safety and ethical reasons, 
this arm of the intervention was eliminated. The failure to have data collected with ‘pump on’ for 
both CON and CIRC conditions limits our capacity to clearly demonstrate that ‘pump off’ 
reduces the risk of hypoglycemia compared to ‘pump on’. However, with this study design, it 
was still possible for us to determine if participants respond differently to CON versus CIRC 
with basal insulin suspension. Another limitation in our study is that we did not include plasma 
free insulin measurements and this information would have provided insight regarding the 
impact of basal insulin suspension at the start of two different forms of exercise. A number of 
groups have recently demonstrated that exercise increases circulating free insulin concentrations 
in patients on CSII when basal insulin rates are kept constant (82), lowered (84) or suspended 
altogether (83) before exercise start. It is likely that increases in adipose tissue blood flow with 
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exercise (184) may be facilitating tissue depot uptake of insulin, which may contribute to an 
increased risk for exercise-associated hypoglycemia. The greater drop in glycemia during CON 
versus CIRC is likely related to higher levels of counterregulatory hormones released and/or 
greater lactate production during CIRC (87).  
Al Khalifah and colleagues (185) showed that individuals with a good level of aerobic 
fitness (based on the norms for age and sex) are more susceptible to hypoglycemia during 
exercise, possibly due to their better insulin sensitivity and their higher work capacity. In our 
study, we terminated exercise on three occasions because of documented hypoglycemia (twice 
during CON; once during CIRC). However, one participant had a VO2max of 59.8 mL·kg·min-1 
and the other 39.7 mL·kg·min-1, so fitness level likely did not explain the incidence of 
hypoglycemia in our study.   
Due to the increased risk for exercise-associated dysglycaemia, the usual clinical 
recommendation is to increase the frequency of SMBG before, during, and following PA 
participation (186, 187). However, it can be difficult, or undesirable at times, to perform SMBG 
during exercise, especially in competition where the activity must be stopped in order to ‘test’. In 
fact, in activities such as swimming, cycling, and skydiving, it becomes incredibly challenging, 
and in some cases impossible, to test BG level frequently while exercising. Previous studies have 
assessed the accuracy of perceiving BG level in individuals with T1D (137, 177) but few have 
focused on exercise per se. Cox and colleagues (137) found that although BG level estimations 
were highly variable across participants, very few dangerous errors were made in estimating BG 
level. In another study that assessed the BG level estimation accuracy in adolescents, a poor 
correlation (r = 0.35) was found between measured and perceived BG level during 60 minutes of 
CON steady-state cycling exercise (188). In general, adolescents tended to underestimate their 
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own BG level when they were hyperglycemic and overestimate their own BG level when they 
were hypoglycemic during exercise. This phenomenon was also more apparent with CIRC in the 
present study (Figure 3.5). In the conditions of which our study was designed, the majority of 
participants were found to accurately estimate their own BG level during both forms of exercise 
when they were provided with a reference BG value 10 minutes before exercise. We also found 
that the accuracy of the BG level estimations was better during CON (r = 0.83) compared to 
CIRC (r = 0.33) (Figure 3.5). The reason for this difference is unclear, but may be attributed to 
the frequent variation in exercise intensities throughout the 40-minute CIRC session, which may 
mask the capacity to estimate BG level. Another limitation is that it is unclear how critical a 
reference value is for improving an individual’s estimations of BG concentrations during 
exercise. Future studies should include a subset of participants that are not provided with a 
reference BG value before exercise as a comparison, or perhaps a visit in which participants are 
blinded to their own pre-exercise BG level. 
Previous studies have investigated the accuracy of various CGM systems during IHE 
versus CON, although findings remain inconclusive (189-191). Bally et al. (190) found 
comparable CGM accuracy during IHE and CON whereas Moser and colleagues (189) revealed 
CGM overestimation during IHE. More recently, Taleb et al. (191) compared the performance of 
two current and widely used CGM systems (Dexcom G4® Platinum, Medtronic EnliteTM with 
MiniLink® transmitter) at rest and during exercise; finding that both products had lower 
performance during exercise compared to rest. Similarly in the present study, CON revealed 
lower performance in comparison to rest and recovery periods. The higher MARD during CON 
may be attributed to the more rapid drop in glycemia compared to CIRC (Table 3.3). However, 
based on the overall MARD values in our study, the enhanced EnliteTM/iPro2 CGM performance 
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appears more accurate than the real-time CGM systems used in the previous study (191). The 
limitation with iPro2 CGM, however, is that glucose values are not reported in real-time and as 
such can only be used for retrospective analysis.           
Numerous studies have demonstrated delayed hypoglycemia post exercise, typically 
occurring from 8-12 hours in recovery from prolonged activity (120, 121, 126, 192, 193). 
Similarly in our study, 12 hours post-exercise, the percent of time spent in hypoglycemia 
(defined as a sensor glucose < 3.9 mmol·L-1) was slightly higher following CON (10%) versus 
CIRC (3%) (P = 0.3; Figure 3.6 b). Some common suggestions to help reduce nocturnal 
hypoglycemia include reducing basal insulin rates overnight, reducing fast-acting insulin with 
the evening meal, and/or consuming low glycemic index food at bedtime, although further 
research in this area is required (192).  
In conclusion, basal insulin suspension at the onset of exercise leads to a greater drop in 
glycemia during CON versus CIRC. CON also modestly increased the percent of time spent in 
hypoglycemia 12 hours following exercise. More effective strategies are needed to reduce the 
barriers associated with exercise such as the fear of hypoglycemia (113). In addition, the type of 
exercise performed may also impact an individual’s estimations of their BG level. Following a 
baseline glucose meter reading, estimating BG level during exercise should be done with 
caution, particularly in those individuals with hypoglycemia unawareness. Both frequent SMBG 
and CGM use for exercise are highly recommended for active individuals with T1D to increase 
safety and to help with decision support from healthcare providers (13). Based on our findings 
that circuit-based exercise deteriorates BG level estimations compared to continuous, moderate-
intensity aerobic exercise, this study supports the need for increased vigilance around monitoring 
BG levels during activities that are interspersed with frequent variation in exercise intensities. 
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Table 3.1: Individual anthropometric and clinical characteristics 
 
 
Subject ID 
 
Age 
(Yrs) 
 
Sex 
(M/F) 
 
Height 
(cm) 
 
Body 
Mass 
(kgs) 
 
Diabetes 
Duration 
(Yrs) 
 
TDD 
(Units) 
 
Basal 
Insulin 
(%) 
 
Body 
Fat 
(%) 
 
 
VO2max 
(mL/kg/min) 
 
 
 
HR 
Peak 
(bpm) 
 
HbA1c 
(%) 
1 35 M 174 80.5 12 50 37 22.0 49.9 203 7.9 
2 34 F 182 78.0 31 46 57 27.9 37.9 195 7.7 
3 27 F 167 70.0 19 35 49 29.4 41.6 199 7.1 
4 49 M 184 75.1 35 24 71 16.6 47.7 188 7.4 
5 19 M 177 72.7 5 50 35 11.3 65.0 201 6.8 
6 44 M 173 72.8 41 23 38 8.3 59.8 175 5.5 
7 26 F 170 75.6 9 47 49 34.6 35.6 189 8.0 
8 19 M 187 74.6 7 48 42 9.8 74.5 200 6.9 
9 24 M 183 78.0 14 65 55 14.5 56.7 208 8.2 
10 53 F 156 56.6 3 23 42 30.8 42.7 160 5.9 
11 24 F 170 75.1 2 29 37 31.3 40.5 184 6.2 
12 31 F 165 65.3 3 25 46 25.6 39.7 174 6.1 
Mean ± SD 32 ± 11 M = 6 F = 6 175 ± 9.1 72.9 ± 6.5 16 ± 13 39 ± 14 47 ± 11 21.8 ± 9.4 50.1 ± 13.7 191 ± 14 7.0 ± 0.9 
 
        Note: HR, heart rate; TDD, total daily insulin dose; VO2max, maximal oxygen consumption.  
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Table 3.2: Clarke error grid analyses 
 
 
Zones 
 
CON Exercise 
 
 
 CIRC Exercise 
A 50/70 (71%) 44/70 (63%) 
B 18/70 (26%) 24/70 (34%) 
C 0/70 (0%) 1/70 (1%) 
D 2/70 (3%) 0/70 (0%) 
E 0/70 (0%) 1/70 (1%) 
 
Note: Clarke Error Grid zones A–E during CON versus CIRC exercise. Zone A, values within 
20% of the measured BG (CON 71%, CIRC 63%); Zone B, points are outside of 20%, but would 
not lead to inappropriate treatment (CON 26%, CIRC 34%); Zone C, points leading to 
unnecessary treatment (CON 0%, CIRC 1%); Zone D, points indicate potentially dangerous 
failure to detect hypo- or hyperglycemia (CON 3%, CIRC 0%); Zone E, points that would 
confuse treatment of hypo- for hyperglycemia and vice versa (CON 0%, CIRC 1%).  
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Table 3.3: Sensor performance data: pre-, during, and post-exercise 
 CON Exercise CIRC Exercise P Value 
Pre-Exercise 
MARD (%) 9.86 ± 0.08 8.15 ± 0.07 0.37 
During Exercise 
MARD (%) 
12.00 ± 0.12 6.96 ± 0.06   0.03 * 
Post-Exercise 
MARD (%) 10.44 ± 0.10 10.02 ± 0.14 0.89 
 
Note: MARD, mean absolute relative difference expressed as a percentage (%) ± SD,  
*P < 0.05.   
  
63 
 
 
Figure 3.1: Timeline for CON and CIRC exercise sessions. 
Both of the exercise sessions were conducted at either 1100 or 1600 h depending on participant 
availability (this was consistent for each individual). Basal insulin was suspended at the onset of 
both CON and CIRC exercise conditions and resumed to the normal rate immediately post-
exercise (n = 12). *Arrival to laboratory.  
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Figure 3.2: Relative change in BG concentration with exercise. 
Data represents CIRC (circle) and CON exercise (triangle) pre-, during, and post-exercise. 
Hashed box represents the exercise session (40-min). Data are expressed relative to the BG level 
at the onset of exercise (time = 0). Data are expressed as mean ± SD, n = 12.  
* denotes significance of P < 0.05.  
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Figure 3.3: Energy expenditure and percent of VO2max. 
(a) Energy expenditure in kilocalories (kcal) during CIRC and CON exercise sessions and (b) the 
percent of VO2max during CON and CIRC exercise (n = 12). Data are expressed as mean ± SD, 
n = 12. * denotes significance of P < 0.05. 
  
66 
 
 
Figure 3.4: Lactate concentrations during exercise (mmol/L). 
Data represents lactate level at the start (t = 0), middle (t = 20 min), and end (t = 40 min) of 
exercise during both CIRC and CON conditions (n = 11). Data are expressed as mean ± SD, n = 
12. * denotes significance of P < 0.05. 
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Figure 3.5: Clarke error grids and Bland-Altman plots. 
(a) Clarke Error Grids comparing measured BG concentrations with perceived BG concentration 
during CON exercise (green triangles) and CIRC exercise (blue circles). The BG values are 
separated into zones A–E that represent the clinical implications of estimation errors. (b) Bland–
Altman plots comparing the difference between measured and perceived BG values within two 
standard deviations. A BG measurement was taken 10-min before the onset of exercise and 
participants used this value as a reference during exercise. In general, participants could 
accurately estimate their BG level during exercise, particularly during CON exercise. During 
CON exercise, the best-fit y-intercept was 1.97 – 0.44 mmol/L and CIRC exercise y-intercept 
was 4.20 – 0.95 mmol/L (P < 0.05).  
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Figure 3.6: Interstitial glucose and percent time in range. 
(a) Twelve-hour recovery CGM glycemia following CON (light shade) and CIRC exercise (dark 
shade). Data represent mean ± SD of 12 hours post-exercise from 1200–0000 or 1800–0600h. (b) 
Percent time spent in hypoglycemia, euglycemia, and hyperglycemia following CON versus 
CIRC exercise sessions (n = 8). CGM, continuous glucose monitor. 
  
69 
 
 
4.0 ACADEMIC PAPER 2 
 
 
No disadvantage to ‘pump off’ versus ‘pump on’ during 
intermittent high intensity exercise and recovery in adults with type 
1 diabetes. 
 
 
In preparation for submission to Canadian Journal of Diabetes, 2018 
  
70 
No disadvantage to insulin ‘pump off’ versus ‘pump on’ during intermittent high intensity 
exercise and recovery in adults with type 1 diabetes. 
 
Short title: Insulin ‘pump on’ versus ‘pump off’ during exercise 
 
Dessi P. Zaharieva MSc a, Ali Cinar PhD b, c, Loren Yavelberg MSc a, Veronica Jamnik PhD a, 
and Michael C. Riddell PhD a, d  
 
a – School of Kinesiology & Health Science, Faculty of Health, Muscle Health Research Centre and 
Physical Activity & Chronic Disease Unit, York University, Toronto, ON  
b  – Department of Biomedical Engineering, Illinois Institute of Technology, Chicago, IL 
c – Department of Chemical & Biological Engineering, Illinois Institute of Technology, Chicago, IL 
d – LMC Diabetes & Endocrinology, Toronto, ON 
 
Correspondence to: 
Dr. Michael Riddell, Ph.D. 
School of Kinesiology and Health Science 
York University 
4700 Keele Street, Toronto, ON, M3J 1P3 
 
 
 
Keywords: Hypoglycemia, Exercise, Insulin Pump, Continuous Glucose Monitoring 
71 
Abstract 
Background: A common strategy to reduce the risk of hypoglycemia during aerobic 
exercise in patients with type 1 diabetes is to decrease or suspend insulin delivery using 
continuous subcutaneous insulin infusion (CSII) pump therapy. Insulin ‘pump on’ has been 
compared to ‘pump off’ during prolonged walking in adolescents with type 1 diabetes, with 
some efficacy observed with ‘pump off’, although some patients developed post-exercise 
hyperglycemia. Intermittent high intensity exercise typically does not result in hypoglycemia in 
patients with type 1 diabetes and may result in post-exercise hyperglycemia. The effect of ‘pump 
on’ vs. ‘pump off’ during intermittent high intensity exercise is unclear. The goal of this study 
was to compare the impact of ‘pump on’ vs. ‘pump off’ on blood glucose concentration during 
an intermittent high intensity bout of exercise.  
Methods: Twelve adults (six females) with type 1 diabetes using CSII and in good 
metabolic control (HbA1c = 7.0 ± 0.9%) were recruited for the study. Participants completed a 
maximal aerobic capacity test, followed by two intermittent high intensity exercise bouts that 
were 40 minutes in duration. The two insulin adjustment strategies included 1) insulin pump set 
to 50% of the usual basal insulin (‘pump on’) or 2) insulin suspended (‘pump off’) for the 
duration of exercise, in random order. Blood glucose measurements were recorded every 10 min 
and after providing subjects with an initial reference glucose value, participants were blinded to 
their glucose and asked to estimate their levels during exercise.  
Results: There were no differences in the oxygen consumption, heart rate, or energy 
expenditure between ‘pump on’ vs. ‘pump off’ (P > 0.05). Blood glucose levels were higher in 
‘pump off’ (146 ± 22 mg/dL) vs. ‘pump on’ (133 ± 38 mg/dL) at exercise start (P < 0.05) but by 
the end of exercise, glucose levels were similar in ‘pump off’ (118 ± 36 mg/dL) vs. ‘pump on’ 
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(120 ± 46 mg/dL) (P = 0.9). Based on a regression analysis, participants were able to estimate 
glucose levels more accurately during ‘pump on’ (r2 = 0.46) vs. ‘pump off’ (r2 = 0.11). Overall, 
the percent time in hypoglycemia 12h post-exercise was slightly higher following ‘pump on’ (5 ± 
8%) compared to ‘pump off’ (1 ± 2%), but not significantly different (P = 0.3). 
Conclusion: During intermittent high intensity exercise, we found no advantage or 
disadvantage of ‘pump on’ vs. ‘pump off’ on glycemia. In summary, intermittent high intensity 
exercise can be performed with insulin ‘pump on’ or ‘pump off’ with no noticeable effect on 
glycemia during the activity. However, ‘pump on’ during intermittent high intensity exercise 
may increase the risk for late-onset hypoglycemia post-exercise.  
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Introduction 
Intermittent high intensity exercise is thought to cause less of a decline in blood glucose 
concentration compared to aerobic exercise in patients living with type 1 diabetes because of the 
increase in hepatic glucose production that is stimulated by counterregulatory hormones (25). 
Therefore, hypoglycemia is generally more likely to occur during continuous steady state aerobic 
exercise as compared to intermittent high intensity exercise (116, 124). Similarly, a number of 
studies have demonstrated that during intermittent high intensity exercise, a decline in blood 
glucose concentration does still occur, particularly if the activity is performed in a non-fasted 
state when insulin levels may be significantly elevated (124, 174, 193, 194). As such, guidelines 
often recommend reducing basal insulin rates 60-90 minutes before any form of exercise 
(continuous steady state aerobic or intermittent high intensity exercise) that is performed for 
more than 30 minutes to better protect against the likelihood of hypoglycemia (13, 14).  
Particularly with unplanned exercise where basal or bolus insulin adjustments cannot be 
made in advance of the activity, the options during exercise are limited to 1) additional 
carbohydrate ingestion and/or 2) basal insulin reduction at exercise onset. The Diabetes Research 
in Children Network (DirecNet) study group found that discontinuing basal insulin infusion (i.e. 
‘pump off’) during 60 minutes of walking/light jogging is an effective strategy for reducing 
hypoglycemia in children with type 1 diabetes, but the risk of hyperglycemia is increased (176). 
Admon et al. (115) also compared ‘pump on’ (with a 50% basal rate reduction) versus ‘pump 
off’ during 40-45 minutes of unplanned continuous steady state submaximal cycling (at ~60% of 
VO2max) in adolescents with type 1 diabetes and found that leaving the insulin ‘pump on’ had 
no advantage or disadvantage on glycemia during the activity, but resulted in an increased risk 
for late-onset hypoglycemia post-exercise. Whether ‘pump on’ versus ‘pump off’ impacts 
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glycemia during or after intermittent high intensity exercise in adults is unclear. Although the 
drop in glycemia does not appear to be as significant with intermittent high intensity or mixed 
exercise compared to aerobic exercise, some research suggests that it can increase the risk of 
delayed, nocturnal hypoglycemia (193, 195), while other studies have found no increased risk of 
nocturnal hypoglycemia (88, 116, 174, 196).  
The primary purpose of this study was to determine the impact of 1) a 50% basal insulin 
rate (‘pump on’) versus 2) insulin pump suspension (‘pump off’) during 40 minutes of 
intermittent high intensity exercise in adults living with type 1 diabetes. The secondary outcomes 
were to evaluate the accuracy of estimating blood glucose level when participants were provided 
with their measured (actual) blood glucose value 10 minutes pre-exercise and to determine 
whether ‘pump on’ versus ‘pump off’ impacts nocturnal glycemia.  
Methods 
Study Participants 
This study was approved by the Research Ethics Board at York University and was 
registered at clinicaltrials.gov in 2017 (identifier: NCT03034798). The ‘pump off’ arm of this 
study was previously published and includes the same set of participants (116). A total of twelve 
individuals (6 male, 6 female) with type 1 diabetes were recruited. All participants were on 
continuous subcutaneous insulin infusion (CSII) therapy for at least three months; in fair 
glycemic control (last HbA1c ≤ 9.0% or 75 mmol/mol) engaged in regular physical activity 
participation, and reported monitoring blood glucose levels regularly using a handheld glucose 
meter (four or more times per day). Exclusion criteria included frequent and unpredictable 
hypoglycemia, unable to exercise on a regular basis due to an injury, or having conditions that 
may make exercise unsafe (i.e. high blood pressure, late pregnancy, etc.). 
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Experimental Design 
This study was a randomized crossover design that included a total of three visits in the 
Human Performance Laboratory at York University. During the initial visit, anthropometric data 
(age, height, body mass, body fat percentage, waist circumference, and blood pressure) was 
collected followed by a maximal oxygen consumption (VO2max) test. Using an incremental-to-
maximum effort treadmill protocol, VO2max and peak heart rate were measured followed by a 
two-minute break and a supramaximal workload with increasing incline to confirm the 
attainment of VO2max (179). All participants were asked to avoid alcohol and caffeine 
consumption and refrain from all forms of vigorous exercise (i.e. activities > six metabolic 
equivalents) for 24-hours prior to each study visit. The Physical Activity Readiness 
Questionnaire for Everyone (PAR-Q+) was used to screen participants for any complications 
(178).  
Following the VO2max test, participants were fitted with a professional (retrospective, 
non real-time) continuous glucose monitor (CGM; iProTM2, Medtronic, MiniMed®, Northridge, 
CA) and an EnliteTM sensor placed on the abdomen according to the manufacturer’s 
recommendations. Participants wore the CGM for one week and were instructed to use the 
glucose meter provided (Contour® Next Link, Ascensia Diabetes Care, Parsippany, NJ) for self-
monitoring of blood glucose (SMBG) throughout the study. The CGM was placed 
subcutaneously at least 24 hours prior to exercise visits 2 and 3.  
To accommodate participant availability, the experimental visits were completed in the 
late morning (~1100h, n=6) or in the late afternoon (~1600h, n=6) and were kept consistent for 
each participant for the two experimental visits (i.e. pump on versus pump off, see below). 
Participants were asked to consume the same pre-exercise meal, of their choice, and take their 
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usual bolus insulin for the meal at least four hours before arriving to the laboratory to ensure 
little or no active bolus insulin at exercise onset. Participants were also asked to refrain from 
additional food consumption following their last meal before exercise, unless hypoglycemia 
developed ([blood glucose] < 70 mg·dL-1). If hypoglycemia developed prior to exercise, study 
participants were instructed to treat with 16 grams of dextrose (Dex4®, AMG Medical Inc., QC) 
and continue to monitor their own glucose. 
All study visits were separated by at least 24 hours between experimental visits. 
Participants wore a disposable armband (MetriaTM IH1; Vancive, USA) to measure physical 
activity and energy expenditure throughout the study. The experimental visits consisted of an 
intermittent high intensity circuit exercise session of treadmill walking (four min); marching on 
the spot with dumbbells (45 sec); squats with front sweep (60 sec); four jumping jacks; 
quadruped (30 sec); two jumping jacks; four push-ups; prone forearm planks (20 sec); marching 
on the spot with dumbbells (30 sec); weighted ball lifts (60 sec); four push-ups; prone forearm 
plank (20 sec), and cycling at a moderate intensity workload (four min). The individual circuit 
(~13 minutes in duration) was then repeated three times in order to achieve a total duration of 40 
minutes of exercise. In recovery, participants remained seated in a chair for 30 minutes and 
blood glucose concentration were determined using SMBG at 20 minutes and 30 minutes post-
exercise before being sent home. For both experimental visits, participants were asked to 
consume a similar meal of their choice and take their usual bolus insulin for the meal. 
Basal Insulin Adjustments 
Basal insulin rates were kept at the patients’ usual rate (i.e. 100%) until exercise start 
time. Participants completed 40 minutes of intermittent high intensity exercise with either a) 
insulin pump suspended (pump off) or with b) basal insulin reduced by 50% at the onset of 
77 
exercise (pump on), in a randomized and counterbalanced fashion. In all experimental 
conditions, the basal insulin rate was resumed to the usual rate (i.e. 100%) immediately post-
exercise. Fingerstick capillary blood glucose measurements were determined every 10 minutes 
throughout exercise using a handheld glucose meter (Contour® Next Link, Ascensia Diabetes 
Care, ON). If hypoglycemia ([blood glucose] < 70 mg·dL-1) developed during activity, the 
exercise was terminated immediately and participants were asked to ingest 16 grams of oral 
dextrose (Dex4®, AMG Medical Inc., QC). If blood glucose level did not rise above the 
hypoglycemic threshold by 15 minutes following dextrose treatment, this procedure was repeated 
until the individual’s glucose level was restored. Lactate concentrations were also measured pre-
exercise, during, and immediately post-exercise using a fingerstick blood sample and lactate 
analyzer (Scout+, EKF Diagnostics, Cardiff, UK). 
Blood Glucose Estimations 
For both experimental visits, capillary blood glucose level was measured 10 minutes pre-
exercise and revealed to the participant. During exercise, participants were blinded to their 
measured blood glucose values and directed to estimate their glucose levels for each 
measurement (every 10 minutes of exercise). If hypoglycemia occurred during exercise, the 
measured blood glucose value was immediately revealed to the participant and the exercise was 
terminated. The discrepancy between estimated and measured glucose was assessed using a 
Clarke Error Grid (180) (using measured and estimated blood glucose levels) and a modified 
Bland Altman plot (181) [(measured blood glucose – (estimated blood glucose)) / measured 
blood glucose].  
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Statistics 
 Two-way repeated measures ANOVA were used to compare blood glucose levels and 
lactate concentrations between the pump on and pump off conditions. If hypoglycemia 
developed at any point during exercise, the lowest glucose value was carried out until the end of 
exercise for statistical analysis. A paired t-test was used to compare relative VO2, heart rate, and 
energy expenditure between pump on and pump off conditions. The 12-hour recovery CGM data 
is represented as median and interquartile range (IQR). Using CGM analyses, the percent time 
spent in euglycemia (70-180 mg/dL), hypoglycemia (< 70 mg/dL), and hyperglycemia (> 180 
mg/dL) was compared between both treatment arms in the 12 hours following exercise. 
Significant differences in the percent time in euglycemia, hyperglycemia, and hypoglycemia 
were compared using a Wilcoxon non-parametric test. All statistical analyses and graphs were 
generated using GraphPad Prism Version 7.0 (GraphPad Software, CA). All statistical 
significance was set a priori to P < 0.05 for all tests and data are shown as mean ± standard 
deviation (SD). 
Results 
All participants in this study were adults (32 ± 11 years of age), using insulin pump 
therapy (basal insulin 47 ± 11%), taking either insulin Lispro (Humalog®, Eli Lilly, Indianapolis, 
IN n=2) or insulin Aspart (NovoRapid®, Novo Nordisk, Bagsværd, Denmark, n=10), with a total 
daily insulin dose of 39 ± 14 units (0.5 ± 0.17 units/kg). Diabetes duration was 16 ± 13 years and 
HbA1c was 7.0 ± 0.9% (53 ± 10 mmol/mol). Participants had an average VO2max of 50.1 ± 13.7 
mL·kg·min-1 (range: 35.6 to 75.1 mL·kg·min-1) with a peak heart rate of 191 ± 14 beats per 
minute. Participants’ self-reported physical activity levels ranged from moderate-to-highly 
active.  
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 Figure 4.1A represents the absolute blood glucose concentration from 10 minutes pre-
exercise until 30 minutes post-exercise and there were no significant differences in glycemia 
during exercise across both conditions (P > 0.05). Hypoglycemia occurred in 1 of 12 participants 
(8%) during exercise for both ‘pump on’ and ‘pump off’ conditions. Figure 4.1B represents the 
relative change in blood glucose concentration from baseline until 30 minutes post-exercise in 
both conditions. When the data was normalized to baseline glucose (t = 0), the relative drop in 
glycemia was less in the ‘pump on’ versus ‘pump off’ condition from 20 minutes of exercise 
until 30 minutes into recovery (P < 0.05). 
Figure 4.2A represents the mean energy expenditure expressed in kilocalories (kcals), 
while Figure 4.2B shows the relative work intensity expressed as a percent of VO2max, during 
the two experimental sessions. The relative VO2 was 55 ± 13% versus 55 ± 10% (P = 0.6) and 
the estimated energy expenditure during the 40-minute exercise bout was 376 ± 52 kcal versus 
363 ± 61 kcal (P = 0.6) in ‘pump on’ and ‘pump off’ arms, respectively.  
Figure 4.3 represents the lactate concentrations pre-exercise, in the middle of exercise, 
and immediately post-exercise for both treatment conditions. There was a significant increase in 
lactate levels from the start to the end of exercise (P < 0.05), but there was no difference between 
conditions.   
Figure 4.4A represents a Clarke error grid comparing the measured blood glucose versus 
estimated glucose concentration during pump on and pump off exercise arms. Based on the 
regression analysis for the Clarke Error Grid, participants were able to more accurately estimate 
their blood glucose concentration during the ‘pump on’ condition (r2 = 0.46) compared to ‘pump 
off’ (r2 = 0.11) condition. Figure 4.4B represents the Bland-Altman plots for measured versus 
perceived glucose levels during both ‘pump on’ and ‘pump off’ exercise conditions. With ‘pump 
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on’ during exercise, there was a positive bias (18 ± 56 mg/dL) and therefore, on average, the 
measured blood glucose level was higher than the perceived blood glucose level of patients (P = 
0.01). However, there was no significant bias with ‘pump off’ during exercise (2 ± 71 mg/dL). 
 Table 4.1 demonstrates the blood glucose concentration (estimated versus measured) as a 
percent of time spent in each zone (A–E) of the Clarke Error Grid during ‘pump on’ and ‘pump 
off’ conditions. These zones describe the likelihood of inappropriate treatment based on the 
estimated glucose values using measured blood glucose values as the reference (180). Based on 
the Clarke error grid analysis, participants tended to be more accurate at estimating blood 
glucose concentrations during exercise with ‘pump off’ compared to ‘pump on’ (97% vs. 91% of 
values in zones A and B; P = 0.05, Chi-square).    
Figure 4.5A demonstrates the interstitial glucose 12-hour recovery data from 1200–0000h 
or 1800–0600h for ‘pump on’ and ‘pump off’ exercise sessions. Due to technical issues with the 
data upload of multiple CGM devices, the 12-hour recovery data represents only a subset of 
study participants (n = 7). The CGM values reported as mean ± SD (median, IQR) were 158 ± 54 
(157, 109-200) mg/dL and 145 ± 32 (144, 111-178) mg/dL in the ‘pump on’ and ‘pump off’ 
conditions, respectively (P = 0.4). Figure 4.5B represents the percent time spent in euglycemia 
(70-180 mg/dL), hyperglycemia (> 180 mg/dL), and hypoglycemia (< 70 mg/dL) in the 12 hours 
following exercise across both conditions. The mean percent time spent in euglycemia during the 
12-hour recovery period was 61 ± 32% in the ‘pump on’ condition versus 72 ± 16% in the ‘pump 
off’ condition (P = 0.3). The average percent time spent in hyperglycemia was 34 ± 35% versus 
27 ± 16% in the ‘pump on’ compared to ‘pump off’ treatment arms (P = 0.7). The percent time 
spent in hypoglycemia was slightly higher following ‘pump on’ (5 ± 8%) compared to ‘pump 
off’ (1 ± 2%), but this difference was not statistically significant (P = 0.3).    
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Discussion 
 For patients with type 1 diabetes, the duration, timing, intensity of exercise, active insulin 
in the circulation, and previous carbohydrate intake are just some of the factors that need to be 
considered and can impact the insulin dosing strategy necessary to maintain euglycemia during 
exercise (13). Maintaining blood glucose concentration in a target range remains an ongoing 
challenge in diabetes management, particularly for those individuals that do not plan in advance 
of physical activity and exercise. According to recent exercise guidelines for type 1 diabetes in 
children and adults (13, 78), significant pre-planning is necessary to improve the time spent in an 
optimal glucose range and decrease the risk of hypoglycemia during exercise. For example, 
reductions in basal insulin are recommended as early as 60-90 minutes pre-exercise (2, 13, 14, 
78) and additional basal rate adjustments may be necessary based on personal experiences (197). 
Interestingly, based on the current techniques used pre-, during, and post-exercise, Pinsker et al. 
(182) reported that most people adjust insulin needs and carbohydrate intake around exercise 
start time, but often still reported experiencing hypoglycemia following exercise. Maintaining 
blood glucose concentration in a target range remains an ongoing challenge in diabetes 
management, particularly for those individuals that do not plan in advance of exercise. 
In this study, we demonstrate that there was no advantage or disadvantage to leaving the 
‘pump on’ versus ‘pump off’ during 40 minutes of intermittent high intensity exercise (no 
significant differences). When the data are represented as absolute glucose concentrations, no 
significant differences were found during intermittent high intensity exercise between both 
‘pump on’ and ‘pump off’ conditions. However, when the data are normalized to baseline blood 
glucose (Figure 4.1B), the relative drop in glycemia from the start to the end of exercise was less 
in the ‘pump on’ versus ‘pump off’ conditions (12 mg/dL versus 28 mg/dL, P = 0.002). For 
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unknown reasons, at exercise start, the average blood glucose concentration was lower in the 
‘pump on’ versus ‘pump off’ condition (133 ± 38 mg/dL versus 146 ± 23 mg/dL, respectively; P 
< 0.05).  
In both insulin pump conditions, hypoglycemia occurred in 1/12 (8%) participant’s 
during exercise. Although there were no significant differences observed in blood glucose 
concentrations during exercise, the ‘pump on’ versus ‘pump off’ percent time spent in 
hypoglycemia in the 12-hour period following exercise varied slightly (5% in ‘pump on’ versus 
1% in ‘pump off’, P = 0.3). In the 12-hour recovery period following exercise, a total of 4/7 
(57%) participants experienced hypoglycemia in the ‘pump on’ condition versus 1/7 (14%) in the 
‘pump off’ condition. Therefore, reducing basal insulin by 20% at bedtime, or the consumption 
of a bedtime snack, may still be required to help protect against nocturnal hypoglycemia 
following high intensity interval exercise, especially in cases where insulin infusion is not 
suspended during exercise (13). 
 Some patients with diabetes make a claim that they can estimate their glucose level 
during exercise and that they know if hypoglycemia or hyperglycemia is developing. To examine 
this possibility, we compared the measured glucose concentration to estimated blood glucose 
during exercise using a Clarke error grid analysis. We found that participants were indeed able to 
estimate glycemia fairly accurately during both ‘pump on’ and ‘pump off’ exercise conditions 
(91% and 97% of values in zones A and B for ‘pump on’ vs. ‘pump off’, respectively), although 
for unclear reasons the accuracy did improve slightly when the pump was removed.  
 A number of limitations exist in this study that are important to mention. First, this study 
included a small sample size of participants with diabetes, in good metabolic control, with 
relatively high fitness levels based on their pre-determined VO2max. As such, our findings may 
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not translate well across a larger population of patients living with type 1 diabetes that may be in 
poor metabolic control and have lower fitness levels. Second, we compared intermittent high 
intensity exercise with pump on versus pump off; however, did not keep the time of day 
consistent between the study participants, although the time of day for exercise was consistent 
within patients. Studies have shown that morning versus afternoon exercise can impact glycemia 
differently (144, 198), with the latter placing a greater risk for hypoglycemia in late recovery. 
Third, the exercise was 40 minutes in duration and therefore, it would be valuable for future 
studies to assess intermittent high-intensity exercises of both shorter and longer duration to better 
understand if ‘pump on’ versus ‘pump off’ impact glycemic outcomes in a wider variety of 
exercise durations and intensities. Finally, due to technical issues with the data upload of 
multiple CGM devices, the 12-hour recovery data represents only a small subset of study 
participants (n = 7). We also did not standardize the meals post-exercise and this may have 
contributed to the glycemic excursions that are apparent in the 12-hour recovery data.  
 In summary, during a 40-minute bout of intermittent high intensity exercise, there were 
no significant differences in blood glucose concentrations with ‘pump on’ as compared to ‘pump 
off’. Although high intensity exercise has been shown to cause less of a decline in blood glucose 
level when compared to aerobic exercise in some studies (124), the former can be associated 
with a significant the drop in glycemia that places individuals at risk for hypoglycemia (174, 
193). Interestingly, during exercise, although absolute blood glucose levels were not significantly 
different between trials, there was a slightly higher percent time spent in hypoglycemia overnight 
in the ‘pump on’ treatment arm. Therefore, insulin pump suspension (‘pump off’) during 
intermittent high intensity exercise can be implemented for at least 40 minutes without impacting 
acute glycemia and may be associated with less post-exercise, late-onset hypoglycemia.  
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Table 4.1: Clarke Error Grid Analysis 
 
Zones 
 
‘Pump On’ Exercise 
 
 
‘Pump Off’ Exercise 
A 41/70 (58%) 44/70 (63%) 
B 23/70 (33%) 24/70 (34%) 
C 0/70 (0%) 1/70 (1%) 
D 6/70 (8%) 0/70 (0%) 
E 0/70 (0%) 1/70 (1%) 
 
Note: Clarke Error Grid zones A-E during ‘pump on’ vs. ‘pump off’ exercise conditions. Zone A 
= Values within 20% of the measured blood glucose (‘Pump On’ 58%, ‘Pump Off’ 63%), Zone B 
= Points are outside of 20%, but would not lead to inappropriate treatment (‘Pump On’ 33%, 
‘Pump Off’ 34%), Zone C = Points leading to unnecessary treatment (‘Pump On’ 0%, ‘Pump 
Off’ 1%), Zone D = Points indicate potentially dangerous failure to detect hypo- or 
hyperglycaemia (‘Pump On’ 8%, ‘Pump Off’ 0%), Zone E = Points that would confuse treatment 
of hypo- for hyperglycaemia and vice versa (‘Pump On’ 0%, ‘Pump Off’ 1%). 
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Figure 4.1: Absolute and relative change in blood glucose concentration. 
A, data represents absolute blood glucose levels from 10 mins pre-exercise to 30 minutes post-
exercise. B, data represents relative change in blood glucose during ‘pump on’ and ‘pump off’ 
conditions. Black represents ‘pump off’ condition. Red represents ‘pump on’ condition. Data 
represents mean ± SD, n = 12.   
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Figure 4.2: Energy expenditure and percent of VO2max. 
A, Energy expenditure in kilocalories (kcal) over 40 minutes of high intensity interval exercise 
with ‘pump on’ versus ‘pump off’ and B, the relative work rate as percent of VO2max during 
‘pump on’ versus ‘pump off’ exercise conditions (n = 12). Data represent mean ± SD. 
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Figure 4.3: Lactate concentrations with pump on vs. pump off (mmol/L). 
Data represents lactate levels at the start (t = 0), middle (t = 20 min), and end (t = 40 min) of 
exercise during both ‘pump on’ (red) and ‘pump off’ (black) conditions (n = 10). Data represent 
mean ± SD.  
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Figure 4.4: Clarke error grids and Bland-Altman plots. 
A, Clarke error grids comparing measured blood glucose concentration with estimated glucose 
concentration during intermittent high intensity exercise with ‘pump off’ (black) and ‘pump on’ 
(red). The blood glucose values are separated into zones A–E that represent the clinical 
implications of estimation errors. B, Bland–Altman plots comparing the difference between 
measured and estimated glucose values within two standard deviations. A blood glucose 
measurement was taken 10-mins before the onset of exercise and participants used this value as a 
reference during exercise.   
91 
 
 
Figure 4.5: Interstitial Glucose and Percent Time in Range. 
A represents the 12-hour recovery CGM data following ‘pump on’ (red) condition and ‘pump 
off’ (black) condition. Data represent median and interquartile range of 12-h post-exercise from 
1200–0000 or 1800–0600h. B represents percent time spent in hypoglycemia, euglycemia, and 
hyperglycemia following ‘pump on’ and ‘pump off’ (n = 7) conditions. CGM, continuous 
glucose monitor.  
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Abstract 
Background: For individuals with type 1 diabetes on continuous subcutaneous insulin 
infusion (CSII), strategies to reduce exercise-associated hypoglycemia typically include basal 
rate reduction (BRR) and/or carbohydrate feeding, although the timing and amount of BRR 
necessary to prevent hypoglycemia is unclear. The goal of this study was to determine if a BRR 
set 90 minutes pre-exercise can better attenuate hypoglycemia vs. pump suspension at exercise 
onset. Methods: Seventeen individuals (13 females) with type 1 diabetes completed three 60-
minute treadmill exercise (~50% of VO2peak) visits in a randomized crossover design. The 
insulin strategies included: a) pump suspension at exercise onset; b) 50% BRR set 90 minutes 
pre-exercise; and c) 80% BRR set 90 minutes pre-exercise. Results: With no significant 
difference in starting blood glucose across all conditions (P>0.05), the 80% BRR was associated 
with the smallest reduction in glycemia during exercise (P=0.01). With pump suspension at 
exercise onset, 7/17 participants developed hypoglycemia vs. 1/17 in the BRR conditions 
(P<0.05). Following a standardized meal post-exercise, glucose rose in the pump suspension and 
50% BRR (both P<0.05), but failed to rise in the 80% BRR condition (P=0.16). Based on 
interstitial glucose, overnight percent time in range was 83±7%, 83±6%, and 78±8% and percent 
time in hypoglycemia was 2±2%, 1±1%, 5±3% for 80% BRR, 50% BRR, and pump suspension, 
respectively (P>0.05). Conclusion: Overall, a 50-80% BRR set 90 minutes pre-exercise 
optimizes open-loop glucose control and decreases hypoglycemia risk during exercise better than 
pump suspension at exercise onset, while not compromising the post-exercise meal overall 
glucose control.  
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Introduction 
In order to maintain blood glucose homeostasis during exercise, circulating insulin 
concentration normally decreases and glucagon levels increase to promote hepatic glucose 
production (199). However, in individuals with type 1 diabetes, due to the absolute destruction of 
the insulin-producing beta cells in the pancreas, patients become dependent on exogenous insulin 
via multiple daily injections or continuous subcutaneous insulin infusion (CSII) (16). CSII 
therapy uses only short-acting insulin for both continuous basal insulin infusion (regulates your 
glucose levels in between meals) and bolus insulin infusion (often taken before a meal or to 
correct hyperglycemia) (1). In this patient population, specifically during aerobic exercise, 
insulin levels tend to not drop fast enough, even if insulin delivery is suspended, and there may 
be an attenuated glucagon response (13). In fact, individuals living with type 1 diabetes can have 
increased circulating exogenous insulin levels during exercise, either when subcutaneous basal 
insulin infusion rates are held constant (82) or even if a temporary basal rate reduction (BRR) is 
set one-hour before exercise (84). 
For active individuals with type 1 diabetes, common strategies to help reduce the risk of 
hypoglycemia include increasing carbohydrate ingestion before or during exercise (200, 201), 
reducing the pre-meal bolus insulin dose (123, 202), and/or performing a BRR before exercise 
onset (83, 84, 117). General exercise guidelines for open-loop insulin delivery suggest BRR at 
least 60-90 minutes before the onset of exercise, with little evidence to substantiate the 
recommendation (13, 14, 119, 203). In reality, patients often disconnect or suspend insulin 
infusion at exercise start and resume basal insulin immediately post-exercise (182). This may be 
in part due to forgetting to set a BRR pre-exercise, participating in unplanned exercise, or trying 
to prevent post-exercise rebound hyperglycemia. Pump suspension appears to be effective in 
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limiting hypoglycemia during circuit exercise, but may not be that effective in eliminating the 
drop in glycemia during aerobic exercise (115, 116). The DirecNet study group showed that in a 
pediatric population (n=49), insulin pump suspension at the start of a 75-minute aerobic exercise 
bout attenuated the drop in glycemia compared to no pump suspension, but it did not completely 
eliminate hypoglycemia risk and promoted increased hyperglycemia risk post-exercise (204). 
Franc et al. (83) suggested that without additional carbohydrates, the most effective strategy to 
reduce hypoglycemia for 30 minutes of spontaneous exercise is an 80% BRR (i.e. 20% of the 
usual basal rate) throughout activity and for two hours post-exercise, although a significant drop 
in glycemia should still be expected. Thus, pump suspension at exercise onset may attenuate the 
drop in glycemia, but does not protect against hypoglycemia during aerobic exercise and leaving 
the pump suspended or disconnected in recovery in many cases appears to contribute to post-
exercise hyperglycemia (83).  
The study objective was to determine which BRR strategy best attenuates the drop in 
glycemia during prolonged aerobic exercise in patients with type 1 diabetes using CSII. The 
change in glucose was examined for the exercise period and for two hours following a 
standardized meal post-exercise. This study is referred to as the Omnipod® Type 1 diabetes 
Insulin Management for Exercise (OmniTIME) Study.  
Methods  
Study Participants 
The experimental protocol conformed to the standards set by the Declaration of Helsinki 
and was approved by the Research Ethics Board at York University. The study was registered at 
clinicaltrials.gov in 2017 (identifier: NCT03130101). Enrollment criteria included participants 
17-65 years of age, duration of diabetes > one year; on CSII > one month (total daily dose of at 
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least 0.25 U/kg); and last HbA1c ≤ 9.9 % or 85 mmol/mol. All participants were using Omnipod® 
Insulin Management System (Insulet, Billerica, MA) and either insulin lispro (Humalog®, Eli 
Lilly, Indianapolis, IN n=5) or insulin aspart (NovoRapid®, Novo Nordisk, Bagsværd, Denmark, 
n=12). Exclusion criteria included frequent and unpredictable hypoglycemia; unable to exercise 
regularly due to an injury; having conditions that may make exercise unsafe (i.e. high blood 
pressure, late pregnancy, etc.); and/or physician diagnosis of active diabetic retinopathy or 
neuropathy. Written informed consent was obtained from all participants before study initiation. 
Fitness Assessment (Visit 1) 
Anthropometric measurements including height, body weight, blood pressure, and body 
fat percentage were completed during the initial assessment. Participants were asked to complete 
a Physical Activity Readiness Questionnaire for Everyone (PAR-Q+) to screen for any 
cardiovascular complications (178). Once cleared to exercise, participants completed the 
International Physical Activity Questionnaire – Short Form (IPAQ-SF) based on self-reported 
activity. Participants were also asked to complete Gold (205) and Clarke (206) questionnaires to 
categorize hypoglycemia awareness. Using an incremental-to-maximum effort treadmill 
protocol, VO2peak and peak heart rate were measured with a portable metabolic unit (K5, 
COSMED, Rome, Italy) and heart rate monitor (Polar Electro, Kemple, Finland). 
Participants wore a continuous glucose monitoring (CGM) device (Dexcom G4® or G5®, 
San Diego, CA) on the abdomen or arm according to the manufacturer’s instructions and were 
instructed to use their Personal Diabetes Manager (PDM; Omnipod®, Insulet, Billerica, MA) for 
self-monitoring of blood glucose (SMBG) with the associated blood glucose test strips 
(FreeStyle Lite, Abbott, Laboratories, Chicago, IL) and for CGM calibrations whenever 
necessary throughout the study. 
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Experimental Visits (Visits 2-4) 
Participants were asked to avoid alcohol and caffeine consumption and refrain from all 
forms of vigorous exercise (i.e. activities > six metabolic equivalents) for 24 hours prior to each 
visit. Female participants were not tested during the luteal phase because research suggests that 
estrogen levels are higher particularly during this phase of the menstrual cycle and this may 
impact fuel selection by increasing the rate of fat utilization (207). Participants were asked to 
consume the same lunch of their choice for each visit with their usual mealtime bolus insulin no 
later than 11:30AM and to refrain from consuming additional food or drink following the 
lunchtime meal, unless hypoglycemia (< 70 mg/dL) developed. Participants completed the 
following BRR strategies in a randomized crossover fashion: a) pump suspension (i.e. 0% of 
basal insulin) for the duration of activity, starting at the onset of exercise; b) a 50% BRR (i.e. 
50% of basal insulin), set 90 minutes in advance of exercise for the duration of activity; and c) an 
80% BRR (i.e. 20% of basal insulin), set 90 minutes in advance of exercise for the duration of 
activity. Based on the recent exercise consensus statement (13), blood glucose targets for 
exercise were between 70-360 mg/dL. Using SMBG, participants were asked to monitor their 
glucose levels 90 minutes before exercise start time. If glucose values were between 70-90 
mg/dL, 8g of dextrose was recommended to help achieve glycemic target. If blood glucose was > 
270 mg/dL, blood ketones were tested (FreeStyle Precision Neo, Abbott Laboratories, Abbott 
Park, IL) and exercise could proceeded if levels were < 0.6 mmol/L. The principal student 
investigator phoned each participant at ~1:30PM as a reminder to set BRR to the appropriate 
amount for the study duration depending on the condition (i.e. perform a 50% or 80% BRR until 
the end of exercise). Participants arrived at the laboratory no later than 2:30PM and began 
exercise at 3:00PM for all conditions. Participants had no active or ‘on-board’ insulin at exercise 
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onset and this was confirmed by examining their pump history to ensure that no additional 
insulin was given following the lunchtime bolus. The experimental visits consisted of 60 minutes 
of treadmill walking/light jogging at 45-55% of the participant’s pre-determined VO2peak and all 
visits were separated by at least 24 hours. The exercise was divided into four 15-minute bouts 
with 5-minute rest periods in between, similar to previous research (81). Substrate oxidation 
rates (i.e. fat and carbohydrate) were calculated using the expired gas collection during the last 5 
minutes of the first and last bouts of exercise (208).  
Capillary fingerstick blood glucose measurements were determined every 15 minutes 
throughout exercise using a standardized laboratory glucose meter (Contour® Next Link, 
Ascensia Diabetes Care, Parsippany, NJ). This blood glucose-monitoring device has a high level 
of accuracy as compared to a laboratory standard (209) and we regularly performed quality 
control tests using the control solution provided by the manufacturer. All glucose measurements 
were completed in duplicate and repeated if the values differed by > 10 mg/dL. If a participant 
developed hypoglycemia (< 70 mg/dL) based on SMBG, they were instructed to stop exercising 
(if it was during exercise) and an initial 16 grams of oral dextrose (Dex4®, AMG Medical Inc., 
QC, Canada) was provided. If exercise was suspended due to hypoglycemia, participants 
returned to the treadmill to complete the exercise portion only once blood glucose concentration 
reached > 81 mg/dL. For the analysis, the change in glucose was calculated based on the 
participants’ glucose value at exercise start and the last value measured immediately at the end of 
exercise, according to the following:  
Change in glucose = baseline (exercise start time) glucose – end of exercise glucose * 
* Note: If the exercise was stopped early because of hypoglycemia, then the last exercise glucose 
value was used for analysis (210). 
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In all conditions, basal insulin was returned to the usual rate immediately post-exercise. 
Participants rested for 30 minutes post-exercise, and then consumed a standardized meal. Meals 
were kept consistent within each participant; however, differed slightly between participants 
depending on food allergies and/or dietary restrictions (i.e. lactose intolerant, vegan, vegetarian). 
Meal composition consisted of ~30-50g of carbohydrates, ~10-20g of protein, and ~5-15g of fat 
(Lean Cuisine, Nestlé, CA). The amount of bolus insulin administered at the post-exercise meal 
was based on the carbohydrate content of the meal and the patient’s own individualized insulin 
to carbohydrate ratio, insulin sensitivity index, and glycemic targets pre-programmed into their 
PDM. Bolus insulin was reduced by 25% of the total dose to account for the increase in insulin 
sensitivity post-exercise (211). If an insulin correction was suggested based on the patient’s 
PDM settings (i.e. usual care), the full correction dose was given. Bolus insulin was administered 
~10 minutes before meal consumption. Following the meal, capillary glucose was measured 
every 30 minutes for a total of 90 minutes before participants were sent home.    
All participants were asked to consume a small, standardized snack (Glucerna® bar, 20g 
carbohydrates, 3g fibre, 10g protein; Abbott Laboratories, Abbott Park, IL) before bedtime with 
their usual bolus insulin, and set a 20% BRR for six hours to reduce the likelihood of post-
exercise nocturnal hypoglycemia (13). 
Laboratory Assays 
Plasma samples were collected with additional capillary blood just before exercise onset, 
30 minutes into exercise, immediately before meal consumption, and 90 minutes post-meal and 
later used to measure circulating free insulin concentrations (Crystal Chem Insulin ELISA, Elk 
Grove Village, IL) as per manufacturer’s recommendations. In an attempt to remove antibody-
bound insulin, polyethylene glycol 6000 (PEG, BioShop, ON, Canada) was used to create a PEG 
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precipitate (modified from Nakagawa et al. (212)). A total of 50 μL of 25 percent aqueous PEG 
and phosphate buffer solution (pH 7.4) was added to 50 μL of each sample and lightly spun with 
a Vortex mixer (Vortex-Genie® 2, Scientific Industries, Inc., NY) for 10 seconds. Samples were 
then centrifuged at 10,000 x g for 5 minutes and the supernatant was extracted and analyzed for 
circulating free insulin concentration.     
Statistics  
 Statistical significance was set a priori P<0.05 unless otherwise indicated and a Tukey’s 
post-hoc test was used if significant interactions were found. All statistical analyses were 
conducted using GraphPad Prism Version 7.0 (GraphPad Software, CA). The changes in glucose 
concentration, carbohydrate and fat oxidation rates, and respiratory exchange ratio from the first 
to the last bout of exercise were compared using two-way repeated measures ANOVA. A one-
way repeated measures ANOVA was used to compare each of the following: baseline glucose, 
change in blood glucose, nadir glucose, decremental area under the curve (AUC), and mealtime 
bolus insulin across all three conditions. The median and interquartile range (IQR) were used to 
report age, duration of diabetes, MET-min/week, absolute and relative VO2, heart rate, fat and 
carbohydrate oxidation rates, blood glucose at exercise onset, change in blood glucose from the 
start of exercise, area under the curve, nadir glucose, time to first hypoglycemic event, amount of 
carbohydrate intake for the hypoglycemia rescue, mealtime bolus insulin, and overnight CGM 
recovery data. Significant differences in the percent time in euglycemia (70-180 mg/dL), 
hyperglycemia (>180 mg/dL), and hypoglycemia (<70 mg/dL) were compared using a 
nonparametric Friedman test. 
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Results 
A total of 17 participants (4 male, 13 female) were recruited for this study. Participants 
were all adults (age 31 ± 10 [28; 25–35] years; mean ± SD [median; IQR]), with a BMI of 25.3 ± 
2.5 kg/m2, and HbA1c of 6.5 ± 0.5 % (47 ± 5 mmol/mol). The total daily insulin dose was 31 ± 8 
units (0.43 ± 0.1 U/kg) and diabetes duration was 14 ± 10 (10; 5–21) years. Based on two 
questionnaires used to assess hypoglycemia awareness (Gold score = 3 ± 1 and Clarke score), 
five participants had reduced hypoglycemia awareness and 12 were hypoglycemia aware. Based 
on the IPAQ-SF, participants were moderate to highly active (MET-mins/week = 2,805 ± 1,365 
[2,782; 1,937–3,746]), as such the participant group could be categorized as active, but not 
highly fit based on BMI or VO2peak (41.6 ± 5.9 mL·kg·min-1). 
The cardiometabolic and glycemic outcome variables are all shown in Table 1. The 
relative exercise intensity across all three experimental conditions was 50.3 ± 3.3% of VO2peak 
and heart rate was 123 ± 12 beats per minute. The respiratory exchange ratio values did not differ 
significantly across the three conditions (P > 0.05). In the 80% and 50% BRR arms, 
carbohydrate oxidation rates tended to decrease from the start to end of exercise (both, P = 0.06), 
but remained constant during pump suspension (P = 0.45). Fat oxidation rates did not change 
from the start to end of exercise across any of the conditions (P > 0.05).  
Figure 5.1A represents the absolute glucose concentrations from pre-exercise until the 
end of the meal challenge across all three conditions. Prior to exercise start (minus 10 minutes), 
blood glucose was higher in 50% BRR compared to 80% BRR (P < 0.001). Blood glucose at 
exercise onset (denoted as t = 0) was also significantly higher in 50% BRR compared to the other 
two conditions (Figure 5.1A, Table 5.1, both P < 0.001). From 10 minutes pre-exercise until the 
end of the meal challenge, glucose concentration was higher in 50% BRR compared to pump 
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suspension (all P < 0.001). From 30 minutes into exercise until 90 minutes into the meal 
challenge, blood glucose was also higher for 80% BRR versus pump suspension (P < 0.01). 
During the meal challenge, blood glucose concentration tended to be lower in pump suspension 
as compared to the two other arms (P < 0.01; Figure 5.1A). However, the greatest rise in 
glycemia was apparent in pump suspension as compared to the other two other arms (P < 0.001). 
Blood glucose rose at mealtime in pump suspension and in 50% BRR (both P < 0.001), but 
failed to rise significantly in the 80% BRR arm (P = 0.16). The mean ± SD (median; IQR) 
mealtime bolus insulin was 2.9 ± 1.1 (2.6; 2.2–3.5) U (80% BRR), 3.1 ± 1.2 (3.8; 1.9–3.9) U 
(50% BRR), and 2.6 ± 1.1 (2.3; 1.7–3.5) U (pump suspension) (not significantly different, Table 
5.1). 
Figure 5.1B shows the change in blood glucose concentration from 30 minutes pre-
exercise to 90 minutes post-meal challenge, normalized to starting exercise glucose level. There 
was a significant trial by time interaction for the change in blood glucose during exercise (P < 
0.001). Specifically, the change in blood glucose from the start to end of exercise was -31 ± 58, -
47 ± 50, and -67 ± 41 mg/dL in 80% BRR, 50% BRR, and pump suspension conditions, 
respectively (P = 0.008). The decremental AUC was greatest in pump suspension compared to 
80% BRR (P = 0.007). Also, nadir blood glucose during exercise was lower in pump suspension 
versus 50% BRR (P = 0.02). The highest number of hypoglycemic events occurred during pump 
suspension (n = 7/17, 41%) compared to 50% and 80% BRR (both n = 1/17, 6%, P < 0.02, Chi-
square). If hypoglycemia occurred during exercise, the average carbohydrate intake required to 
return blood glucose to target range was 19 ± 6 grams (16; 16–16 grams) and the average time 
before resuming exercise was 19 ± 4 minutes (17; 16–21 minutes). The time to the first 
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hypoglycemic event ranged between 29-51 minutes during exercise in the nine hypoglycemic 
events that occurred during the 51 total exercise sessions.  
Figure 5.2 represents circulating free insulin concentrations across all conditions. At 
exercise start, circulating free insulin concentration was higher in pump suspension compared to 
80% BRR (P = 0.02) and 50% BRR (P = 0.04). Insulin concentration fell during exercise in all 
conditions (P = 0.01, main effect of time). However, there was no significant difference in 
insulin concentration among the three treatment arms by the end of the meal challenge. In 
examining the pre- and post-meal insulin levels specifically, we observed a rise in insulin 
concentrations in 82% of all cases (if all treatment conditions are combined). However, we noted 
a drop in insulin in the other 18% of cases. The mean plasma insulin concentration pre-meal was 
67 pmol/L increasing to 94 pmol/L (i.e. 52% increase, P = 0.02). It may be that the variability in 
insulin levels and/or the noise of the insulin assay limited our ability to observe the expected rise 
in insulin concentrations 90 minutes following meal ingestion. 
Figure 5.3A represents interstitial glucose from 10:00PM-7:00AM post-exercise across 
all conditions. Interstitial glucose remained relatively stable overnight with no difference across 
any of the three conditions (P > 0.05). The mean ± SEM (median, IQR) for glucose levels 
overnight was 131 ± 12 (122, 97–152) mg/dL, 136 ± 10 (131, 103–160) mg/dL, and 140 ± 13 
(135, 105–169) mg/dL in 80% BRR, 50% BRR, and pump suspension conditions, respectively 
(P > 0.05). Figure 5.3B represents the mean percentage of time in euglycemia (70-180 mg/dL), 
hyperglycemia (> 180 mg/dL), and hypoglycemia (< 70 mg/dL). The percent time in the 
euglycemia range (mean ± SEM) for 80% BRR was 83 ± 7%, for 50% BRR was 83 ± 6%, and 
for pump suspension was 78 ± 8% (not significantly different; P = 0.8). The time spent in 
hyperglycemia was similar across all treatment arms at 15 ± 7%, 16 ± 6%, and 17 ± 8% for the 
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80% BRR, 50% BRR, and pump suspension arms, respectively (P = 0.9). The time spent in 
hypoglycemia was slightly higher with pump suspension (5 ± 3%), compared to the other two 
arms (2 ± 2% and 1 ± 1% for the 80% BRR and 50% BRR, respectively), but was not significant 
(P = 0.4). 
Discussion 
Regular physical activity is at the cornerstone of care for people living with type 1 
diabetes for a number of health and fitness reasons (13). However, maintaining reasonable 
glucose control for prolonged moderate-intensity aerobic activities remains a major challenge, 
even for patients on CSII therapy (182). If prolonged exercise is to be performed soon after a 
meal, then bolus dose reductions by 25-75%, depending on the intensity and duration of the 
activity help limit hypoglycemia (123). However, if the activity is three or more hours after a 
meal with bolus insulin, then a BRR may be a more appropriate approach for those using CSII 
(13).  Previous studies have shown that even with pump disconnect (115, 116), or with a 
temporary BRR (by 50-80%) set up to 40 minutes before exercise (84, 117), hypoglycemia 
remains a concern during aerobic exercise. Although recent guidelines recommend a BRR set 
60-90 minutes pre-exercise for patients with type 1 diabetes on CSII (13, 14, 78, 203), we know 
of only one study published to date that has examined the efficacy of a 50% BRR set 60 minute 
pre-exercise until 60 minutes post-exercise (84). Therefore, the aim of the present study was to 
determine the efficacy of three different BRR strategies (one for spontaneous exercise, two for 
pre-planned exercise) on attenuating the drop in glycemia during and after prolonged aerobic 
exercise in adults with type 1 diabetes on CSII. 
Roy-Fleming et al. (117) recently published that an 80% BRR up to 40 minutes pre-
exercise is insufficient to reduce hypoglycemia during a 45-minute bout of submaximal aerobic 
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exercise. One of the main differences in our study was that the BRR was set much earlier (i.e. 90 
minutes pre-exercise) in an attempt to lower circulating insulin before exercise onset. We show 
that 50-80% BRR set 90 minutes before prolonged aerobic exercise better protects against 
hypoglycemia than pump suspension at exercise onset, likely because this forecast strategy 
results in lower circulating insulin levels at the start of exercise as compared to pump suspension 
at exercise onset. In the pump suspension condition at exercise onset, 7/17 (41%) participants 
experienced hypoglycemia during exercise, whereas only 1/17 (6%) experienced hypoglycemia 
in both 80% BRR and 50% BRR (P < 0.05). Pump suspension at exercise onset helps with 
attenuating the drop in blood glucose concentration as compared to leaving the pump at the usual 
basal rate (i.e. 100%) (176), but this approach is clearly not sufficient to eliminate hypoglycemia 
risk if patients initiate exercise with a normal or only slightly elevated blood glucose level, as 
seen in our study (i.e. 41% of subjects developed hypoglycemia with pump suspension). 
It is important to note, however, that a more aggressive approach (i.e. 50-80% BRR set 
90 minutes pre-exercise) may eliminate the risk of hypoglycemia, but may also cause some 
patients to have elevated blood glucose at exercise onset or contribute to rebound hyperglycemia 
post-exercise (13). However, we found that 50-80% BRR did not lead to overt hyperglycemia 
before the onset of exercise nor did it result in hyperglycemia in early recovery. Interestingly, for 
unknown reasons, 50% BRR resulted in a higher starting blood glucose level as compared to 
80% BRR and pump suspension. Moreover, from the start to end of the meal challenge, the 
greatest rise in glycemia was observed in pump suspension and 50% BRR. Pump suspension 
causing the largest rise in glycemia is likely attributable to the 7/17 participants that were treated 
for hypoglycemia during exercise. Thus, treating hypoglycemia during exercise with a 
carbohydrate snack (~15-20 g), while essential for safety reasons, may compromise glucose 
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tolerance at the upcoming meal. Interestingly in Figure 5.1A-B, blood glucose returned near the 
baseline pre-exercise glucose level in all conditions and 80% BRR did not compromise glycemia 
during the meal challenge. Thus, exercise before a meal, even with a BRR, appears to be 
associated with a very modest glycemic excursion at the meal following exercise. It should also 
be mentioned that overall glucose control during the meal challenge was not different among the 
three treatment strategies and that all approaches resulted in excellent overall glucose control in 
the evening post-exercise (Figure 5.3A-B).  
At the onset of exercise, lower circulating free insulin concentrations were apparent in the 
80% and 50% BRR, both set 90 minutes pre-exercise, as compared to pump suspension at 
exercise onset. Circulating free insulin continued to decline across all conditions from the start to 
end of exercise, thereby demonstrating that all strategies appear to lower circulating insulin 
levels during exercise. Previous literature has shown a modest short-term exercise-related 
increase in circulating insulin, followed by an accelerated decline in concentrations as the 
exercise continues (83, 84). However, we did not find this initial rise in insulin level during the 
first 30 minutes of exercise, possibly because not enough earlier time points were examined to 
profile the true kinetic changes in insulin levels in our study. Interestingly, circulating free 
insulin levels did not rise markedly at mealtime in our study (Figure 5.2), although a majority of 
subject participants did have a small rise in circulating insulin levels. The failure to observe a 
meal-related rise in circulating insulin levels may have been because of the prolonged reduction 
in basal insulin infusion before the meal (lasting up to 165 minutes) and the relatively small dose 
of insulin that was administered at mealtime (the meal bolus was reduced by 25% to account for 
increased insulin sensitivity post-exercise). 
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Importantly, and for the first time, we show that a 50-80% BRR set 90 minutes before 
prolonged aerobic exercise does not cause overt hyperglycemia pre-exercise, and also attenuates 
the drop in glycemia during aerobic exercise. However, we also acknowledge that no singular 
approach is likely to work for all individuals. Specifically, Supplemental Figure 5.4 shows the 
individual and the mean participant change in glycemia during exercise in each of the three BRR 
strategies. As can be observed, one participant developed hypoglycemia in all three conditions, 
some developed a significant rise in glucose, and some tended to have minimal glucose 
excursions. Thus, BRR strategies attenuate the drop in glycemia during prolonged aerobic 
exercise, but may still need to be individualized for any given patient. 
This study had a number of strengths including random crossover design, standardization 
of the meal and snack following exercise, and the measurement of circulating free insulin. 
However, this study also had a number of limitations that need to be mentioned. There are 
multiple factors that may limit our ability to translate the present findings across a wider type 1 
diabetes population. For example, the participants enrolled in this study were primarily female, 
with very good HbA1c (6.5 ± 0.5 % or 47 ± 5 mmol/mol) as determined using a point-of-care 
device and all participants were using Omnipod® Insulin Management System (Insulet, Billerica, 
MA) CSII therapy. In addition, we did not have information on potential lipodystrophy and 
lipohypertrophy and we did not do a run-in period to assess participants’ usual basal insulin rates 
prior to study enrolment. We also only examined exercise at one time of day (late afternoon) and 
with one type and intensity of exercise (prolonged moderate intensity walking/light jogging). 
Finally, we failed to examine if other factors, such as menstrual phase, fitness, or disease 
duration influenced our findings. Future studies should examine if these results translate to a 
larger patient population. 
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In conclusion, we found that a 50-80% BRR performed 90 minutes before the onset of 
prolonged aerobic exercise optimizes open-loop glucose control and decreases hypoglycemia 
risk during exercise while not compromising the post-exercise meal glucose control in patients 
living with type 1 diabetes. These findings support recent guidelines that pre-planned BRR well 
in advance of prolonged exercise is an effective strategy to reduce hypoglycemia risk and 
minimize the need for carbohydrate feeding during the activity (13). Whether the type 1 diabetes 
community can adopt this pre-planning strategy effectively still needs to be determined. 
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 80% BRR 50% BRR Pump Suspension (At t = -90 mins) (At t = -90 mins) (At t = 0 mins) 
Absolute VO2 (L/min) 20.7 ± 3.33 21.1 ± 3.63 21.0 ± 3.33 20.1 (18.6-22.6) 21.2 (18.8-22.8) 20.9 (19.9-22.6) 
Relative VO2 (%) 49.8 ± 3.11 50.7 ± 3.89 50.5 ± 3.04 49.1 (47.7-52.6) 49.4 (47.9-53.9) 50.7 (48.7-52.4) 
Heart rate (bpm) 122 ± 11 124 ± 12 124 ± 13 124 (118-130) 130 (116-133) 126 (118-133) 
EXERCISE TIME 10-15 mins 55-60 mins 10-15 mins 55-60 mins 10-15 mins 55-60 mins 
Respiratory exchange ratio 0.87 ± 0.04 0.86 ± 0.05 0.87 ± 0.05 0.86 ± 0.03 0.87 ± 0.05 0.88 ± 0.06 0.9 (0.8-0.9) 0.9 (0.8-0.9) 0.9 (0.8-0.9) 0.9 (0.8-0.9) 0.8 (0.8-0.9) 0.9 (0.8-0.9) 
Carbohydrate oxidation (g/min) 2.06 ± 0.6 1.87 ± 0.5 2.15 ± 0.7 1.91 ± 0.5 1.84 ± 0.6 1.82 ± 0.7 1.9 (1.8-2.4) 1.8 (1.6-2.1) 2.1 (1.8-2.4) 1.9 (1.7-2.0) 1.7 (1.4-2.1) 1.7 (1.5-1.8) 
Fat oxidation (g/min) 0.29 ± 0.1 0.32 ± 0.2 0.31 ± 0.1 0.32 ± 0.1 0.34 ± 0.2 0.31 ± 0.2 0.3 (0.2-0.4) 0.3 (0.2-0.4) 0.3 (0.2-0.4) 0.3 (0.3-0.4) 0.3 (0.3-0.4) 0.3 (0.2-0.4) 
Blood glucose (mg/dL) at exercise start 164 ± 41 191 ± 49 * 164 ± 45 157 (133-171) 184 (153-221) 157 (142-180) 
∆ glucose (mg/dL) from start-end of exercise -31 ± 58 -47 ± 50 -67 ± 41 * -32 (-74 to 11) -45 (-88 to -14) -65 (-90 to -38) 
Decremental area under curve (AUC) -64 ± 110 -89 ± 99 -142 ± 81 * -86 (-141 to 20) -86 (-143 to -6) -136 (-186 to -79) 
Nadir glucose (mg/dL) during exercise 122 ± 47 137 ± 50 97 ± 45 * 112 (86-146) 148 (95-148) 88 (67-103) 
Time to first hypoglycemic event (mins) 45 30 40 ± 11 45 (30-45) 
Number of hypoglycemic events 1 1 7 * 
Mealtime bolus insulin (units) 2.9 ± 1.1 3.1 ± 1.2 2.6 ± 1.1 2.6 (2.2-3.5) 3.8 (1.9-3.9) 2.3 (1.7-3.5) 
Table 5.1: Cardiometabolic and glycemic outcome variables. 
Data represented as mean ± SD or median (IQR), n=17. Note: 10-15 mins and 55-60 mins refer to the last 5 minutes of the beginning and end of 
exercise where metabolic data was collected. * indicates significantly different from the other two treatment arms (P < 0.05). 
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Figure 5.1: Absolute and relative change in blood glucose level. 
A, absolute blood glucose concentration during exercise and meal challenge across all treatment 
arms. B, relative change in blood glucose concentration during exercise and meal challenge 
across all treatment arms. * represents 80% BRR vs. pump suspension. † represents 50% BRR 
vs. 80% BRR. ‡ represents 50% BRR vs. pump suspension. Data represents mean ± SEM.
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Figure 5.2: Circulating free insulin concentrations. 
Circulating insulin concentrations from the start to the end of exercise across all treatment arms. 
* represents pump suspension vs. both 50% BRR and 80% BRR. Data represents mean ± SEM.
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Figure 5.3: Interstitial glucose and percent time in range. 
A, Overnight recovery CGM glucose data from 10:00PM – 7:00AM across all treatment arms. 
Data represent median and IQR. B, Percent time spent in euglycemia, hyperglycemia, and 
hypoglycemia (n = 15). Data represents mean ± SEM. CGM, continuous glucose monitor.
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Supplemental Figure 5.4: Individual and mean change in glucose concentration. 
A, 80% BRR; B, 50% BRR; and C, pump suspension. * denotes hypoglycemia developed (< 70 
mg/dL) during exercise. Colour coding used to differentiate between participants and carried out 
between treatment arms. Baseline blood glucose concentration denoted above each subject that 
experienced hypoglycemia during exercise (mg/dL). 
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Abstract 
Background: Real-time continuous glucose monitor (rtCGM) devices track glucose 
levels in the interstitial fluid and help detect glycemic excursions associated with exercise, 
meals, and insulin dosing in patients with type 1 diabetes. However, the delay in equilibrium 
between interstitial and blood glucose levels during exercise and meals may result in rtCGM 
underestimating the true change in glycemia during activity and post exercise feeding. The 
purpose of this study was to examine rtCGM discrepancies during continuous steady state 
moderate intensity aerobic exercise and the meal post exercise as compared to two commonly 
used self-monitoring of blood glucose (SMBG) devices.  
Methods: A total of 17 adults (13 female, 4 male) with type 1 diabetes using insulin 
pump therapy (OmniPod®, Insulet, USA) and rtCGM (Dexcom®, USA) completed 60 min of 
exercise on three occasions. A standardized meal was given 30 min post-exercise. Blood glucose 
levels were measured during exercise and meal recovery using two SMBG devices: glucose 
meter 1 (Contour® Next Link; Ascensia Diabetes Care, USA); and b) glucose meter 2, 
[Omnipod® Personal Diabetes Manager; (PDM) with built-in glucose meter (FreeStyle, Abbott 
Laboratories, USA)], while rtCGM was measured with a third device [either Dexcom G4® (n=4) 
or G5® (n=13)], which was calibrated with the subjects’ PDM.  
Results: Glucose meter 1 values were higher than glucose meter 2 and rtCGM across all 
time points during exercise and meal challenge (both P<0.05). Because of this initial bias and 
since rtCGM was calibrated to glucose meter 2, all devices were normalized to the baseline 
glucose concentration. SMBG devices showed a similar decline in blood glucose during exercise 
and similar rise during mealtime, while the rtCGM time delay was ~10-15 mins. Mean absolute 
relative difference (MARD) values for rtCGM as compared to glucose meter 1 were 12±9%, 
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11±9%, and 14±11% during rest, exercise, and meal, respectively (P=0.06). Similarly, MARD 
values for rtCGM as compared to glucose meter 2 were 11±9%, 17±14%, and 11±10% during 
rest, exercise, and meal, respectively (P=0.001). Based on Clarke Error Grid analyses, rtCGM 
values were in zones A and B 99-100% of the time relative to glucose meter 1 and 94-99% of the 
time for glucose meter 2 (P>0.05).  
Conclusion: In summary, rtCGM values underestimate the drop in glycemia during 
exercise and appear to lag behind blood glucose values by ~10-15 mins when glucose levels are 
rapidly changing. Therefore, if hypoglycemia is suspected during exercise, individuals should 
confirm glucose levels with a fingerstick capillary glucose measurement.    
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Introduction 
A real-time continuous glucose monitor (rtCGM) consists of a wearable subcutaneous 
sensor containing an electrode used to automatically measure interstitial glucose approximately 
every 5 minutes and a transmitter that sends these readings to an insulin pump, mobile device, or 
remote receiver (7). The sensor relies on glucose molecules in the interstitial fluid that initiate the 
release of electrons on the electrode (7). These electrons generate a current that is proportional to 
the glucose level and the current is relayed to a transmitter that is attached to the sensor. 
Glucose-monitoring devices have been shown to detect greater glucose variability (42), rate of 
change in glucose concentration, and incidence of hypoglycemia compared to self-monitoring of 
blood glucose (SMBG) using a traditional glucose meter, a lancing device, and capillary blood 
sampling (213). Since rtCGM systems can provide insight into glucose patterns and overall 
diabetes management, these devices have recently been included in the clinical guidelines and 
standards of care for individuals with diabetes, particularly if they are dosing insulin (146, 214).  
One common measure of rtCGM accuracy is mean absolute relative difference (MARD), 
which is the mean absolute difference between the reference (often SMBG) and interstitial 
glucose divided by the reference. Successive generations of devices have improved accuracy 
with a lower MARD when comparing to the laboratory standards (Yellow Springs Instruments 
[YSI] glucose analyzer) for plasma glucose measurements leading to non-adjunctive status, so 
that insulin dosing and decision-making around hypoglycemia treatment can be made using some 
of these devices (214-216). Kovatchev et al. (217) reported that using rtCGM for insulin dosing 
decisions is feasible at a MARD of 10% or lower. Whether MARD remains stable in rtCGM 
throughout dynamic changes in glucose (often associated with exercise and meal ingestion) is 
unclear. 
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In an earlier field study (79), rtCGM was shown to help guide patients on when to initiate 
carbohydrate feeding during physical activity in active adolescents and young adults with type 1 
diabetes. However, that study did not determine if the sensor glucose was an accurate reflection 
of the SMBG during physical activity. More recently, CGM devices have been heavily 
scrutinized in the context of exercise due to the apparent lag in equilibrium between interstitial 
and blood glucose (165, 167, 189, 218). This lag is often attributed to: a) physiologic lag affected 
by blood flow (165); b) sensor reaction time to glucose (219); and c) signal processing (163). 
These discrepancies between rtCGM devices and SMBG may impact insulin-dosing decisions 
and carbohydrate replacement, particularly around exercise and during meals when glucose 
levels can change rapidly. In line with this, Biagi and colleagues (220) reported an increase in 
MARD from 9.5% to 16.5% during aerobic exercise. Interestingly, Adolfsson et al. (221) 
reported that MARD values tended to increase with vigorous-to-maximal intensity exercise (e.g. 
football, cross-country skiing) compared to low-to-moderate intensity activities (e.g. golf) in 
adolescents with type 1 diabetes. However, this has not been consistently observed in studies 
examining intermittent high intensity exercise (190, 191), likely because glucose levels tend not 
to change as dramatically because of a rise in glucose counterregulatory hormones and lactate 
levels (13). 
The primary purpose of this study was to assess the accuracy of newer rtCGM technology 
compared to SMBG using two different blood glucose meters during prolonged, continuous 
steady state moderate-intensity ‘aerobic’ exercise and the meal post-exercise in adults living with 
type 1 diabetes. Our hypothesis is that rtCGM accuracy and MARD values will deteriorate 
during prolonged, aerobic exercise and during the meal challenge post exercise. 
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Methods 
 
Study Participants 
The present study conformed to the standards set by the Declaration of Helsinki and was 
approved by the Research Ethics Board at York University. The study was registered at 
clinicaltrials.gov in 2017 (identifier: NCT03130101). This is ancillary data from a previously 
published study (122) and we used the rtCGM data for a secondary analysis here. A total of 17 
individuals (4 male, 13 female) with type 1 diabetes were recruited for the study. The inclusion 
criteria included 17-65 years of age, duration of diabetes > one year; using insulin pump 
treatment (Omnipod® Insulin Management System, Insulet, Billerica, MA) for at least one 
month; a total daily insulin dose of at least 0.25 units/kg; and HbA1c ≤ 9.9% (85 mmol/mol). The 
exclusion criteria included unpredictable hypoglycemia; unable to perform regular exercise due 
to injury; having conditions that may make exercise unsafe (i.e. high blood pressure, late 
pregnancy, etc.); and/or physician diagnosis of active diabetic retinopathy or neuropathy. Written 
informed consent was obtained from all participants prior to study initiation. 
Experimental Design 
All exercise testing took place at York University in the Clinical Human Exercise 
Laboratory. Participants took part in one preliminary visit and three experimental visits in which 
aerobic exercise was performed with different basal insulin rate settings to help mitigate the risk 
for hypoglycemia (122). The preliminary testing consisted of completing a consent form, 
questionnaires, anthropometric measurements, and a peak oxygen consumption (VO2peak) test. 
The experimental visits included three continuous steady state moderate intensity aerobic 
exercise bouts with different adjustments in basal insulin, completed in a randomized, counter-
balanced fashion. Participants were asked to refrain from all forms of vigorous-to-maximal 
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exercise (i.e. activities > six metabolic equivalents) for 24 hours prior to each visit and were 
asked to avoid alcohol and caffeine consumption during the monitoring period. During the 
experimental visits, female participants were not tested during the luteal phase, where applicable. 
Preliminary Testing (Visit 1) 
 
During the preliminary testing, height, body mass, blood pressure, body fat percentage 
(Tanita Scale, model TBF-612, Arlington Heights, Ill), and HbA1c (A1cNow+, Roxon Medi-tech 
Ltd., QC) were measured. The VO2peak test was an incremental-to-maximum treadmill protocol 
and was measured using a portable metabolic system (K5, COSMED, Rome, Italy) and heart rate 
monitor (Polar Electro, Kemple, Finland). The metabolic unit measures breath-by-breath expired 
oxygen and carbon dioxide concentrations using an oxygen sampling line, turbine flowmeter, 
harness, facemask and head strap. 
Continuous Glucose Monitor 
 
All participants were instrumented with rtCGM sensor and transmitter (Dexcom G4® or 
G5®, San Diego, CA) at least 24 hours prior to testing and were provided with a receiver or 
mobile app to track interstitial glucose levels throughout the study. A total of seven participants 
were trained on the operation of rtCGM and the remaining 10 participants were asked to 
continue using their own rtCGM throughout the study duration and to calibrate their rtCGM 
using their Personal Diabetes Manager (PDM) for SMBG. Of the 17 participants, four used 
rtCGM with Dexcom G4® Platinum with 505 algorithm (started prior to the study) and the 
remaining (n=13) used rtCGM with Dexcom G5® throughout the study. Participants wore rtCGM 
for one week at a time and were instructed to use their PDM for SMBG using the built-in glucose 
meter and associated blood glucose test strips (FreeStyle Lite, Abbott, Laboratories, Chicago, 
IL). Following an initial warm-up period of two-hours after sensor insertion, participants were 
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advised to calibrate at least once every 12-hours using their own PDM glucose meter. If testing 
was scheduled ≥ one week apart, participants were asked to insert a new sensor at least 24 hours 
prior to the next experimental visit. All rtCGM data was uploaded to a Healthcare Professional 
Dexcom Clarity® account and later retrieved for interstitial glucose analysis. 
Experimental Sessions (Visits 2-4) 
 All participants completed three aerobic exercise visits that were separated by at least 24 
hours and all sessions were pooled for this analysis. Participants were asked to consume the same 
lunch of their choice and take their usual mealtime bolus insulin (plus correction, if necessary) 
no later than 11:30AM. The three insulin adjustment strategies included a) pump suspension 
(100%) at exercise start, for the duration of the activity; b) a 50% basal reduction, set 90 minutes 
pre-exercise for the duration of the activity; and c) an 80% basal reduction, set 90 minutes pre-
exercise for the duration of the activity. For the 50% and 80% reduction arms, the principal 
student investigator phoned each participant at 1:30PM as a reminder to reduce basal insulin for 
at least four hours. Exercise start time was 3:00PM for all experimental visits and consisted of 60 
minutes of aerobic exercise, broken down into four 15-minute bouts with 5-minute rest periods 
in between. The exercise was a continuous steady state moderate-intensity (45-55% of VO2peak) 
walk/light jog on a treadmill and was followed by a standardized meal challenge. 
 SMBG was determined at baseline/rest (i.e. 10 minutes prior to exercise and just before 
exercise start), every 15 minutes during exercise, and every 30 minutes during meal recovery 
according to good practice as described by Hortensius et al. (222). The following two blood 
glucose devices were used: a) glucose meter 1 (Contour® Next Link, Ascensia Diabetes Care, 
Parsippany, NJ); and b) glucose meter 2 (Omnipod® PDM; Insulet, Billerica, MA). All SMBG 
measurements were completed in duplicate for both meters and in triplicate if the second glucose 
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value differed by > 10 mg/dL from the first measurement. For analysis purposes, the average of 
the SMBG values were used if duplicates were performed while the average of the closest two 
values were used if triplicates were performed. Basal insulin rates were resumed back to the 
usual (100%) rate immediately following the cessation of exercise. If hypoglycemia ([blood 
glucose] < 70 mg/dL) developed during exercise, participants were instructed to suspend 
exercise and 16 grams of oral dextrose (Dex4®, AMG, QC, Canada) was provided. Following a 
15-minute rest period to confirm recovery from hypoglycemia using SMBG (glucose meter 2), 
the exercise was resumed. After exercise, following a 30-minute period resting in a chair, all 
participants consumed a standardized meal containing ~30-50g of carbohydrates, ~10-20g of 
protein, and ~5-15g of fat (Lean Cuisine, Nestlé, CA) and blood glucose levels were monitored 
for 90 minutes post-meal. 
Statistics 
Statistical significance was set a priori at P < 0.05. All three conditions (50% BRR, 80% 
BRR, and pump suspension) were analyzed separately and because there were no significant 
differences between conditions, all data was pooled for this analysis. For absolute and change in 
glucose during exercise (i.e. delta from baseline), the data were pooled across the three exercise 
conditions. For absolute and change in glucose data, a two-way repeated measures ANOVA was 
conducted to compare all devices during exercise and in the meal recovery post-exercise. Data 
are represented as mean ± SEM. During rest, exercise, and recovery, there was no difference in 
Dexcom G4® and G5® glucose data when analyzed separately (data not shown), therefore all 
rtCGM data were pooled for all analyses. The ‘rest’ time points includes all 10 minute pre-
exercise, exercise start, and pre-meal data. The ‘exercise’ time points includes 15-, 30-, 45-, and 
60-minutes of exercise. The ‘meal’ time points include 30-, 60-, and 90-minutes following meal 
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ingestion. All of the graphics and statistical analyses were completed using GraphPad Prism 
Version 7.0 (GraphPad Software, CA). Capillary blood glucose was measured using two 
different glucose meter devices and each was used as the reference to evaluate the accuracy of 
the rtCGM. The MARD was calculated using the absolute relative difference between the 
glucose meter value and rtCGM value over the glucose meter value multiplied by 100. A one-
way ANOVA was used to compare MARD values during rest, exercise, and meal recovery for 
glucose meter 1 and glucose meter 2. A paired t-test was used to compare MARD values during 
exercise for glucose meter 1 versus glucose meter 2.  
Results 
The anthropometric measurements for all 17 participants (13 females, 4 males) are 
summarized below. The participants recruited for this study were adults (age 31 ± 10 years; 
mean ± SD), on insulin pump therapy and in good metabolic control (HbA1c 6.5 ± 0.5% or 48 
mmol/mol).  
Since blood glucose measurements were completed in duplicate for both glucose meter 1 
and glucose meter 2, the coefficient of variance (CV) was calculated during rest, exercise, and 
meal recovery for both devices. For glucose meter 1, the CV between the first and second blood 
glucose reading was 1.8 ± 1.4% during rest and exercise, and 1.7 ± 1.6% during meal recovery. 
For glucose meter 2, the CV between the first and second blood glucose reading was 2.2 ± 1.9% 
during rest, 2.3 ± 2.0% during exercise, and 2.2 ± 1.7% during the meal recovery.  
Figure 6.1A represents the absolute glucose concentrations as measured by all three 
devices during aerobic exercise and in the meal post-exercise. From 10 minutes pre-exercise to 
the end of meal challenge, glucose meter 1 was significantly higher than glucose meter 2 and 
rtCGM across all time points (P < 0.05). From 15 minutes into exercise until the end of exercise, 
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interstitial glucose was significantly higher than glucose meter 2 (P < 0.05). Interstitial glucose 
was significantly lower than glucose meter 2 from 30-60 minutes post-meal (P < 0.05). Because 
of the positive bias of glucose meter 1 as compared to the other two devices, and since rtCGM 
was calibrated to meter 2, the glucose data from all three devices were normalized to the pre-
exercise value (at time = 0). With this data normalization, the change in glucose during exercise 
and meal recovery was nearly identical between the two SMBG devices (Figure 6.1B). However, 
from 15 minutes into exercise until the end of exercise when blood glucose was dropping, 
interstitial glucose was significantly higher than both glucose meters (both P < 0.05). In 
recovery, when blood glucose was rising; however, interstitial glucose was significantly lower 
than glucose meter 1 and glucose meter 2 at 30 minutes following meal ingestion (P < 0.05). At 
the start and end of the meal challenge, interstitial glucose was significantly higher than glucose 
meter 1 (P = 0.01).  
Figure 6.2 represents the MARD values during the following time points: rest, exercise, 
and meal for rtCGM as compared to glucose meter 1 and glucose meter 2. The MARD value for 
rtCGM as compared to glucose meter 1 was 12 ± 9% during rest, 11 ± 9% during exercise, and 
14 ± 11% during the meal post-exercise (Figure 6.2A, P = 0.06). The MARD values for rtCGM 
as compared to glucose meter 2 was 11 ± 9% during rest, 17 ± 14% during exercise, and 11 ± 
10% during the meal post-exercise (Figure 6.2B, P < 0.001). The MARD values during exercise 
were significantly higher in glucose meter 2 as compared to glucose meter 1 (P < 0.001).  
 Figure 6.3A represents Clarke Error Grid analyses with glucose meter 1 compared to 
rtCGM at rest, exercise, and during the meal challenge. Based on regression analyses, the r-
squared values for glucose meter 1 versus rtCGM were r2 = 0.84, r2 = 0.85, and r2 = 0.75 during 
rest, exercise, and meal challenge, respectively. Similarly, Figure 6.3B represents Clarke Error 
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Grid analyses with glucose meter 2 versus rtCGM at rest, exercise, and during the meal 
challenge. Based on regression analyses, the r-squared values for glucose meter 2 versus rtCGM 
were similar at r2 = 0.82, r2 = 0.82, and r2 = 0.73 during rest, exercise, and meal challenge, 
respectively (not significantly different from glucose meter 1, P > 0.05). 
Table 6.1 represents the Clarke Error Grid zones A–E that are used to depict the 
likelihood of inappropriate treatment based rtCGM values as compared to SMBG. For glucose 
meter 1 as compared to rtCGM, 99% of values fell in zones A and B during rest and exercise, 
while 100% of values were in zones A and B during the meal challenge. For glucose meter 2 as 
compared to rtCGM, 99% of values fell in zones A and B during rest and the meal challenge, 
while 94% of values were in zones A and B during exercise. 
Discussion 
 Previous literature has looked at rtCGM performance during both aerobic and anaerobic 
exercise (189-191, 220); however, to our knowledge, this is the first study to measure rtCGM 
accuracy during a structured 60-minute aerobic exercise bout using primarily Dexcom G5® 
technology (n=13). The remaining participants (n=4) wore Dexcom G4® Platinum with the 
updated software and 505 algorithm. In addition, our analysis showed no difference with the G4® 
data removed; therefore, all rtCGM data were pooled. Collectively, these more recent studies 
suggest that sensor accuracy, even with newer algorithms and technology, may be compromised, 
particularly during prolonged exercise when glucose levels tend to change rapidly (189, 191, 
220, 223). 
The present study assessed the accuracy of rtCGM compared to two different glucose 
meters during exercise and in recovery. First, we show that glucose meter 1 tended to report 
higher than glucose meter 2, as has been noted in other comparisons (224). Second, we found 
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that rtCGM had better congruence with glucose meter 2 versus glucose meter 1, likely because 
the rtCGM was calibrated to glucose meter 2. As such, in a real-world setting, we recommended 
that patients use the same glucose meter for regular SMBG and calibrations. Third, we found that 
after normalizing glucose values to the pre-exercise (i.e. baseline, time = 0) glucose 
concentration, rtCGM values underestimated the drop in glucose during exercise and lag 
significantly behind both meter readings by ~10-15 minutes. These findings may have critical 
implications for the development of hybrid closed-loop or automated insulin delivery systems for 
exercise since these devices may inadvertently over-deliver insulin when plasma glucose is 
dropping but sensor glucose fails to drop or may even rise (223). In contrast, for the meal 
response after exercise, the delayed rise in sensor glucose may result in insulin under-delivery as 
compared to plasma glucose and/or SMBG values.  
A number of studies have examined the accuracy of rtCGM during exercise; some using 
SMBG as a reference (221), while others compare venous blood as the reference, using a glucose 
analyzer (190, 191, 225). The laboratory standard for CGM accuracy is most commonly a 
glucose analyzer (Yellow Springs Instrument, Xylem Inc., OH) (226, 227); however, we chose 
two commonly used SMBG meters as separate reference values in this study. In a real-world 
setting, patients will not have glucose analyzers available to use as a reference during exercise, 
and therefore, SMBG is a more realistic reference measurement. Interestingly, according to a 
recent study that used capillary blood glucose concentration as a reference for CGM accuracy as 
compared to venous blood found that SMBG as the reference was associated with significantly 
lower MARD values as compared to plasma glucose as measured by a glucose analyzer 
(HemoCue measurement system, Ängelholm, Sweden) (228).  
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Measuring rtCGM accuracy may be negatively impacted if the reference method is 
different from the method that is used to calibrate the rtCGM device (228). In the present study, 
all rtCGM calibrations were made using patient’s own PDM glucose meter (referred to as 
glucose meter 2). As such, glucose meter 2 and rtCGM values were not different during rest (P > 
0.05), but CGM lag was apparent during exercise. Although rtCGM lag was evident during 
exercise versus both glucose meter devices, glucose meter 1 values also started higher than 
rtCGM values during rest, likely because the rtCGM calibrations were made using glucose meter 
2 (Figure 6.1A). As such, we normalized the data for all three devices to baseline glucose to help 
determine if the change in glucose was accurately reflected by rtCGM as compared to SMBG. 
As can be observed in Figure 6.1B, rtCGM lags behind SMBG during exercise and significantly 
underestimates the drop in glucose as compared to SMBG (P < 0.001). Unfortunately, we did not 
measure plasma glucose levels using a standardized glucose analyzer, so it is currently unclear 
which glucose meter was more accurate or if the drop in glucose as measured by rtCGM was a 
true underestimation of circulating plasma glucose concentrations. However, with the data that 
we collected, we found a low CV (%) between the first and second glucose reading for both 
glucose meter 1 (1.8 ± 1.5%) and glucose meter 2 (2.2 ± 1.9 %).  
Despite a clear lag in interstitial glucose as measured by rtCGM during exercise, we 
found that sensor glucose levels had good congruency during the meal challenge. More 
specifically, as shown in Figure 6.3A, 100% of the values are in Zones A and B of the Clarke 
Error Grid during the meal challenge. It is important to recognize that the regression analysis 
alone does not differentiate which points are in Zones A to E. For example, the values that are in 
Zone D could lead to failure to detect hypoglycemia or hyperglycaemia and in Figure 6.3A 
during the meal, all of the points fell in safe and acceptable Zones A and B.  
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In summary, rtCGM technology helps patients closely monitor glucose levels and make 
appropriate changes in order to prevent dysglycemia. Numerous studies have reported that 
regular use of rtCGM lowers the time spent in hypoglycemia, and improves HbA1c and quality of 
life in both children and adults with type 1 diabetes (229-232). However, we conclude that the 
accuracy of rtCGM is negatively impacted by aerobic exercise and patients need to be aware of 
this potential rtCGM time delay. More specifically in our study, the rtCGM lag time was ~10-15 
minutes behind SMBG readings during exercise relative to two different SMBG devices. Due to 
this clinically important delay in interstitial glucose versus SMBG, we suggest patients increase 
vigilance and perform more frequent fingerstick capillary glucose monitoring around exercise. In 
addition, one solution to rtCGM lag as described by Turksoy and colleagues (233) includes 
incorporating wearable technology with automated insulin delivery which can better detect the 
changes in glucose levels and shows promise in the prevention of hypoglycemia during exercise. 
Few studies have assessed the accuracy of rtCGM and flash glucose monitor devices in patients 
with type 1 diabetes in outpatient settings (234, 235), therefore, future studies should also focus 
on comparing the newest and most advanced CGM technology in outpatient settings with a 
greater emphasis on exercises of varying intensities and durations. 
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Table 6.1: Clarke Error Grid Zones 
Zones 
Glucose Meter 1 vs. CGM Glucose Meter 2 vs. CGM 
Rest Exercise Meal Rest Exercise Meal 
A 122/153 (80%) 164/204 (80%) 115/153 (75%) 129/153 (84%) 141/204 (69%) 127/153 (83%) 
B 29/153 (19%) 38/204 (19%) 38/153 (25%) 23/153 (15%) 52/204 (25%) 25/153 (16%) 
C 0/153 (0%) 0/204 (0%) 0/153 (0%) 0/153 (0%) 0/204 (0%) 0/153 (0%) 
D 2/153 (1%) 2/204 (1%) 0/153 (0%) 1/153 (1%) 11/204 (5%) 1/153 (1%) 
E 0/153 (0%) 0/204 (0%) 0/153 (0%) 0/153 (0%) 0/204 (0%) 0/153 (1%) 
 
Notes: Clarke Error Grid zones A-E comparing glucose meter 1 vs. CGM and glucose meter 2 vs. CGM during rest, exercise, and 
meal post-exercise. Zone A = Values within 20% of glucose meter, Zone B = Points are outside of 20%, but would not lead to 
inappropriate treatment, Zone C = Points leading to unnecessary treatment, Zone D = Points indicate potentially dangerous failure to 
detect hypo- or hyperglycaemia, Zone E = Points that would confuse treatment of hypo- for hyperglycaemia and vice versa. 
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Figure 6.1: Absolute and relative change in blood glucose level. 
A, Absolute values of glucose meter 1, glucose meter 2, and CGM during exercise and meal challenge. # represents glucose meter 1 
different than CGM and glucose meter 2 (P < 0.05). * represents CGM different than glucose meter 2 (P < 0.05). B, Change in 
glucose levels (relative to time = 0) across all three devices during exercise and meal challenge. + represents CGM different than 
glucose meter 1 and glucose meter 2 (P < 0.05). $ represents CGM different than glucose meter 1 (P = 0.01). Data represents mean ± 
SEM, n=17.  
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Figure 6.2: Mean absolute relative difference (%). 
A, Mean absolute relative difference (MARD) comparing CGM to glucose meter 1 during rest, 
exercise, and meal. B, MARD comparing CGM to glucose meter 2 during rest, exercise, and 
meal. # represents MARD during exercise is significantly different compared to rest and meal 
recovery (P < 0.05). 
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Figure 6.3: Clarke error grids during rest, exercise and meal recovery. 
A, Clarke error grids comparing glucose meter 1 with CGM values during rest, exercise, and meal. B, Clarke error grids comparing 
glucose meter 2 with CGM values during rest, exercise, and meal.
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7.0 GENERAL DISCUSSION AND SUMMARY OF 
FINDINGS
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7.1 Discussion 
 The general goals for clinicians and healthcare practitioners around glycemic 
management for their patients living with type 1 diabetes is to help improve the percent time 
spent in a targeted glucose range, reduce the frequency and number of hypoglycemia incidences, 
and ultimately reduce or maintain HbA1c levels < 7.0%. Individuals with type 1 diabetes are 
advised to participate in at least 150 minutes of regular physical activity weekly, for a variety of 
health and fitness reasons, with no more than two days of rest in between and incorporate 
additional resistance training 2-3 times per week (14). Unfortunately, being physically active 
with diabetes can sometimes be at odds with the glycemic management goals. Insulin dose 
adjustments are often required for patients with type 1 diabetes in anticipation of exercise. The 
amount and type of insulin adjustment will also likely differ depending on the intensive insulin 
therapy used to manage diabetes (i.e. MDIs vs. CSII). The goal of this thesis is to help develop 
better glycemic management strategies for a variety of exercise settings in patients with type 1 
diabetes using CSII. 
For patients using CSII therapy, we showed that insulin pump suspension at the start of a 
40-minute bout of continuous steady state moderate intensity exercise leads to a greater drop in 
blood glucose level compared to vigorous-to-maximal intensity circuit-based exercise (116). In 
this study, we observed that this type of exercise (i.e. predominantly ‘aerobic’) not only 
increased the likelihood of hypoglycemia during activity, but in the 12-hour recovery period 
post-exercise as well. As such, from this study, it is apparent that pre-exercise insulin reduction 
is necessary to reduce the likelihood of hypoglycemia. 
In general, to reduce the risk of hypoglycemia for prolonged aerobic exercise well after 
meal absorption (i.e. 3 or more hours after a meal), basal insulin dose reductions are 
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recommended for patients using CSII ~60–90 minutes before exercise, when possible (13, 14). 
For vigorous-to-maximal intensity exercise and short duration vigorous-to-maximal intensity 
resistance exercise, insulin reductions are often not required during exercise, and even a small 
insulin correction may be required after exercise if hyperglycemia ensues (132).  
Patients with type 1 diabetes often experience post-exercise nocturnal hypoglycemia and 
therefore, a greater emphasis needs to be placed on the importance of rtCGM and more frequent 
and closer monitoring of blood glucose levels after unusual and prolonged activity. Ideally, 
planned activity should follow a regular pattern (i.e. same time of day, same intensity, same 
duration) so that insulin dose strategies can be incorporated routinely with some degree of fine-
tuning based on individual responses.  
Unfortunately, there is limited clinical research that supports the current exercise 
guidelines for basal rate reductions in anticipation of aerobic exercise for patients living with 
type 1 diabetes (13). Even with the current evidence around basal insulin adjustments well in 
advance of exercise (84, 117), hypoglycemia is still a significant risk for most patients during 
aerobic exercise. Therefore, we tested the effectiveness of 50% and 80% basal insulin reductions 
set 90 minutes in advance of aerobic exercise to try and prevent hypoglycemia. We found that a 
50-80% basal rate reduction set 90 minutes before aerobic exercise can significantly attenuate 
the drop in glycemia versus insulin pump suspension at exercise onset (122). Although effective 
at reducing hypoglycemia during aerobic exercise, future research should also focus on more 
practical approaches requiring less advanced planning, such as a modified basal rate reduction at 
exercise start time with some carbohydrate feeding, that can reach a wider patient population.   
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7.2 Summary of Findings  
Academic paper #1 investigated the effects of basal insulin suspension at the start of 
exercise on blood glucose level during continuous versus circuit-based exercise in individuals 
with type 1 diabetes on CSII. Although exercise guidelines recommend reducing basal insulin 
well in advance of exercise, in reality, many individuals with type 1 diabetes disconnect or 
suspend basal insulin at exercise start, particularly in the case of unplanned exercise. Our 
findings confirm that during 40 minutes of continuous steady state exercise there was a 
significantly greater drop in glycemia compared to circuit-based exercise. However, we also 
found that circuit-based exercise deteriorates blood glucose estimations compared to continuous, 
moderate-intensity aerobic exercise. This study provides patients and clinicians with valuable 
insight into how different exercise intensities impact glycemia. Particularly with the increased 
risk of hypoglycemia during continuous steady state exercise, research studies still need to 
optimize insulin reduction strategies to prevent hypoglycemia. In summary, if 40 minutes of 
unplanned CON exercise is being performed, pump suspension at exercise onset likely will not 
prevent the drop in glycemia and additional carbohydrate feeding may be necessary. 
Alternatively, with unplanned activity, patients can choose CIRC exercise with pump suspension 
instead, as the drop in glycemia may not be as drastic. 
Academic paper #2 examined the impact of ‘pump on’ versus ‘pump off’ on blood 
glucose concentration during intermittent high intensity exercise and 12 hours in recovery. We 
found that prolonged intermittent high intensity exercise can be performed with insulin ‘pump 
on’ or ‘pump off’ with no noticeable difference on glycemia during the activity. However, ‘pump 
on’ during intermittent high intensity exercise may increase the risk for hypoglycemia in the 12 
hours following exercise. Our hypothesis was that ‘pump off’ would lead to a smaller drop in 
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glycemia versus ‘pump on’ during intermittent high intensity exercise. Having found no 
significant differences in blood glucose levels between conditions, now patients with type 1 
diabetes looking to perform up to 40 minutes of intermittent high-intensity exercise have the 
option of ‘pump on’ or ‘pump off’. These data are especially valuable for patients with type 1 
diabetes who prefer to disconnect their insulin pump for comfort reasons during intermittent high 
intensity exercise because it does not appear to negatively impact glycemia. In fact, in the 12-
hour recovery period after exercise, ‘pump off’ led to less time in hypoglycemia compared to 
‘pump on’ and therefore, may be the preferred strategy during intermittent high intensity 
exercise. 
 Academic paper #3 investigated whether a 50% or 80% BRR set 90 minutes before 
prolonged, continuous steady state exercise can better attenuate the drop in glycemia versus 
pump suspension at exercise onset in patients with type 1 diabetes on CSII. Based on the 
findings from academic paper #1 and previously published research (83), we decided to test an 
earlier BRR strategy in attempt to reduce circulating free insulin levels pre-exercise. In this 
study, we found that a 50-80% BRR set 90 minutes pre-exercise optimizes glucose control and 
decreases the risk of hypoglycemia during exercise better than pump suspension at exercise 
onset. Interestingly, this basal rate reduction set 90 minutes pre-exercise did not compromise the 
meal recovery glucose control in patients living with type 1 diabetes. Based on the individual 
blood glucose data, we also found variability in glucose responses among participants during 
exercise in each of the three BRR strategies. As such, the BRR strategies that we tested were 
able to effectively attenuate the drop in glycemia during prolonged aerobic exercise. However, it 
is important to note that one BRR strategy may not apply for all and may still need to be 
individualized for any given patient. 
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Academic paper #4 examined the accuracy of rtCGM during prolonged, continuous 
steady state exercise and during meal recovery in adults living with type 1 diabetes. Our findings 
confirm that rtCGM underestimates the drop in glycemia during exercise and lags behind blood 
glucose concentration by ~10-15 mins when glucose levels are changing rapidly. This was the 
first study to test the accuracy of newer rtCGM technology (Dexcom G4® Platinum with 505 
algorithm and G5®) during prolonged continuous steady state exercise. Overall, patients need to 
be aware of this potential rtCGM time delay as it may impact specific insulin-dosing decisions 
and/or carbohydrate feeding during exercise. In addition, patients need to be aware of the 
importance of using the same blood glucose-monitoring device for rtCGM calibrations and 
regular SMBG testing. Ultimately, whether patients with type 1 diabetes are using rtCGM or 
SMBG, it is important to increase vigilance and perform more frequent fingerstick capillary 
glucose monitoring around exercise as additional safety measures. An additional suggestion 
would be for patients using CSII therapy and rtCGM to set higher limits for low blood glucose 
alarms during physical activity and exercise. Also, since the accuracy of rtCGM devices is highly 
correlated with the glucose rate of change, patients with diabetes should attempt to exercise with 
lower circulating insulin ‘on-board’ to minimize glucose variability.  
7.3 Future Considerations 
Although many of the strategies described above should help healthcare providers further 
promote regular physical activity and exercise for patients with type 1 diabetes, we cannot ignore 
that recommendations are not always practical and attainable due to the extensive pre-planning 
required. Therefore, future considerations should include the incorporation of hybrid closed-loop 
therapy to improve overall glucose control and reduce the likelihood of hypoglycemia in a 
variety of exercise settings. Studies have already demonstrated that single-hormone (insulin-
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only) hybrid closed-loop systems can improve overall glycemic control and reduce HbA1c levels; 
however, many of these systems still struggle to effectively reduce the initial drop in glycemia 
that is commonly associated with aerobic exercise and ultimately prevent hypoglycemia (151, 
223). 
Since a single-hormone hybrid closed-loop system may not be the solution for preventing 
exercise-associated hypoglycemia, particularly with unplanned exercise, then future research 
should consider more exercise studies with the use of dual-hormone (insulin and glucagon) 
hybrid closed-loop systems. Recently, Castle and colleagues (168) showed that the addition of 
glucagon delivery to a closed-loop system with wearable technology used to detect exercise can 
reduce hypoglycemia in physically active adults with type 1 diabetes. Despite optimal insulin 
and glucagon delivery with hybrid closed-loop systems, the main driver of the algorithm is an 
accurate rtCGM device. In our studies, we showed an important clinical lag in rtCGM 
technology during aerobic exercise. Further research is required in this area, particularly to 
consider how different exercise intensities, durations, and times of day can impact glycemia. 
Industry partners and research need to continue improving the accuracy of all rtCGM devices, 
particularly when insulin and/or glucagon dosing will be automated in future commercialized 
hybrid closed-loop devices.  
In addition to dual-hormone hybrid closed-loop studies around exercise, a greater focus 
should be placed on longer duration or exercise training studies in patients with type 1 diabetes. 
Because the current findings are all based on acute, short-term exercise studies, the data needs to 
be very carefully interpreted if the outcomes are translated into clinical practice. In addition, as 
we have shown throughout this thesis, high variability exists among patients with diabetes and 
therefore, the reproducibility of data may be an additional challenge in this field of research. We 
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cannot ignore the importance of current acute exercise research studies in patients with type 1 
diabetes worldwide; however, more collaborative and multidisciplinary projects will allow for 
increased sample sizes and potentially more impactful scientific research outcomes. Overall, 
larger studies will hopefully allow for research outcomes and findings that can be applied to a 
wider patient population. It is also important to note that our studies were limited to patients with 
type 1 diabetes using CSII therapy and different strategies are needed for individuals on MDI 
therapy that have a greater challenge with manipulating basal insulin levels. 
To date, there are very few studies published exploring the potential sex-related 
differences in response to exercise in patients living with type 1 diabetes. Sex-related differences 
have been extensively studied during exercise and are apparent in individuals without diabetes. 
For example, during aerobic exercise, females generally exhibit higher rates of fat oxidation 
(236), higher estrogen concentrations (237), and lower catecholamine (specifically epinephrine) 
responses (238) compared to males. As such, since females tend to deplete less of their glycogen 
stores during exercise compared to males, they may also experience greater protection of blood 
glucose concentration during exercise. Whether sex-related differences exist during exercise in 
patients with type 1 diabetes, but also whether there are possible implications on blood glucose 
responses during exercise is also presently unknown (207). In the Appendix section of this thesis 
dissertation, we graph the blood glucose responses during exercise, separated by males and 
females. Unfortunately, due to the small sample size, we were underpowered and therefore 
unable to draw inferences on sex-related differences in patients with type 1 diabetes during 
exercise. Further research is required to investigate any potential sex-related differences during 
exercise in individuals with type 1 diabetes. 
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7.4 Conclusions 
 Overall this thesis dissertation reveals that different basal insulin strategies can be used to 
improve glucose control depending on the type of activity being performed. We found that pump 
suspension at exercise onset led to a significantly greater drop in glycemia during CON versus 
CIRC exercise. During CON exercise, however, participants were better able to estimate their 
blood glucose concentration when blinded to their measured blood glucose level during activity. 
We also found that intermittent high intensity exercise can be performed with the insulin ‘pump 
on’ or ‘pump off’ with no noticeable effect on glycemia during the activity. However, ‘pump on’ 
during intermittent high intensity exercise may increase hypoglycemia risk in recovery following 
exercise. In order to reduce the likelihood of hypoglycemia during aerobic exercise and in 
recovery for individuals living with type 1 diabetes, insulin dose reductions must be made 
significantly in advance of the activity (90 minutes pre-exercise start) or additional carbohydrate 
feeding will be required. In addition, we showed that even an acute bout of aerobic exercise can 
lead to an increased risk of nocturnal hypoglycemia and reducing basal insulin by 20% at 
bedtime for 6 hours can help combat this risk. Finally, we showed that even with newer rtCGM 
technology, a clinical lag was observed compared to SMBG during 60 minutes of aerobic 
exercise. Therefore, increased vigilance and SMBG is recommended before, during, and after 
exercise for patients with type 1 diabetes. The maintenance of blood glucose concentration in 
optimal glucose range especially during exercise and in recovery remains one of the biggest 
obstacles in the lives of many individuals with type 1 diabetes.  
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Abstract 
Background: Continuous glucose monitoring (CGM) devices capture glucose excursions better 
than self-monitoring of blood glucose (SMBG). However, the accuracy of CGM devices, 
specifically around exercise and insulin-dosing decisions remains a concern.  
Methods: In this case study, one physically active male with T1D, using a hybrid closed-loop 
system, completed 13 continuous steady state moderate intensity or aerobic exercise sessions to 
compare the accuracy of two real-time CGM (rtCGM) devices, one flash glucose monitor (FGM) 
and SMBG.  
Results: At the onset of exercise, glucose levels were significantly higher with FGM (237 ± 45 
mg/dL) versus rtCGM1 (198 ± 34 mg/dL, P=0.0001), rtCGM2 (206 ± 35 mg/dL, P=0.0001), and 
SMBG (215 ± 33 mg/dL, P=0.003), respectively. FGM values rose transiently (P=0.0001) after 
the start of exercise and remained higher than all other devices until 30 minutes of aerobic 
exercise (P<0.05). 
Conclusion: During periods of relatively stable glucose concentrations, rtCGM and FGM may 
correlate well with SMBG; however, a lag effect is observed during steady state moderate-
intensity exercise in individuals with T1D. Both rtCGM and FGM devices tend to overestimate 
glucose values with moderate-intensity exercise therefore, the threshold for carbohydrate feeding 
during aerobic exercise should be initiated at a much higher glucose when using rtCGM or FGM 
devices compared to SMBG.  
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Introduction 
Continuous glucose monitoring (CGM) devices are emerging as the standard of care for 
managing type 1 diabetes (T1D) (146, 161, 239). These new tools allow for the convenience of 
frequent monitoring in a variety of settings and they detect more hypo- and hyperglycemic 
events compared to frequent self-monitoring of blood glucose (SMBG) (41, 240-242). In the 
context of exercise, they are also valuable in detecting activity-related dysglycemia in youth with 
T1D (221). Improvements in accuracy have led to non-adjunctive status, so that insulin dosing 
and hypoglycemic management decisions are possible with several devices (214-216). For 
current and emerging commercial products that modulate continuous subcutaneous insulin 
infusion (CSII), and for future devices that may deliver glucagon as well, efficacy and safety of 
these devices are largely predicated on the accuracy of the integrated CGM.   
 Despite non-adjunctive insulin dosing indications in some of these devices, the use of 
CGM readings for decision-making without confirmatory fingerstick glucose measurements 
remains a concern. Specifically, precautions should be taken during circumstances of rapid 
changes in glucose (e.g. following a meal, during exercise), when symptoms do not match blood 
glucose readings, and in patients with end-stage renal dysfunction, pregnancy, liver disease, and 
other edematous states (7, 226, 243). The physiologic lag in equilibrium between interstitial and 
blood glucose, which may be anywhere between 5-15 minutes (165, 167, 218, 219, 244), can 
cause a clinically important discrepancy between CGM and SMBG during moderate-to-intense 
physical activity (174, 189, 225, 245-247). Due to this lag effect, it remains unclear whether 
CGM use during aerobic activity is adequate for glucose management decisions, including when 
to initiate carbohydrate replacement to avoid hypoglycemia and determine the appropriate 
amount and/or timing of carbohydrate ingestion. 
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Blood glucose levels tend to fall with continuous steady state moderate intensity or 
aerobic exercise (81, 84, 116) and rise with vigorous-to-maximal intensity exercise (87, 248, 
249). Previous studies have shown reduced CGM accuracy during exercise due to the lag effect 
combined with rapidly changing glucose levels resulting in a large absolute difference between 
sensor glucose and the laboratory standard (e.g. Yellow Springs Instrument [YSI] glucose 
analyzer) (190, 191, 220).  
The data presented here examined the concurrent use of three commonly used glucose-
monitoring devices (two real-time continuous glucose monitors (rtCGM), and one flash glucose 
monitor [FGM]) in conjunction with SMBG during aerobic exercise to determine whether the 
information derived from these devices could be used effectively to guide carbohydrate intake to 
avoid hypoglycemia. 
Methods 
A male subject with T1D (age 40 years; diabetes duration 25 years; HbA1c 6.5%; and 
body mass index 24.9), experienced in marathon running was studied over two months. He 
averaged ~25 miles of moderate-intensity running per week in 3-4 workouts. Written informed 
consent was obtained from the participant for this case report. The subject reported no significant 
diabetes-related complications or hypoglycemia unawareness based a score of two for the Clarke 
and Gold questionnaires, respectively (205, 206).   
The subject wore a Food and Drug Administration (FDA) approved HCL insulin delivery 
system (Medtronic MiniMed 670G insulin pump with HCL algorithm, Guardian® Sensor 3 
glucose sensor with Guardian Link 3 transmitter [Minneapolis, MN, USA], rtCGM1), Dexcom 
G5® mobile CGM system (San Diego, CA, USA), rtCGM2, and Abbott FreeStyle Libre FGM 
system (Chicago, IL, USA). The FGM was placed on the upper arm while the rtCGM devices 
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were placed on the abdomen or upper buttocks at least 24 hours prior to exercise. SMBG and all 
calibrations were performed using a Contour® Next Link glucose meter (Ascensia Diabetes Care, 
Parsippany, NJ, USA) according to manufacturer recommendations. 
To reduce the likelihood of hypoglycemia, and based on personal experience, the HCL 
insulin pump was placed in an ‘exercise target mode’ (i.e. target set to 150 mg/dL) one-hour 
prior to the onset of exercise, disconnected during exercise, and reconnected immediately 
following exercise. Pre-exercise meals were consumed > four hours prior to exercise with usual 
insulin dosing, to help minimize the drop in glucose during exercise due to residual bolus insulin 
(13). To achieve a starting blood glucose target of 180-200 mg/dL, carbohydrate 
supplementation (16-20g) was used 60 minutes prior to exercise if blood glucose levels were 
below this range. 
In each session, SMBG were recorded 10-minutes before and after exercise and every 10-
minutes during exercise. A total of 13 exercise sessions were completed over a period of two 
months, each consisting of ~60 minutes of running per session, either outdoors on a flat course or 
on a treadmill with a consistent pace of 7 minutes and 15 seconds per mile, at a moderate-
intensity. Carbohydrate gels (GU Energy Gel, 22g of maltodextrin, Berkeley, CA) were used to 
avoid hypoglycemia based on SMBG values and rate of change based on previous experiences 
(absolute SMBG < 140 mg/dL with decrease > 2 mg/dL/min (one straight down trend arrow on 
the Dexcom G5® mobile CGM system) or < 180 mg/dL with rapidly changing blood glucose > 3 
mg/dL/min (two straight down trend arrows on the Dexcom G5®). 
Statistical Analysis 
Glucose measurements among all devices (SMBG, rtCGM1, rtCGM2, and FGM) were 
compared using a two-way repeated measures ANOVA. MARD was calculated using the 
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difference between the reference glucose meter (SMBG) and glucose-monitoring device 
(rtCGM1, rtCGM2, and FGM) and dividing it by the reference, then multiplied by 100. A one-
way ANOVA was used to compare the difference between MARD across all devices when 
complete datasets were available (12 sessions had complete data across all glucose monitoring 
devices). In addition, a one-way ANOVA was used to compare devices at the start and end of 
exercise, the glucose at which point carbohydrate was initiated, and the rate of change in glucose 
at the time of carbohydrate ingestion. Tukey’s post hoc multiple comparisons test was used when 
significant interactions were found. All analyses were conducted using GraphPad Prism version 
7.0 (GraphPad Software, CA, USA). All of the data are represented as mean ± standard deviation 
(SD) and the statistical significance was set a priori to P < 0.05, unless otherwise indicated. 
Results 
Full datasets capturing glucose data from SMBG and all three interstitial glucose-
monitoring devices were captured in 12 of 13 exercise sessions. Missing data occurred for one 
rtCGM2 device because of signal loss.  
Table A1 represents the results of glucose testing across all devices and carbohydrate 
intake during aerobic exercise, while Table A2 shows the statistical comparisons across all of the 
devices. Capillary blood glucose concentrations, as measured by SMBG, dropped rapidly during 
exercise, from 215 ± 33 to 104 ± 23 mg/dL (P = 0.0001) even with significant carbohydrate 
intake (60 ± 24 grams per session) and the HCL system set to an ‘exercise target mode’ one hour 
before exercise and the pump suspended during activity. SMBG values were markedly lower (by 
about 30-35%) than the three glucose-monitoring devices, particularly the FGM that tended to 
show a transient rise in glucose concentrations. Moreover, the rate of change (i.e. drop rate) in 
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glucose at the initiation of carbohydrate feeding was much higher with SMBG (4.0 ± 1.8 
mg/dL/min) versus rtCGM1 (0.8 ± 1.6 mg/dL/min) (P = 0.002). 
Table A3 represents the MARD during rest and exercise when comparing SMBG to each 
glucose-monitoring device (rtCGM1, rtCGM2, and FGM, respectively). MARD was lower at 
rest compared to exercise when comparing SMBG to all other devices (Table A3). Specifically, 
during rest, rtCGM2 was significantly lower compared to FGM (P = 0.02). During exercise, the 
MARD for rtCGM1 and rtCGM2 was significantly lower than the MARD for FGM (both P < 
0.001). 
Figure A1 illustrates glucose data from the three glucose-monitoring devices and SMBG 
across the 13 exercise sessions. Based on repeated measures ANOVA, a trial by time interaction 
was found (P = 0.0001). At exercise onset, glucose levels were higher with FGM (237 ± 45 
mg/dL) versus rtCGM1 (198 ± 34 mg/dL, P = 0.0001), rtCGM2 (206 ± 35 mg/dL, P = 0.0001), 
and SMBG (215 ± 33 mg/dL, P = 0.003), respectively. FGM values rose transiently (P = 0.0001) 
after the start of exercise and remained higher than all other devices until 30 minutes of exercise 
(P < 0.05). SMBG values were lower than FGM from the start until the cessation of exercise (P 
< 0.05). SMBG were also lower than rtCGM1 and rtCGM2 from 10- to 50-minutes of exercise 
(both P < 0.05). Figure A2 is the supplemental information that represents individual glucose 
data for all devices (rtCGM1, rtCGM2, FGM, and SMBG) across the 13 exercise sessions.   
Discussion  
This case study demonstrates that while rtCGM and FGM may correlate well with SMBG 
during periods of relative glucose stability, a clinically important lag effect is observed during 
aerobic exercise when glucose levels are declining rapidly. This discrepancy between SMBG and 
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interstitial glucose monitoring devices (i.e. rtCGM and FGM) may impact critical decision-
making for carbohydrate replacement during planned exercise and routine physical activity. 
This study also demonstrates that the absolute differences in glucose concentration 
between SMBG and rtCGM or FGM were greatest in the first 30 minutes after the onset of 
exercise as blood glucose levels showed the most rapid decline. Interestingly, FGM reported 
significantly higher readings compared to all other devices during the first 30 minutes of activity 
and frequently reported a rise after the start of exercise (Figure A1).  
Individuals with T1D tend to require carbohydrate feeding during prolonged aerobic 
exercise and often use CGM trend arrows to guide when to initiate feeding (182, 250). The 
amount of carbohydrate intake required to avoid hypoglycemia varies depending on the intensity 
and duration of exercise, familiarity of activity, and other factors (13). In this case study, during 
aerobic exercise, carbohydrate intake of ~ 60 ± 24 grams per hour (i.e. 0.73 g/kg/hr) was 
sufficient to prevent hypoglycemia when ingested as glucose levels began dropping. It is notable 
that SMBG levels dropped markedly during exercise despite using a HCL system set in ‘exercise 
target mode’ 60 minutes pre-exercise and with pump suspension during exercise- further 
highlighting the challenge that aerobic exercise places on developing HCL systems (15).  
Given that the accuracy of glucose monitoring devices appears dependent on the glucose 
rate of change, efforts should be made to minimize glucose variability by considering insulin 
‘on-board’ and intensity and type of exercise. The use of mini-dose glucagon in a HCL system 
during exercise or subcutaneously prior to exercise may emerge as an effective alternative to 
insulin reduction and increased carbohydrate intake (161, 251).  
Limitations of this case study include the use of SMBG as a reference compared to all 
glucose monitoring devices since YSI glucose was not available (226-228). However, use of 
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capillary versus venous blood for CGM accuracy is generally associated with significantly lower 
MARD values (228).  
Conclusions 
Due to the observed lag in interstitial glucose as compared to SMBG during exercise, we 
recommend to initiate carbohydrate feeding sooner (i.e. when glucose is ~200 mg/dL and 
dropping) when the patient is relying on rtCGM or FGM devices for decision-making. Whether 
this recommendation holds true for all exercise situations remains unclear. Future studies should 
increase the sample size and include women, children, and adolescents. In addition, the potential 
impact of rtCGM and FGM device location and day-of-wear on accuracy should also be 
investigated. 
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Table A1: Glucose testing and carbohydrate intake during 60 minutes of steady state, 
continuous exercise. 
 SMBG 
(Contour Next) 
rtCGM1 
(Guardian®) 
rtCGM2 
(Dexcom G5®) 
FGM 
(FreeStyle Libre) 
Glucose at exercise onset 
(mg/dL) 215 ± 33 198 ± 34 206 ± 35 237 ± 45 
Glucose after 60-min 
exercise (mg/dL) 104 ± 23 120 ± 26 120 ± 32 141 ± 29 
Glucose at which 
carbohydrate intake 
initiated 
143 ± 32 194 ± 43 196 ± 34 225 ± 45 
Rate of glucose drop 
(mg/dL/min) at time 
carbohydrate intake 
initiated 
4.0 ± 1.8 0.8 ± 1.6 1.9 ± 1.8 1.9 ± 2.7 
Note: Data represents mean ± SD.  
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Table A2: Statistical analysis of “glucose testing and carbohydrate intake during 60 minutes of 
steady state, continuous exercise” (as shown above). 
 SMBG   
vs. 
rtCGM1 
SMBG   
vs. 
rtCGM2 
SMBG  
vs.     
FGM 
rtCGM1 
vs. 
rtCGM2 
rtCGM1 
vs.     
FGM 
rtCGM2 
vs.     
FGM 
Glucose at exercise onset 
(mg/dL) X    X X 
Glucose after 60-min 
exercise (mg/dL)   X  X X 
Glucose at which 
carbohydrate intake 
initiated 
X X X  X X 
Rate of glucose drop 
(mg/dL/min) at time 
carbohydrate intake 
initiated 
X X     
Note: ‘X’ represents statistically significant difference between devices (P < 0.05).  
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Table A3: Mean absolute relative difference (MARD) comparing SMBG to rtCGM1, rtCGM2, 
and FGM during rest and during exercise 
 rtCGM1 
(Guardian®) 
rtCGM2 
(Dexcom G5®) 
FGM 
(FreeStyle Libre) 
MARD at Rest (%) 9 ± 5 6 ± 6 * 11 ± 8 
MARD During Exercise 
(%) 29 ± 24 31 ± 21 44 ± 24 # 
Note: Data represents mean±SD, * significantly different from FGM; P=0.02. # significantly 
different from rtCGM1 and rtCGM2 (both P < 0.001). 
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Figure A1: Absolute glucose concentrations for all devices (rtCGM1, rtCGM2, FGM, and 
SMBG) across 13 exercise sessions. * indicates that FGM is significantly higher than all other 
device (rtCGM1, rtCGM2, and SMBG), α indicates that SMBG values are significantly lower 
than both rtCGM1 and rtCGM2, and # indicates that SMBG remained significantly lower than 
FGM values from the start to the end of exercise. Significance was set to P<0.05. 
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Figure A2: Additional individual glucose data for all devices (rtCGM1, rtCGM2, FGM, and SMBG) across 13 exercise sessions.
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Appendix B: Ethics Approval 
 
Study #1 & #2: Adjusting insulin pump basal levels for exercise in adults with T1D 
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Study #3 & #4: Omnipod type 1 diabetes insulin management for exercise study (OmniTIME 
Study) 
 
 
  
OFFICE OF RESEARCH ETHICS (ORE)
5th Floor, York Research Tower,
4700 Keele Street, Toronto ON
Canada M3J 1P3
Tel 416-736-5914, Fax 416-650-8197
www.research.yorku.ca
Memo
To: Michael Riddell, Kinesiology
From: Alison M. Collins-Mrakas, Sr. Manager and Policy Advisor, Research Ethics
Issue Date: Wed Mar 01 2017
Expiry
Date: Thu Mar 01 2018
RE: OmniPod Type 1 diabetes Insulin Management for Exercise study (Omni-
TIME-study)
Certificate #: e2017 - 073
I am writing to inform you that the Human Participants Review Sub-Committee has reviewed
and approved the above project.
Should you have any questions, please feel free to contact me at: 416-736-5914 or via email at:
acollins@yorku.ca.
Yours sincerely,
Alison M. Collins-Mrakas M.Sc., LLM
Sr. Manager and Policy Advisor,
Office of Research Ethics
RESEARCH ETHICS: PROCEDURES to ENSURE
ONGOING COMPLIANCE
Upon receipt of an ethics approval certificate, researchers are reminded that they are required to
ensure that the following measures are undertaken so as to ensure on-going compliance with
Senate and TCPS ethics guidelines:
1. RENEWALS: Research Ethics Approval certificates are subject to annual renewal.
a. Researchers will be reminded by ORE, in advance of certificate expiry, that the
certificate must be renewed
i. Researchers have 2 weeks to comply to a reminder notice;
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Appendix C: Questionnaires 
 
Physical Activity Readiness Questionnaire for Everyone: 
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Hypoglycemia Awareness Questionnaires: 
Clarke Score: Survey items used to categorize aware or having reduced 
awareness of hypoglycemia in subjects 
 
1) Check the category that best describes you (check one only): 
________ I always have symptoms when my blood sugar is low  
________ I sometimes have symptoms when my blood sugar is low  
________ I no longer have symptoms when my blood sugar is low  
 
2) Have you lost some of the symptoms that used to occur when your blood sugar was low? 
________ Yes  ________ No  
 
3) In the past 6 months, how often have you had moderate hypoglycemia episodes? (Episodes 
where you might feel confused, disoriented, or lethargic and were unable to treat yourself) 
________ Never  ________ Once or twice  
________ Every other month  ________ Once a month  
________ More than once a month  
 
4) In the past year, how often have you had severe hypoglycemia episodes? (Episodes where you 
were unconscious or had a seizure and needed glucagon or intravenous glucose) 
________ Never  ________ 1 time  ________ 2 times  ________ 3 times  
________ 4 times  ________ 5 times  ________ 6 times  ________ 7 times 
________ 8 times  ________ 9 times  ________ 10 times  ________ 11 times  
________ 12 or more times   
 
5) How often in the last month have you had readings < 3.9 mmol/L with symptoms? 
________ Never  ________ 1 to 3 times  ________ 1 time/week  
________ 2 to 3 times/week  ________ 4 to 5 times/week  ________ Almost daily  
 
6) How often in the last month have you had readings < 3.9 mmol/L without any symptoms? 
________ Never ________ 1 to 3 times  ________ 1 time/week  
________ 2 to 3 times/week  ________ 4 to 5 times/week  ________ Almost daily  
 
7) How low does your blood sugar need to go before you feel symptoms?  
________ 3.4-3.9 mmol/L  ________ 2.8-3.3 mmol/L  
________ 2.2-2.7 mmol/L  ________ < 2.2 mmol/L  
 
8) To what extent can you tell by your symptoms that your blood sugar is low?  
________ Never  ________ Rarely  
________ Sometimes  ________ Often  
________ Always   
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The Gold Score:  
Do you know when your hypos are commencing? Please circle a number: 
 
 
 
 
Always Aware              Never Aware 
 
Awareness:  1     2         3             4     5         6              7 
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Medical Health Questionnaire: 
Medical History 
 
Name: (First, Last)  
 
Age:  
 
DOB: (mm/dd/yyyy)  
 
Sex:  
Male 
 
Female 
Email Address:  
 
Phone Number:  
 
 
When were you diagnosed with diabetes? (Date, including year) 
 
 
What type of insulin pump are you currently using? 
• Medtronic, Animas, One Touch, OmniPod, etc. 
 
How long have you been on insulin pump therapy? (Approximately)  
 
What type of insulin are you using? 
• Novorapid, Humalog, Lantus, etc. 
 
What was your last HbA1c reading?  
When was it? 
 
Have you ever worn a Continuous Glucose Monitor (CGM)?  
(If YES) How long have you been using one?  
 
 
 
YES 
 
 
NO 
Have you had any severe hypoglycemic episodes in the last 6 months?  
Severe = Hospitalizations  
If so, when?  
 
YES 
 
NO 
 
What are your current basal rates if on insulin pump? (List below) 
 
 
     
 
 
     
 
How active are you? (Circle below) 
Not Active 
(0-1 day(s) a 
week) 
Mild 
(2-3 days a 
week) 
Moderate 
(4-5 days a 
week) 
Active 
(6+ days a week) 
Elite 
(National or 
international 
level sport) 
 
What is your TOTAL, daily insulin dose (average)? __________________ units 
Sedentary day: ________________________________ 
  
200 
 
 
 
 
 
 
 
 
 
 
ANTHROPOMETRICS 
1. Sex:      □ M     □ F 
 
2. Date of birth (dd/mm/yyyy):    __ __ / __ __ / __ __ __ __             Age:   __________ 
3. a) Dominant hand:       □ L     □ R                                
 
4. Race/Ethnicity:   
□ White                                               □ American Indian/Alaska Native/Native Canadian 
□ Asian                                                □ Native Hawaiian or Other Pacific Islander  
□ Black or African American             □ Other: ____________________________  
 
5. Weight:   ___ ___ ___ . ___ kg /lbs (circle kg or lbs)     
 
6. Height:    ___ ___ ___ . ___ cm/in (circle cm or in) 
 
7. Systolic BP (SBP): (1) ___ ___ ___ mm Hg          (2) ___ ___ ___ mm Hg          
Average: ___ ___ ___ mm Hg 
 
8. Diastolic BP (DBP): (1) ___ ___ ___ mm Hg        (2) ___ ___ ___ mm Hg          
Average: ___ ___ ___ mm Hg 
 
9. Resting/Basal Heart Rate (HR): (1) ___ ___ ___ bpm     (2) ___ ___ ___ bpm      
Average: ___ ___ ___ bpm 
 
10. Allergies: 
a) Latex:   □ Y   □ N                  Other(s): 
______________________________________________________ 
b) Food restrictions (e.g. vegetarian/celiac/lactose): _________________________ 
 
11. Menstruation (approximate date of menstruation): ______________________ (or N/A) 
 
12. a) Percent body fat (Tanita %): _______________       
b) NIH Waist Circumference (cm): _____________ 
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13. MEDICATIONS 
1. NAME OF 
MEDICATION 
 
TYPE 
TABS 
(digits) 
DOSAGE 
(mg) 
 □ Statin              □ B-blocker               □ Anti-platelet 
□ Fibrate            □ ARB                       □ Anti-obesity 
□ Lipid               □ Ca+ chan. Block     □ Birth control 
□ Ace inhibit      □ Other anti-HTN     □ Daily multivitamin 
□ Diuretic           □ Anti-depressant      
□ Other:______________ 
  
2. NAME OF 
MEDICATION 
 
TYPE 
TABS 
(digits) 
DOSAGE 
(mg) 
 □ Statin              □ B-blocker                □ Anti-platelet 
□ Fibrate            □ ARB                        □ Anti-obesity 
□ Lipid               □ Ca+ chan. Block      □ Birth control 
□ Ace inhibit      □ Other anti-HTN      □ Daily multivitamin 
□ Diuretic           □ Anti-depressant      
□ Other:______________ 
  
3. NAME OF 
MEDICATION 
 
TYPE 
TABS 
(digits) 
DOSAGE 
(mg) 
 □ Statin               □ B-blocker                □ Anti-platelet 
□ Fibrate             □ ARB                         □ Anti-obesity 
□ Lipid                 □ Ca+ chan. Block     □ Birth control 
□ Ace inhibit      □ Other anti-HTN      □ Daily multivitamin 
□ Diuretic           □ Anti-depressant      
□ Other:______________ 
  
4. NAME OF 
MEDICATION 
 
TYPE 
TABS 
(digits) 
DOSAGE 
(mg) 
 □ Statin              □ B-blocker                □ Anti-platelet 
□ Fibrate            □ ARB                        □ Anti-obesity 
□ Lipid               □ Ca+ chan. Block      □ Birth control 
□ Ace inhibit      □ Other anti-HTN      □ Daily multivitamin 
□ Diuretic           □ Anti-depressant      
□ Other:______________ 
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DIABETES INFORMATION 
 
14. Date of Diagnosis (dd/mm/yyyy): __ __ / __ __ / __ __ __ __ 
 
15. Type of Regimen: □ OmniPod     □ Other: ________________________ 
 
16. Current Basal Rates: 
(a) _____________________ (U/hr) + Time               (e) _____________________ (U/hr)                  
(b) _____________________ (U/hr) + Time               (f) _____________________ (U/hr)            
(c) _____________________ (U/hr) + Time               (g) _____________________ (U/hr)            
(d) _____________________ (U/hr) + Time               (h) _____________________ (U/hr)            
 
17. Type of Insulin: 
    □ NPH                     □ Lantus/Insulin Glargine          □ Novorapid/Insulin Aspart          □ Novolin 30/70       
    □ Lente                   □ Levemir/Insulin Detemir        □ Apidra/Glulisine                          □ Humulin N 
    □ Ultralente           □ Regular Insulin                         □ Humalog/Insulin Lispro         
18. Diabetes Complications: 
    Has a doctor ever told the patient they have: 
    High blood pressure   □ Y     □ N               Nephropathy               □ Y     □ N                 
    Retinopathy                 □ Y     □ N               Neuropathy                  □ Y     □ N 
19. Does the patient have a history of cardiovascular disease?  □ Y     □ N 
If yes, further details: 
______________________________________________________________________ 
20. History of Lows: 
When the patient feels low, do they test and record their blood glucose?   □ Y     □ N 
Do they treat with carbohydrates?   □ Y     □ N 
Does the low usually resolve itself within ~15 minutes?   □ Y     □ N 
Do they usually feel (know) when they are low?   □ Y     □ N 
21. Has the patient been hospitalized due to hypoglycemia and/or required 3rd party 
assistance in the past 6 months?   □ Y     □ N  
 
22. Current glucometer (make/model):   ________________________________ 
23. Total daily insulin dose (average): __________________________________ Units 
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PERSONAL CONTACT INFORMATION 
 
 
1. Your Complete Legal Name 
 
 First            Middle 
 
 Last 
 
 
 
2. Address 
 
   Street Address 
 
  
   (PO Box/Apt #) 
  
      City     Province                   Postal 
              Code 
 
 
3. Telephone 
 
Home:  ___ ___ ___ - ___ ___ ___ - ___ ___ ___ ___      
Work:  ___ ___ ___ - ___ ___ ___ - ___ ___ ___ ___ 
Cell:  ___ ___ ___ - ___ ___ ___ - ___ ___ ___ ___              
 
4. Email 
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EMERGENCY CONTACT INFORMATION  
1. Name of Emergency Contact & Relationship to Participant 
 
   First                       
 
   Last 
 
  Relationship to Participant:  
2. Telephone 
 
Home:  ___ ___ ___ - ___ ___ ___ - ___ ___ ___ ___      
Work:  ___ ___ ___ - ___ ___ ___ - ___ ___ ___ ___ 
Cell:  ___ ___ ___ - ___ ___ ___ - ___ ___ ___ ___              
 
3. Email 
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Appendix D: Recruitment Flyers   
 
Participants will complete 3 visits to the Human Performance Laboratory at York University.  
1) Treadmill test to measure maximal aerobic capacity  
2) Aerobic steady-state exercise on treadmill  
3) Anaerobic, interval circuit training 
Participants will be provided with continuous glucose monitor, sports armband, and 
bioharness during exercise visits 
 
Please contact Dessi Zaharieva (dessi@yorku.ca) for further information and study details!  
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Appendix E: Consent Forms 
 
Informed Consent Form 1 
Date: ____________________________ 
 
Project Title: Adjusting insulin pump basal levels for exercise in youth and adults with type 1 
diabetes. 
 
Principal Investigators:    Principal Student Investigator: 
Dr. Michael Riddell, Ph.D. (Professor)  Dessi Zaharieva (Ph.D. Candidate, 2014) 
Department: Kinesiology & Health Science  Department: Kinesiology & Health Science 
(416) 736-2100 ext. 22324    dessi@yorku.ca, (416) 893-1697 
York University     York University 
 
Dr. Veronica Jamnik, Ph.D. (Associate Professor) 
Department: Kinesiology & Health Science 
(416) 736-2100 ext. 22995 
York University 
 
Purpose of the Research: The purpose of the study is to determine the ideal basal rate 
adjustments using insulin pump therapy during various exercise modalities in individuals with 
type 1 diabetes. This is phase 1 of a 4-year projected project that will be carried out at York 
University in the Human Performance Laboratory under the co-supervision of Dr. Michael 
Riddell and Dr. Veronica Jamnik. Future studies will use these basal rate adjustments together 
with the artificial pancreas algorithm to monitor blood glucose concentrations during physical 
activity and daily living. The overall goal is to improve diabetes management and create more 
freedom in the lives of those affected by type 1 diabetes. 
 
This research will be presented at conferences in the future, although no specific conference has 
been selected at this time. We also aim to publish this data in an academic journal, and share the 
information with the companies involved (Medtronic Inc., Canada, Vancive Medical, USA, and 
Zephyr Technology Corporation, USA). All participants will remain anonymous. 
 
What You Will Be Asked to Do in the Research: A total of 4 sessions will be required for this 
project. All visits will be carried out at York University in the Fitness Laboratory of Dr. Jamnik, 
located at 126 Bethune. The first will be a familiarization session that requires completed 
informed consent, anthropometric measurements, continuous glucose monitor connection, 
medical history questionnaire, PAR-Q Plus questionnaire, and an initial VO2max test. This session 
is estimated to take approximately 1.5 hours. The subsequent sessions will be three experimental 
trials of steady-state aerobic exercise as well as anaerobic circuit exercise. The experimental 
sessions (3) will require a bioharness strapped around the chest to measure physiological 
variables including heart rate, energy expenditure, etc. and finger capillary blood glucose (BG) 
measurements. These sessions will take ~2 hours each to complete.  
Familiarization Session (Visit 1): During this session, you will be asked to complete the medical 
history questionnaire and informed consent. A Physical Activity Readiness Questionnaire (PAR-
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Q+) will also be conducted to measure your pre-exercise health. An example of a question on the 
PAR-Q+ questionnaire includes: “Has your doctor ever said that you have a heart condition or 
high blood pressure: Yes or No”. You will then have your height, weight, and body fat measured. 
An investigator of the same sex will conduct your measurements of body fat using skinfold 
calipers and this will be done in a private room. You will also be asked to complete a test of your 
maximal oxygen consumption (VO2max) by running on a treadmill while the speed and incline are 
increased every 2 minutes until you reach exhaustion. You will be asked to refrain from drinking 
caffeinated beverages or ingesting caffeine supplements for the day of each experimental trial.    
        
Experimental Sessions (Visit 2-4): You will be provided with a continuous glucose monitor 
(CGM) for the duration of the study and asked to insert the CGM on the same day as Visit 2. 
Upon entry to the laboratory, you will be asked to check your own BG levels using a contour 
link glucometer (Bayer, Canada) provided. Also, 10-minutes prior to exercise, a BG 
measurement will be taken. The first exercise protocol will consist of a 40-minute jog on a 
treadmill at ~40-50% of VO2max. Regular finger capillary blood samples will be collected every 
10-15-minutes during exercise. You will be asked to prick your own finger using your own 
lancing device during the experimental portion. Once the exercise session is complete, you will 
be asked to remain in the laboratory for 30-minutes for additional BG measurements and to 
ensure hypoglycemic episodes do not occur post-exercise. You will be given the Bayer Next 
Link glucometer to monitor BG levels throughout the evening and night. Visit 3 and 4 will be 
circuit type exercises (e.g. jumping jacks, plank, squats, etc.) for ~40 minutes. These visits are 
usually completed on the following week (after visit 1 and 2).  
 
The participants will be fitted with a CGM that will provide constant real-time measurements of 
blood glucose values. The CGM may cause some discomfort upon insertion. This is a small 
glucose sensor that is inserted superficially into the surface of the skin and this will be done by 
the lead nurse practitioner. Since all of the participants that will be recruited will be insulin pump 
users, they will already have prior experience inserting an infusion set which also uses a needle 
under the surface of the skin. The CGM insertion will likely be a similar sensation as the infusion 
set, with a slight tingling upon insertion that stops immediately once inserted. The CGM will 
remain taped to the skin for the remainder of the experimental protocol (5-6 days). To make the 
CGM insertion more comfortable, participants will be given the option to insert the sensor with 
an auto-insertion device if they have done so in the past and prefer this option. This plastic 
device is used specifically with the CGM to make the insertion pain-free. The principal 
investigator (Dr. Michael Riddell) has extensive experience providing suggestions on proper 
insertion if necessary.  
 
Participants will also be fitted with a lifestyle assessment system sports armband (Metria IH1, 
Vancive USA) that will be placed on the surface of the skin on the left upper portion of the arm. 
The principal student investigator (PSI) will apply this armband on the participant and it will 
remain on the skin for one week. Participants may do all of their regular physical activity and 
shower with the device and it will be returned to the PSI at the end of the week. The data from 
the CGM and the sports armband will be collected and uploaded on a computer and sent out to 
the participant for a detailed review of the data. 
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Risks and Discomforts: There are some mild to moderate risks associated with the participation 
of this study. Exercise can be associated with cardiovascular adverse events in very rare 
circumstances in the general population (angina, heart attack) and people with diabetes have a 
higher risk for cardiovascular disease compared with non-diabetics. A recent evidence-based 
review paper (Riddell & Burr, 2011) has shown; however, that the risk of a life-threatening event 
temporally associated with (or attributable to) exercise for people with T1DM is not different for 
the general population. Nonetheless, as a safety precaution, we will screen all participants for 
exercise readiness using the PAR-Q+ screening tool for individuals with metabolic diseases. 
During all visits, blood pressure and heart rate will be monitored throughout exercise using a 
bioharness (Zephyr Technology Corporations, USA) and the criteria for exercise test termination 
will follow the Canadian Society for Exercise Physiologists Clinical Practice Guidelines.  
 
All of the investigators are certified in First Aid & CPR and are able to provide assistance if 
necessary. The subjects will not be eligible to participate if any heart condition exists. Should a 
medical emergency arise, University procedures will take place. Steps include calling 911 and 
providing the following information: location of the building (126 Bethune College), exact 
location of ill person, describe the nature and severity of the medical problem, and provide your 
name (Dessi Zaharieva) and telephone number (416-893-1697). York University Security 
Services will be contacted at ext. 33333 or (416) 736-5333 to be informed of why 911 was 
contacted. The emergency personnel will be met by PI and PSI at the entrance to Bethune 
College.   
  
Other more common but less serious risks of exercise do exist with this population. With type 1 
diabetes individuals during exercise, there is an increased risk of hypoglycemia (low blood 
sugar) or hyperglycemia (high blood sugar). Fluctuations in BG levels are common during 
exercise, and hypoglycemia often occurs with endurance-type exercises. Hypoglycemia may 
cause dizziness, fatigue, shakiness, and/or tingling in the limbs. In this study, capillary glucose 
will be monitored ~every 15 minutes and volunteers will also wear a continuous interstitial 
glucose monitor (iPro, Medtronic, Canada). Dextrose will be supplied to all subjects prior to the 
onset of exercise and this will likely prevent any drastic reductions in BG levels. Since BG 
concentrations are being monitored so frequently, investigators will be able to notice 
hypoglycemic trends developing long before they place the individual at risk for any adverse 
event associated with severe hypoglycemia. If BG or interstitial glucose drops below 3.5 
mmol/L, the exercise will be terminated immediately and additional "fast-acting" carbohydrate 
will be given orally (Dex4, AMG Medical, USA).   
     
Similarly, the CGM may cause some discomfort upon insertion. This is a small glucose sensor that is 
inserted into the surface of the skin by yourself or the investigator (Dr. Michael Riddell) if required. 
Since all of the diabetic subjects that will be recruited will be insulin pump users, you will already 
have prior experience inserting an infusion set which also uses a needle under the surface of the skin. 
The CGM insertion will likely be a similar sensation as the infusion set, with a slight tingling upon 
insertion that stops once inserted. The CGM will remain taped to the skin for the remainder of the 
experimental protocol. To make the CGM insertion more comfortable, you will be given the option 
to insert the sensor with an auto-insertion device. This plastic device is used specifically with the 
CGM to make the insertion pain-free. The principal investigator (Dr. Michael Riddell) and principal 
student investigator (Dessi Zaharieva) have extensive experience inserting these devices and can 
provide tips on proper insertion if necessary.     
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 During the VO2max test and exercise sessions, you will be wearing a mouthpiece while running on 
the treadmill and this may be slightly uncomfortable, as breathing may feel slightly restricted. The 
exercise sessions should be more comfortable for the participants since the initial VO2max 
measurements will be complete and subjects will know the feeling of the mouthpiece during exercise. 
With a VO2max test, you will be running on a treadmill until you reach exhaustion. You may 
experience some symptoms of fatigue, nausea, and dizziness, but the may terminate the run if you 
feel that you have reached exhaustion.  
 
Benefits of the Research and Benefits to You: You will complete a VO2max at not cost and learn 
more about your physical fitness. A VO2max test would normally cost $100 to complete outside of the 
research setting.  
 
Participants will also have the benefit of wearing this new armband technology called Metria IH1 
(Vancive, USA) that collects and reports physical activity, activity level, calories burned, sleep 
duration and quality, and more. The sports armband will not cause any immediate benefit to 
participants, but once the data is collected, it will be interesting to view. It is important to keep a 
careful record of activities performed, carbohydrates consumed, and insulin administration in 
order to understand the cause for observed alterations in blood glucose concentrations. By 
identifying any recurring trends, participants may subsequently identify changes that should be 
made to their management techniques. 
 
Voluntary Participation: Your participation in the study is completely voluntary and you may 
choose to stop participating at any time.  Your decision not to volunteer will not influence the 
treatment you may be receiving or the nature of your relationship with York University either now, 
or in the future. 
 
Withdrawal from the Study:  You can stop participating in the study at any time, for any reason, if 
you so decide. Your decision to stop participating, or to refuse to answer particular questions, will 
not affect your relationship with the researchers, York University, or any other group associated with 
this project. In the event you withdraw from the study, all associated data collected will be 
immediately destroyed wherever possible. 
 
Confidentiality: All information you supply during the research will be held in confidence and 
unless you specifically indicate your consent, your name will not appear in any report or publication 
of the research. The data will be collected partially via handwritten notes (VO2max data, blood glucose 
concentrations, and questionnaires), and digital data (CGM, blood glucose concentrations in excel, 
and polar heart rate data, etc. in excel). The data will be archived in a locked facility in 225B 
Lumbers laboratory. Confidentiality will be provided to the fullest extent possible by law. All of the 
hard copies of data will be kept in a safe and secure filing cabinet in the laboratory of Dr. Michael 
Riddell. Only the principal investigator (PI) and principal student investigator (PSI) will have access 
to these files. All of the electronic files will be collected on a personal laptop with password 
protection. Subject identifiers will be collected (participant names, phone number, and email) in 
order to contact the subjects for testing purposes. The participants names will be coded and only the 
PI and PSI will have access to this master list in order to keep the data anonymous. Upon publication 
of data (or after 5 years), the hard copies and electronic data will be destroyed.    
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Questions About the Research?  If you have questions about the research in general or about your 
role in the study, please feel free to contact Dr. Mike Riddell either by telephone at (416) 736-2100, 
extension 22324 or by e-mail (mriddell@yorku.ca). This research has been reviewed and approved 
by the Human Participants Review Sub-Committee, York University’s Ethics Review Board and 
conforms to the standards of the Canadian Tri-Council Research Ethics guidelines. If you have any 
questions about this process, or about your rights as a participant in the study, please contact the Sr. 
Manager & Policy Advisor for the Office of Research Ethics, 5th Floor, York Research Tower, York 
University (telephone 416-736-5914 or e-mail ore@yorku.ca). 
 
 
 
Legal Rights and Signatures: 
 
I _____________________________ __  (insert your name), consent to participate in the study 
“adjusting insulin pump basal levels for exercise in youth and adults with type 1 diabetes.” 
conducted by Dessi Zaharieva. I have understood the nature of this project and wish to 
participate. I am not waiving any of my legal rights by signing this form.  My signature below 
indicates my consent. 
 
 
 
Signature      Date        
Participant 
 
 
 
Signature      Date        
Principal Investigator 
 
Thank you for your assistance in this project. Please keep a copy of this form for your records. 
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Informed Consent Form 2 
Date: ____________________________ 
 
Project Title: OmniPod® Type 1 diabetes Insulin Management for Exercise study (Omni-
TIME-study) 
 
Principal Investigators:    Principal Student Investigator: 
Dr. Michael Riddell, Ph.D. (Professor)  Dessi Zaharieva (Ph.D. Candidate, 2014) 
Department of Kinesiology & Health Science Department of Kinesiology & Health 
Science 
(416) 736-2100 ext. 22324    dessi@yorku.ca, (416) 893-1697 
 
Dr. Veronica Jamnik, Ph.D. (Associate Professor) 
Department of Kinesiology & Health Science 
(416) 736-2100 ext. 22995 
York University 
 
Purpose of the Research: The purpose of this study is to determine the effectiveness of three 
different basal insulin management strategies to reducing blood glucose during prolonged 
aerobic exercise in adults with type 1 diabetes (T1D). All participants will be using an 
OmniPod® (Insulet Corporation, USA) insulin pump. The OmniPod® is a Health Canada 
approved tubing-free insulin pump device that uses an insulin delivery ‘pod’ and a Personal 
Diabetes Manager (PDM). The PDM is a wireless handheld device that programs the pod, 
captures diabetes management events (food, exercise, etc.), and acts as a glucose meter (Abbott 
Freestyle, USA). The project will be carried out at York University in the Clinical Human 
Exercise Laboratory under the supervision of Dr. Michael Riddell. The overall goal of this 
research is to increase the percent time spent in target range during exercise and in recovery. 
 
This research will be presented at conferences in the future, although no specific conference has 
been selected at this time. We also aim to publish this data in an academic journal, and share the 
information with the companies involved (OmniPod®, Insulet Corporation, USA, Abbott 
Freestyle, USA, etc.). All participants will remain anonymous. 
 
What You Will Be Asked to Do in the Research: A total of four sessions will be required for 
this project. All visits will be carried out at York University in the Clinical Human Exercise 
Laboratory, located at Stong room 108. The first visit will be a familiarization session that 
requires completed informed consent, anthropometric measurements, continuous glucose 
monitor (CGM) connection, medical history questionnaire, PAR-Q Plus questionnaire, physical 
fitness assessment, and an initial VO2max test. This session is estimated to take approximately 
1.5 hours. The subsequent sessions will be three experimental trials of prolonged, steady state 
aerobic exercise, lasting 75 minutes. The experimental sessions (three) will require a bioharness 
strapped around the chest to measure physiological variables including heart rate, energy 
expenditure, etc. and finger capillary blood glucose (BG) measurements. These sessions will take 
~2 hours each to complete.  
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Baseline/Screening Session (Visit 1): During this session, you will be asked to complete the 
medical history questionnaire and informed consent. A Physical Activity Readiness 
Questionnaire (PAR-Q+) will also be conducted to measure your pre-exercise health. An 
example of a question on the PAR-Q+ questionnaire includes: “Has your doctor ever said that 
you have a heart condition or high blood pressure: Yes or No”. You will then have your height, 
weight, and body fat measured. An investigator of the same sex will conduct your measurements 
of body fat using skinfold calipers and this will be done in a private room. You will also be asked 
to complete a test of your maximal oxygen consumption (VO2max) by running on a treadmill 
while the speed and incline are increased every 2 minutes until you reach exhaustion. You will 
be asked to refrain from drinking caffeinated beverages or ingesting caffeine supplements for the 
day of each experimental trial.    
        
Experimental Sessions (Visit 2-4): You will be assigned to a sequence of the three experimental 
visits through a randomization process. Each exercise session will be separated by at least three 
days and you will be expected to complete all sessions within ~12 weeks from the time of the 
baseline/screening visit. Upon arrival to the laboratory, you will be asked to prick your own 
finger using your own lancing device. You will be given the Abbott Freestyle PDM to monitor 
BG levels and carbohydrate intake throughout the study. During each of the three exercise 
sessions, a basal rate adjustment will be made before the exercise. The three insulin strategies 
include:  
 
(1) Control Strategy: -100% of usual basal rate at the start of exercise (i.e. pump suspension) 
(2) Strategy 2: -50% of usual basal rate, set 90 minutes pre-exercise for the duration of exercise 
(3) Strategy 3: -80% of usual basal rate, set 90 minutes pre-exercise for the duration of exercise 
 
The exercise will consist of four 15 minute bouts of jogging at 50-60% of the participant’s pre-
determined aerobic capacity, separated by three 5 minute breaks (to simulate what is typically 
done in most team and individual workouts and sports). Regular finger capillary BG samples will 
be collected during exercise. In all three sessions, aerobic exercise (brisk walking/light jogging) 
will be performed in the post-absorptive state, ~4 hours after the last meal with their usual bolus 
insulin given.  
 
You will be provided with a CGM (DexcomTM, USA) for the duration of the study and asked to 
insert the CGM one day before the first experimental session. If participants have never worn a 
CGM (DexcomTM, USA), they will have the option to wear one starting the initial screening visit 
for 7 days. The CGM will provide constant real-time measurements of BG values. The CGM 
may cause some discomfort upon insertion. This is a small glucose sensor that is inserted 
superficially under the surface of the skin and the lead investigator will do this. Since all of the 
participants that will be recruited will be insulin pump users, they will already have prior 
experience inserting a small needle into the skin. The CGM insertion will likely be a similar 
sensation as the ‘pod’ insertion, with a slight tingling upon insertion that stops immediately once 
inserted. The CGM will remain taped to the skin for the remainder of the experimental protocol 
(2-3 weeks). The principal investigator (Dr. Michael Riddell) has extensive experience providing 
suggestions on proper insertion if necessary.  
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Exercise intensity will be monitored continuously using heart rate and activity monitors. You 
will be fitted with a lifestyle assessment system sports armband (Metria IH1TM, Vancive, USA) 
that will be placed on the surface of the skin on the upper portion of the non-dominant arm. The 
principal student investigator (PSI) will apply this armband on your arm and it will remain on the 
skin for one week. You may do all of your regular physical activity and shower with the device 
and it will be returned to the PSI at the end of the week. An accelerometer chest band (ZephyrTM 
bioharness, USA) will also be strapped around your chest during exercise to monitor heart rate 
and removed at the end of each session. The data from the CGM and the sports armband will be 
collected and uploaded on a computer and sent out to the you for a detailed review of the data. 
 
Following each exercise session, you will rest for 30 minutes and then consume a standardized 
meal (~50 g of carbohydrate, ~17g protein and ~8g of fat, Lean CuisineTM). The amount of bolus 
insulin given at the post-exercise meal will be based on the carbohydrate content of the meal and 
your own individualized insulin-to-carbohydrate ratio, insulin sensitivity index, and glycemic 
targets on your OmniPod® PDM. Insulin “corrections” will be given based on the patient’s own 
OmniPod® settings (i.e. usual care). You will be asked to administer your bolus insulin 10-
minutes before the start of consuming the meal. If hypoglycemia occurs prior to the meal (BG ≤ 
3.9 mmol/L), you will be treated with 16 grams of fast acting carbohydrate (Dex4, AMG 
Medical) prior to the meal consumption.  
 
You will be monitored for approximately two hours after the standardized meal prior to 
discharge. CGM monitor low- and high-glucose ‘alerts’ will be activated. You will also be 
instructed to perform a standardized basal rate reduction overnight to help reduce the risk of 
post-exercise nocturnal hypoglycemia (-20% from bedtime for 6 hours). Fingerstick BG will be 
collected ~ every 30-minutes in recovery and upon completion, will be sent home. 
 
Inclusion Criteria 
- Clinical diagnosis of presumed autoimmune type 1 diabetes, receiving daily insulin 
- Last A1C ≤ 9.9% 
- Age: 17-65 years 
- Duration of T1D:  ≥ 2 years 
- Using CSII via OmniPod for at least 1 month (~50:50 bolus basal insulin ratio and on at 
least .25 units of insulin per kilogram body mass per day) 
- Body mass index (BMI) <30 kg/m2 
- In good general health with no conditions that could influence the outcome of the trial, 
and in the judgment of the investigator is a good candidate for the study based on review 
of available medical history, physical examination and clinical laboratory evaluations 
- Willing to adhere to the protocol requirements for the duration of the study 
 
Exclusion Criteria 
- Physician diagnosis of active diabetic retinopathy (proliferative or hemorrhage in past 6 
months) that could potentially be worsened by exercise  
- Physician diagnosis of peripheral neuropathy with insensate feet 
- Physician diagnosis of autonomic neuropathy  
- Medications: 
a. Beta-blockers  
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b. Agents that affect hepatic glucose production such as beta adrenergic agonists, 
xanthine derivatives 
c. Pramlintide 
d. Any other hypoglycemic agent  
- Participation in other studies involving administration of an investigational drug or 
device at the time of screening for the current study or planning to participate in another 
such study during participation in the current study  
- Severe hypoglycemic event defined as the individual requiring a third party or 
hospitalization in the last 3 months 
 
Risks and Discomforts: There are some mild to moderate risks associated with the participation 
of this study. Exercise can be associated with cardiovascular adverse events in very rare 
circumstances in the general population (angina, heart attack) and people with diabetes have a 
higher risk for cardiovascular disease compared with non-diabetics. A recent evidence-based 
review paper (Riddell & Burr, 2011) has shown; however, that the risk of a life-threatening event 
temporally associated with (or attributable to) exercise for people with T1D is not different for 
the general population. Nonetheless, as a safety precaution, we will screen all participants for 
exercise readiness using the PAR-Q+ screening tool for individuals with metabolic diseases. 
During all visits, heart rate will be monitored throughout exercise using the ZephyrTM bioharness 
and the criteria for exercise test termination will follow the Canadian Society for Exercise 
Physiologists Clinical Practice Guidelines.  
 
All of the investigators are certified in First Aid & CPR and are able to provide assistance if 
necessary. Individuals will not be eligible to participate if any heart condition exists. Should a 
medical emergency arise, University procedures will take place. Steps include calling 9-1-1 and 
providing the following information: Location of the building (Stong room 108), exact location 
of ill person, describe the nature and severity of the medical problem, and provide your name 
(Dessi Zaharieva) and telephone number (416-893-1697). York University Security Services will 
be contacted at ext. 33333 or (416) 736-5333 to be informed of why 911 was contacted. The PI 
and PSI will meet the emergency personnel at the entrance to Stong College.   
  
Other more common but less serious risks of exercise do exist with this population. With T1D 
individuals during exercise, there is an increased risk of hypoglycemia (low blood sugar) or 
hyperglycemia (high blood sugar). Fluctuations in BG levels are common during exercise, and 
hypoglycemia often occurs with endurance-type exercises. Hypoglycemia may cause dizziness, 
fatigue, shakiness, and/or tingling in the limbs. In this study, BG will be monitored frequently 
and you will also wear a CGM that displays constant glucose values. Dextrose tablets (Dex4, 
AMG Medical, USA) will be available to all participants if needed at any time. Since BG 
concentrations are being monitored so frequently, investigators will be able to notice 
hypoglycemic trends developing long before they place the individual at risk for any adverse 
event associated with severe hypoglycemia. If BG or interstitial glucose drops below 3.9 
mmol/L, the exercise will be terminated immediately and additional fast-acting carbohydrate will 
be given orally.   
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Similarly, the CGM may cause some discomfort upon insertion. This is a small glucose sensor that is 
inserted into the surface of the skin by yourself or the investigator (Dr. Michael Riddell) if required. 
Since all of the participants that will be recruited will be insulin pump users, they will already have 
prior experience inserting an infusion set which also uses a needle under the surface of the skin. The 
CGM insertion will likely be a similar sensation as the pod, with a slight tingling upon insertion that 
stops once inserted. The CGM will remain taped to the skin for the remainder of the experimental 
protocol. The principal investigator (Dr. Michael Riddell) and principal student investigator (Dessi 
Zaharieva) have extensive experience inserting these devices and can provide tips on proper insertion 
if necessary.     
      
During the VO2max test and exercise sessions, you will be wearing a mouthpiece while running on 
the treadmill and this may be slightly uncomfortable, as breathing may feel slightly restricted. The 
exercise sessions should be more comfortable for you once the initial VO2max is complete because 
you will already know the feeling of the mouthpiece during exercise. With a VO2max test, you will 
be running on a treadmill until you reach exhaustion. Participants may experience some symptoms of 
fatigue, nausea, and dizziness, but may terminate the run if you feel that you have reached 
exhaustion.  
 
Benefits of the Research and Benefits to You: You will complete a VO2max at no cost and learn 
more about your physical fitness. A VO2max test would normally cost $100 to complete outside of 
the research setting.  
 
Participants will also have the benefit of wearing this armband technology (Metria IH1TM, 
Vancive, USA) that collects and reports physical activity, activity level, calories burned, sleep 
duration and quality, and more. The sports armband will not cause any immediate benefit to 
participants, but once the data is collected, it will be interesting to view. It is important to keep a 
careful record of activities performed, carbohydrates consumed, and insulin administration in 
order to understand the cause for observed alterations in BG concentrations. By identifying any 
recurring trends, participants may subsequently identify changes that should be made to their 
management techniques. 
 
Voluntary Participation: Your participation in the study is completely voluntary and you may 
choose to stop participating at any time. Your decision not to volunteer will not influence the 
treatment you may be receiving or the nature of your relationship with York University either now, 
or in the future. 
 
Withdrawal from the Study: You can stop participating in the study at any time, for any reason, if 
you so decide. Your decision to stop participating, or to refuse to answer particular questions, will 
not affect your relationship with the researchers, York University, or any other group associated with 
this project. In the event you withdraw from the study, all associated data collected will be 
immediately destroyed wherever possible. 
 
Confidentiality: All information you supply during the research will be held in confidence and 
unless you specifically indicate your consent, your name will not appear in any report or publication 
of the research. The data will be collected partially via handwritten notes (VO2max data, blood 
glucose concentrations, and questionnaires), and digital data (CGM, blood glucose concentrations in 
excel, and polar heart rate data, etc. in excel). The data will be archived in a locked facility in 225B 
Lumbers laboratory. Confidentiality will be provided to the fullest extent possible by law. All of the 
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hard copies of data will be kept in a safe and secure filing cabinet in the laboratory of Dr. Michael 
Riddell. Only the principal investigator (PI) and principal student investigator (PSI) will have access 
to these files. All of the electronic files will be collected on a personal laptop with password 
protection. Subject identifiers will be collected (participant names, phone number, and email) in 
order to contact the subjects for testing purposes. The participants names will be coded and only the 
PI and PSI will have access to this master list in order to keep the data anonymous. Upon publication 
of data (or after 5 years), the hard copies and electronic data will be destroyed. 
    
Questions About the Research?  If you have questions about the research in general or about your 
role in the study, please feel free to contact Dr. Mike Riddell either by telephone at (416) 736-2100, 
extension 22324 or by e-mail (mriddell@yorku.ca). This research has been reviewed and approved 
by the Human Participants Review Sub-Committee, York University’s Ethics Review Board and 
conforms to the standards of the Canadian Tri-Council Research Ethics guidelines. If you have any 
questions about this process, or about your rights as a participant in the study, please contact the Sr. 
Manager & Policy Advisor for the Office of Research Ethics, 5th Floor, York Research Tower, York 
University (telephone 416-736-5914 or e-mail ore@yorku.ca). 
 
 
 
Legal Rights and Signatures: 
 
I _________________________________ (insert your name), consent to participate in the study 
“OmniPod® Type 1 diabetes Insulin Management for Exercise study (Omni-TIME-study)” 
conducted by Dessi Zaharieva. I have understood the nature of this project and wish to 
participate. I am not waiving any of my legal rights by signing this form.  My signature below 
indicates my consent. 
 
 
Signature      Date        
Participant 
 
 
 
Signature      Date        
Principal Investigator 
 
Thank you for your assistance in this project. Please keep a copy of this form for your records. 
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Appendix F: Additional tables, graphs, & individual data (Paper #1) 
 
 
 
Figure F1: Individual blood glucose concentrations in CIRC vs. CON exercise.  
A, CIRC suspended data. B, CON suspended data. Colour-coding represents each participant and the colour is carried out in both A 
and B. If hypoglycemia developed during activity, the exercise was terminated and participant was treated with dextrose tablets. Data 
points were carried out only until hypoglycemia developed. N=12. 
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Figure F2: Absolute blood glucose concentration during CIRC and CON exercise. 
Data represents CIRC (circle) and CON exercise (triangle) pre-, during, and post-exercise. Grey 
shading represents the exercise session (40-min). Data are expressed as mean ± SD, n = 12.        
* denotes significance of P < 0.05.  
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Figure F3: Male (blue) and female (pink) blood glucose levels during CIRC and CON 
exercise.  
A, CIRC and B, CON. N = 6 males and 6 females. Data represents mean ± SEM.
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Figure F3: Absolute blood glucose concentration during CIRC and CON exercise separated by fitness level.  
A, High VO2max was > 48.0 mL/kg/min (n = 6) and B, Moderate VO2max was < 42.0 mL/kg/min (n = 6). Data represents mean ± 
SD. 
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Appendix G: Additional tables, graphs, & individual data (Paper #2) 
 
 
 
Figure G1: Individual glucose concentration during ‘pump off’ and ‘pump on’ exercise. 
A, ‘Pump off’ exercise. B, ‘Pump on’ exercise. Colour-coding represents each participant and the colour is carried out in both A and 
B. If hypoglycemia developed during activity, the exercise was terminated and participant was treated with dextrose tablets. If 
hypoglycemia occurred, the data points show only until hypoglycemia developed. N=12. 
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Figure G2: Male (blue) vs. female (pink) blood glucose concentrations in pump on and 
pump off exercise.  
A, ‘Pump on’ and B, ‘Pump off’. Total = 6 males and 6 females. Data represents mean ± SEM. 
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Appendix H: Additional tables, graphs, & individual data (Paper #3) 
Subject 
ID 
Sex 
(M/F) 
Age 
(Years) 
Diabetes 
Duration 
(Years) 
Insulin Type TDD (Units/kg) 
Weight 
(kg) 
Height 
(cm) 
BMI 
(kg/m2) 
Body Fat 
(%) 
HbA1c 
(%) 
VO2peak 
(mL/kg/min) 
Omni01 F 26 8 Novorapid 0.39 59.1 156 24.3 25.5 7.2 46.0 
Omni02 M 27 5 Humalog 0.30 77.6 189 21.7 14.3 5.9 37.1 
Omni03 F 28 3 Humalog 0.41 76.2 162 29.1 37.8 6.0 51.0 
Omni04 M 50 34 Novorapid 0.39 78.4 184 23.2 18.1 6.6 59.2 
Omni05 F 24 10 Novorapid 0.45 70.6 174 23.5 26.4 6.8 51.6 
Omni06 F 30 16 Novorapid 0.44 68.8 163 26.0 33.8 6.3 41.6 
Omni07 F 28 19 Novorapid 0.41 75.4 175 24.6 33.1 6.0 44.6 
Omni08 F 25 3 Humalog 0.38 73.3 167 26.2 33.7 6.7 46.2 
Omni09 F 57 25 Novorapid 0.42 71.0 170 24.6 33.9 7.0 37.5 
Omni10 F 40 3 Humalog 0.65 46.4 151 20.3 23.1 7.0 31.6 
Omni11 M 28 4 Novorapid 0.35 88.4 173 29.6 28.5 6.7 53.5 
Omni12 F 22 6 Novorapid 0.58 76.8 168 27.2 36.5 6.6 49.3 
Omni13 M 41 31 Novorapid 0.61 82.6 176 26.7 25.1 7.2 32.7 
Omni14 F 19 7 Novorapid 0.25 75.2 162 28.5 37.0 5.9 42.9 
Omni15 F 35 25 Novorapid 0.37 70.8 166 25.8 29.9 5.7 40.4 
Omni16 F 24 12 Humalog 0.44 57.3 156 23.4 23.2 6.3 44.3 
Omni17 F 28 21 Novorapid 0.54 71.4 167 25.6 32.3 6.0 49.1 
Mean ± 
SD 
13 F 
  4 M 31 ± 10 14 ± 10 
12 Novorapid 
5 Humalog 0.43 ± 0.1 71.7 ± 9.9 168 ± 10 25.3 ± 2.5 29.0 ± 6.8 6.5 ± 0.5 44.6 ± 7.4 
Table H1: Individual baseline anthropometric and descriptive data of all study participants (n=17).
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Table H2: Relative exercise intensity, heart rate, and energy expenditure across all exercise conditions.  
Data represented as mean ± SD, n = 17.  HR = heart rate; EE = energy expenditure. 
 80% BRR 50% BRR Pump Suspension 
Subject ID VO2 
Relative 
VO2 
HR 
(bpm) 
EE 
(Kcal/min) VO2 
Relative 
VO2 
HR 
(bpm) 
EE 
(Kcal/min) VO2 
Relative 
VO2 
HR 
(bpm) 
EE 
(Kcal/min) 
Omni01 22.4 54.1 129 7.50 21.7 52.4 133 7.55 21.6 52.2 133 8.10 
Omni02 17.9 48.2 119 5.58 17.1 46.1 116 5.31 17.2 46.4 118 4.79 
Omni03 21.7 48.4 118 6.89 21.5 48.0 118 6.38 21.8 48.7 119 6.93 
Omni04 27.2 52.6 111 7.78 28.2 54.5 111 8.25 27.1 52.4 109 7.50 
Omni05 25.3 55.2 119 8.16 27.1 59.2 130 8.8 26.0 56.8 126 8.80 
Omni06 17.5 46.8 118 4.68 17.4 46.5 116 4.98 17.5 46.8 124 4.73 
Omni07 20.1 50.1 115 6.56 21.8 54.4 123 6.69 20.2 50.4 111 5.30 
Omni08 24.6 53.2 132 6.99 24.8 53.7 134 7.09 24.6 53.2 132 7.00 
Omni09 19.3 51.5 100 5.52 20.2 53.9 99 5.77 20.3 54.1 100 7.13 
Omni10 16.9 53.4 97 4.93 17.1 54.0 105 4.73 16.3 51.5 101 4.64 
Omni11 24.0 49.9 130 7.62 23.3 48.4 133 6.65 23.9 49.7 139 6.96 
Omni12 22.6 45.8 135 6.87 22.6 45.8 133 6.37 22.6 45.8 136 5.39 
Omni13 14.5 48.2 124 4.62 15.0 49.8 131 4.77 14.8 49.2 124 4.19 
Omni14 19.4 45.3 124 5.91 20.0 46.7 130 6.18 19.9 46.4 130  N/A 
Omni15 18.6 46.1 135 5.88 19.8 49.1 135 N/A  20.9 51.8 138  N/A 
Omni16 19.6 49.1 133 6.22 19.2 48.1 132 6.09 20.9 52.4 132 6.66 
Omni17 20.8 47.7 127 5.95 20.8 47.7 132 6.61 22.1 50.7 138 6.80 
Mean  
±  
SD 
20.7  
±  
3.33 
49.8  
±  
3.11 
122  
±  
11 
6.33 
±  
1.09 
21.0 
±  
3.52 
50.5  
±  
3.89 
124 
±  
11 
6.39 
±  
1.17 
21.0 
± 
3.33 
50.5 
±  
3.04 
124 
±  
13 
6.33 
±  
1.39 
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Figure H1: Individual and mean participant baseline blood glucose level for all exercise 
conditions.  
A, 80% basal reduction; B, 50% basal reduction; C, pump suspension.  
* denotes that hypoglycemia developed. 
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Figure H2: Male (blue) and female (pink) blood glucose levels across all exercise conditions. 
A, 80% BRR; B, 50% BRR; C, pump suspension.  
